var title_f24_23_24944="TB pulmonary lesion";
var content_f24_23_24944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enlarged right-sided hilar lymph nodes with local infiltrate and atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlarged right-sided hilar lymph nodes with local infiltrate and atelectasis caused by tuberculosis. This child was asymptomatic, this lesion having been discovered during a contact investigation conducted after this child's uncle was suspected of having pulmonary tuberculosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R Starke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24944=[""].join("\n");
var outline_f24_23_24944=null;
var title_f24_23_24945="Chapter 6I: Kinins and the kidney";
var content_f24_23_24945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 6I: Kinins and the kidney",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/23/24945/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24945/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24945/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/23/24945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24945/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/23/24945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24945/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/23/24945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kinins are another set of hormones produced in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24945/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The process begins with the secretion of the enzyme kallikrein by the cells in the distal tubule and connecting segment (",
"    <a class=\"graphic graphic_figure graphicRef74570 \" href=\"UTD.htm?25/31/26109\">",
"     figure 1",
"    </a>",
"    ). This enzyme catalyzes the conversion of inactive kininogen (a plasma protein that might also be produced locally) into lysyl-bradykinin and then, in the presence of an aminopeptidase, into bradykinin. Kinin generation probably occurs both in the tubular lumen and, since secreted kallikrein appears to reach the vascular compartment, in the vascular space. On the other hand, filtered kinins are rapidly metabolized by kininases in the proximal tubule and therefore are not likely to have any intratubular effect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24945/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic role of the renal kinins is incompletely understood. Like the prostaglandins, they are vasodilators that may act to minimize renal ischemia in hypovolemic states in which angiotensin II and norepinephrine secretion are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24945/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Their site of production in the distal nephron also suggests that they may have an intraluminal effect on Na+ and water handling in the collecting tubules. Compatible with this hypothesis are the observations that kinins diminish Na+ reabsorption in the inner medulla (by closing Na+ channels in the luminal membrane) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24945/abstract/5\">",
"     5",
"    </a>",
"    ] and impair the ability of ADH to increase local water reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24945/abstract/6\">",
"     6",
"    </a>",
"    ]. The latter effect appears to be indirect, being mediated by kinin-induced prostaglandin production.",
"   </p>",
"   <p>",
"    Renal kinins appear to have a significant role in the developing kidney. The expression of bradykinin receptor mRNA is elevated 10- to 30-fold in neonatal kidney as compared with adult kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24945/abstract/7\">",
"     7",
"    </a>",
"    ]. How kinins act in the maturing kidney is unknown.",
"   </p>",
"   <p>",
"    The kinins are probably not important circulating hormones, since they are rapidly metabolized in the circulation by kininases, one of which is angiotensin converting enzyme. This is the same enzyme that catalyzes the conversion of angiotensin I into angiotensin II.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10083?source=see_link\">",
"     \"Chapter 6J: Erythropoietin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24945/abstract/1\">",
"      Scicli AG, Carretero OA. Renal kallikrein-kinin system. Kidney Int 1986; 29:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24945/abstract/2\">",
"      Fuller PJ, Funder JW. The cellular physiology of glandular kallikrein. Kidney Int 1986; 29:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24945/abstract/3\">",
"      Johnston PA, Bernard DB, Perrin NS, et al. Control of rat renal vascular resistance during alterations in sodium balance. Circ Res 1981; 48:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24945/abstract/4\">",
"      Margolius HS. Theodore Cooper Memorial Lecture. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 1995; 26:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24945/abstract/5\">",
"      Zeidel ML, Jabs K, Kikeri D, Silva P. Kinins inhibit conductive Na+ uptake by rabbit inner medullary collecting duct cells. Am J Physiol 1990; 258:F1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24945/abstract/6\">",
"      Clapham DE, Neer EJ. New roles for G-protein beta gamma-dimers in transmembrane signalling. Nature 1993; 365:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24945/abstract/7\">",
"      el-Dahr SS, Figueroa CD, Gonzalez CB, M&uuml;ller-Esterl W. Ontogeny of bradykinin B2 receptors in the rat kidney: implications for segmental nephron maturation. Kidney Int 1997; 51:739.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7295 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24945=[""].join("\n");
var outline_f24_23_24945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7295|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/31/26109\" title=\"figure 1\">",
"      Kallikrein kinin system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10083?source=related_link\">",
"      Chapter 6J: Erythropoietin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_23_24946="Patient information: Multiple pulmonary nodules (The Basics)";
var content_f24_23_24946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/15/27889\">",
"         Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"./kaposi-sarcoma-the-basics\">",
"         Patient information: Kaposi sarcoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/34/35363\">",
"         Patient information: Lung cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/28/40386\">",
"         Patient information: Lymphoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/1/23570\">",
"         Patient information: Single pulmonary nodule (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/57/25489\">",
"         Patient information: Tuberculosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/14/32993\">",
"         Patient information: Flexible bronchoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1076\">",
"         Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/35/39475\">",
"         Patient information: Tuberculosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Multiple pulmonary nodules (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H592656662\">",
"      <span class=\"h1\">",
"       What are multiple pulmonary nodules?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pulmonary nodules, also called lung nodules, are &ldquo;spots&rdquo; on the lungs that are seen on a chest X-ray or CT scan. A CT scan is an imaging test that creates pictures of the inside of the body. When there are 2 or more spots on the lungs, it&rsquo;s called &ldquo;multiple&rdquo; pulmonary nodules.",
"     </p>",
"     <p>",
"      <strong>",
"       What causes multiple pulmonary nodules?",
"      </strong>",
"      &ndash; Multiple pulmonary nodules are caused by either:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cancer &ndash; Multiple pulmonary nodules can be caused by cancer that started in another part of the body and then spread to the lungs. Sometimes, multiple pulmonary nodules are caused by other types of cancer, called lymphoma or sarcoma.",
"       </li>",
"       <li>",
"        Conditions that are not cancer &ndash; These include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Different types of infections",
"       </li>",
"       <li>",
"        Conditions that involve inflammation, such as sarcoidosis or granulomatosis with polyangiitis",
"       </li>",
"       <li>",
"        Clumps of abnormal blood vessels, called arteriovenous malformations (or &ldquo;AVMs&rdquo; for short)",
"       </li>",
"       <li>",
"        Conditions caused by breathing in harmful substances for many years",
"       </li>",
"       <li>",
"        Conditions caused by using illegal drugs like heroin",
"       </li>",
"       <li>",
"        Scars from an old infection that happened years ago, such as from a fungus, tuberculosis, or chicken pox",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H592656677\">",
"      <span class=\"h1\">",
"       How will my doctor know what is causing my pulmonary nodules?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help figure this out, your doctor will ask about your symptoms and other medical conditions. He or she will want to know whether you worked around harmful substances you could have breathed into your lungs. If you have not had a CT scan done, he or she will order this test.",
"     </p>",
"     <p>",
"      Your doctor will look at your X-ray and CT scan to see the sizes and shapes of the spots, and where they are in your lungs. He or she might be able to tell the cause of the nodules based on this information.",
"     </p>",
"     <p>",
"      If you have old chest X-rays or CT scans, he or she will look at those to see whether the spots have changed over time. If the spots have not changed on CT scans from 2 years ago (or longer), they are unlikely to be cancer. They are most likely a type of scar on the lungs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H592656692\">",
"      <span class=\"h1\">",
"       Will my doctor order more tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor suspects that you have cancer, an infection, or inflammation, he or she will order more tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A skin test for tuberculosis",
"       </li>",
"       <li>",
"        Lab tests on samples of mucus that you cough up",
"       </li>",
"       <li>",
"        An imaging test called a PET scan &ndash; If some of the nodules are",
"        <span class=\"nowrap\">",
"         1/3",
"        </span>",
"        of an inch or bigger, your doctor might order a PET scan. For this test, a doctor puts a substance into your vein through a thin tube called an &ldquo;IV.&rdquo; Then a special camera takes pictures of your lungs. This test can help tell whether pulmonary nodules are likely to be cancer.",
"       </li>",
"       <li>",
"        A procedure called bronchoscopy &ndash; For this test, your doctor will put a thin tube with a camera and light on the end (called a &ldquo;bronchoscope&rdquo;) in your mouth and down into your lungs. During this test, he or she can get samples of mucus from deep inside your lungs. Another doctor will look at the samples under a microscope and do lab tests on them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the results of these tests are unclear and there is a chance that the nodules are cancer or a disease that needs treatment (like an infection), your doctor will do a biopsy. A biopsy is a test that can tell for certain what&rsquo;s causing your pulmonary nodules. During a biopsy, your doctor will get a sample of tissue from 1 of your pulmonary nodules. Then another doctor will look at the sample under a microscope.",
"     </p>",
"     <p>",
"      There are different ways a doctor can do a biopsy. To get a sample of tissue from a pulmonary nodule, your doctor can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Put a needle through your chest and into a nodule in your lungs",
"       </li>",
"       <li>",
"        Do bronchoscopy to get a sample of tissue",
"       </li>",
"       <li>",
"        Do surgery to remove a pulmonary nodule",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H592656707\">",
"      <span class=\"h1\">",
"       What happens next?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Based on your test results and individual situation, your doctor will decide if you need treatment for the nodules.",
"     </p>",
"     <p>",
"      If your nodules are caused by a condition that needs treatment, your doctor will talk with you about what he or she recommends.",
"     </p>",
"     <p>",
"      If your doctor thinks your nodules are a scar on your lungs, you probably won&rsquo;t need treatment. But you might need follow-up visits or CT scans to make sure your condition doesn&rsquo;t change or worsen over time. How often the scans are done depends on your individual situation. Most people have repeat CT scans over the course of about 2 years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H592656724\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"       Patient information: Lung cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25489?source=see_link\">",
"       Patient information: Tuberculosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/15/27889?source=see_link\">",
"       Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=see_link\">",
"       Patient information: Lymphoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=see_link\">",
"       Patient information: Kaposi sarcoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/1/23570?source=see_link\">",
"       Patient information: Single pulmonary nodule (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"       Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"       Patient information: Flexible bronchoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"       Patient information: Tuberculosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/23/24946?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87303 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-EC95FD50DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24946=[""].join("\n");
var outline_f24_23_24946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H592656662\">",
"      What are multiple pulmonary nodules?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H592656677\">",
"      How will my doctor know what is causing my pulmonary nodules?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H592656692\">",
"      Will my doctor order more tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H592656707\">",
"      What happens next?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H592656724\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=related_link\">",
"      Patient information: Flexible bronchoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/15/27889?source=related_link\">",
"      Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=related_link\">",
"      Patient information: Kaposi sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=related_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=related_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/1/23570?source=related_link\">",
"      Patient information: Single pulmonary nodule (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25489?source=related_link\">",
"      Patient information: Tuberculosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_23_24947="Recluse spider eye pattern";
var content_f24_23_24947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eye pattern of a recluse spider",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard S Vetter, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24947=[""].join("\n");
var outline_f24_23_24947=null;
var title_f24_23_24948="Pegvisomant: Drug information";
var content_f24_23_24948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegvisomant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/29/44500?source=see_link\">",
"    see \"Pegvisomant: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Somavert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6133105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Somavert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Growth Hormone Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acromegaly:",
"     </b>",
"     SubQ: Initial loading dose: 40 mg; maintenance dose: 10 mg once daily; doses may be adjusted by 5 mg increments in 4- to 6-week intervals based on IGF-I concentrations (maximum maintenance dose: 30 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F207052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     At initiation of therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal liver function test (LFT): Initiate therapy; monitor LFT monthly for first 6 months, quarterly for next 6 months, then biannually the following year.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baseline LFT elevated but &le;3 x ULN: May initiate therapy with monthly evaluation of LFT for 1 year then biannually the following year.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baseline LFT &gt;3 times ULN: Do not initiate treatment without comprehensive work-up to determine cause; monitor closely if treatment is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     With ongoing therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LFT &ge;3 x but &lt;5 x ULN without signs/symptoms of hepatitis, hepatic injury, or increase in total bilirubin: Continue treatment, but monitor LFT weekly for further increases; perform comprehensive hepatic work-up to rule out alternative cause of hepatic dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LFT &ge;5 x ULN or transaminase &ge;3 x ULN associated with any increase in total bilirubin: Discontinue immediately and perform comprehensive hepatic work-up. If LFTs return to normal, may cautiously consider restarting therapy with frequent LFT monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Signs or symptoms of hepatitis or hepatic injury: Discontinue therapy immediately and perform comprehensive hepatic work-up; discontinue permanently if liver injury is confirmed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Somavert&reg;: 10 mg, 15 mg, 20 mg [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ administration only; to minimize the risk for lipohypertrophy, rotate injection site daily; may administer in upper arm, thigh, abdomen, or buttocks; do not rub injection site. The manufacturer recommends the initial dose be administered under the supervision of prescribing healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acromegaly in patients resistant to or unable to tolerate other therapies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14188881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pegvisomant may be confused with peginesatide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (8% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (&le;14%), nausea (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests abnormal (4% to 12%; &gt;10 x ULN: 1%; &le;15 times ULN: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (4% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&le;23%), non-neutralizing anti-GH antibodies (17%; relevance unknown), flu-like syndrome (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (&le;8%), chest pain (&le;8%), peripheral edema (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (&le;8%), paresthesia (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, anaphylactic/anaphylactoid reactions, hypersensitivity reactions, lipohypertrophy, progressive tumor growth, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pegvisomant, polyethylene glycol, latex, or any other component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Growth hormone (GH) deficiency: Use may be associated with functional GH deficiency in spite of elevated serum GH levels; monitor closely for signs/symptoms of GH deficiency (eg, decreased muscle or bone mass, decreased strength); dose adjustments may be needed to maintain insulin-like growth factor 1 (IGF-1) within age-adjusted normal levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: May increase liver function tests; transient but marked elevations (&le;15 x upper limit of normal [ULN]) in transaminase levels, usually without accompanying hyperbilirubinemia, have been reported with use; transaminase levels often normalized following interruption of therapy; use with caution in patients with hepatic impairment; monitor hepatic function periodically during therapy; discontinue use immediately with signs/symptoms of jaundice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipohypertrophy: May occur following administration; daily rotation of injection site may  prevent or reduce incidence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may affect glucose metabolism; monitor closely; dosage adjustments of antidiabetic therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Growth hormone (GH)-secreting tumors: Pegvisomant may expand GH-secreting tumors causing serious complications; carefully monitor patients with periodic imaging scans of the sella turcica.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use in patients with renal impairment has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Latex: Vial stopper contains latex",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: The manufacturer recommends the initial dose be administered under the supervision of prescribing healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Interferes with commercially available GH assays; do not make dose adjustments based on serum GH concentrations reported from assays; use insulin-like growth factor I (IGF-I) levels to adjust therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Pegvisomant may enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F207035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Somavert Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $135.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (1): $203.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $271.04",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     GH-secreting tumor size, serum glucose, signs and symptoms of growth hormone deficiency, serum IGF-I (every 4-6 weeks after initial dose and dosage change, every 6 months when normalized)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liver function tests (ALT, AST, total bilirubin, and alkaline phosphatase levels):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baseline:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal: Monthly for first 6 months, quarterly for next 6 months, biannually for the next year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Elevated, but &le;3 x ULN: Monitor monthly for at least 1 year, then biannually the next year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;3 x ULN: Withhold treatment; perform comprehensive liver function evaluation (rule out cholelithiasis or choledocholithiasis); if appropriate for treatment, closely monitor hepatic function and clinical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     During therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;3 x but &lt;5 x ULN without signs/symptoms of hepatitis, hepatic injury or increase in total bilirubin: monitor weekly for further increases; perform comprehensive hepatic work-up",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;5 x ULN or transaminase &ge;3 x ULN associated with any increase in total bilirubin: Comprehensive hepatic work-up. If appropriate for treatment monitor closely",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Somavert (AR, AT, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IL, IT, MT, NL, NO, PE, PT, RU, SE, SG, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An analogue of human growth hormone, pegvisomant selectively binds to growth hormone (GH) receptors, blocking the binding of endogenous GH, leading to decreased serum concentrations of insulin-like growth factor-1 (IGF-I) and other GH-responsive proteins. Pegvisomant is made up of a recombinant DNA protein covalently bound to polyethylene glycol (PEG) polymers.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: 57%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 33-77 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10257 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24948=[""].join("\n");
var outline_f24_23_24948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207047\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6133105\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207066\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207050\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207051\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207052\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207029\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207015\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207031\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207030\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14188881\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207064\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207034\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207018\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299832\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207022\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207025\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207035\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207055\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323636\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207027\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539912\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207017\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207033\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10257|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/29/44500?source=related_link\">",
"      Pegvisomant: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_23_24949="What's new in allergy and immunology";
var content_f24_23_24949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in allergy and immunology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/23/24949/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24949/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24949/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/23/24949/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ASTHMA AND COPD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Mepolizumab in eosinophilic asthma",
"    </span>",
"   </p>",
"   <p>",
"    It is hypothesized that anti-eosinophil therapy with the anti-IL-5 monoclonal antibody, mepolizumab, may be beneficial in patients with the combination of uncontrolled asthma and persistent airways eosinophilia despite glucocorticoid therapy. In the multicenter Dose Ranging Efficacy And safety with Mepolizumab in severe asthma (DREAM) trial, over 600 patients with severe recurrent asthma exacerbations and evidence of eosinophilic inflammation (eg, sputum eosinophils, peripheral blood eosinophilia, elevated exhaled nitric oxide) were randomly assigned to one of three doses of mepolizumab, given as 13 monthly infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/1\">",
"     1",
"    </a>",
"    ]. The rate of clinically significant exacerbations was decreased in all mepolizumab groups compared with placebo with the greatest reduction in the highest dose group. However, symptoms and pulmonary function were not consistently improved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H20#H20\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Anti-IL-5 antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FOOD ALLERGY AND INTOLERANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     A second carbohydrate food allergen identified",
"    </span>",
"   </p>",
"   <p>",
"    Most known food allergens are proteins. However, carbohydrate epitopes can also act as allergens, as is seen with delayed immunoglobulin E (IgE)-mediated reactions to galactose-alpha-1,3-galactose (alpha-gal) in meat. A second carbohydrate allergen has been identified in several case series of patients with acute allergic reactions to beverages containing short-chain galactooligosaccharide (scGOS), a prebiotic used as a supplement in cow&rsquo;s milk formula and other beverages [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The patients in these case series all tolerated other dairy products and had no history of cow&rsquo;s milk allergy. All reported cases occurred in Southeast Asia in patients who were over two years of age, suggesting that there is a primary sensitizing agent (eg, aeroallergen) specific to the region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2042?source=see_link&amp;anchor=H13625674#H13625674\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Short-chain galactooligosaccharide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Egg-free influenza vaccine",
"    </span>",
"   </p>",
"   <p>",
"    A trivalent inactivated influenza vaccine (Optaflu), produced using cultured mammalian cells, was approved in Europe for use in adults beginning in the 2007-2008 influenza season. This same vaccine (called Flucelvax) was approved for individuals &ge;18 years of age for the 2012-2013 season by the US Food and Drug Administration in November 2012&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A second egg-free vaccine (Flublok), made using an insect virus (baculovirus) expression system and recombinant DNA technology, was approved in January 2013 by the FDA for adults aged 18 to 49 years. The efficacy and rates of serious adverse events seen with&nbsp;both egg-free&nbsp;vaccines were comparable to standard available influenza vaccines. For&nbsp;patients age 18 or older with egg allergy, we recommend administration of&nbsp;an age-appropriate,&nbsp;egg-free, trivalent inactivated influenza vaccine (TIV) rather than an egg-based inactivated vaccine. However, if the&nbsp;an egg-free&nbsp;vaccine is not readily available, immunization should proceed with egg-based vaccination with appropriate precautions (eg, observation for 30 minutes following vaccination in patients with mild allergic reactions to egg, and immunization supervised by an allergy specialist for patients with a history of severe egg allergic reactions).",
"    <br/>",
"    <br/>",
"    We recommend not using&nbsp;the egg-free vaccine in patients younger than age 18, since the",
"    <span class=\"nowrap\">",
"     baculovirus/recombinant",
"    </span>",
"    DNA-based vaccine appears to be less immunogenic in young children and the immunogenicity of these vaccines and the rates of side effects in this population are otherwise not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H8#H8\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Alternative methods of vaccine production'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link&amp;anchor=H9#H9\">",
"     \"Influenza vaccination in individuals with egg allergy\", section on 'Options for testing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMMUNODEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transplantation and gene therapy for adenosine deaminase deficiency",
"    </span>",
"   </p>",
"   <p>",
"    In the largest case series to date of patients with adenosine deaminase deficiency (ADD) who underwent hematopoietic cell transplantation (n = 106), the overall survival was over 80 percent in those who had a matched sibling or family donor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, survival for matched unrelated donor, haploidentical (mismatched at three of the six HLA loci) related donor, and mismatched unrelated donor transplantations was 67, 43, and 29 percent, respectively. Improvements in gene therapy since the late 1990s now make it a viable alternative to transplantation for some patients who do not have a matched sibling or family donor, based upon cumulative data from small case series. Of the over 40 patients who have undergone gene therapy since 2000, about 70 percent have shown successful outcomes. The importance of nonmyeloablative preconditioning was demonstrated in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/7\">",
"     7",
"    </a>",
"    ]. In this study, gene therapy was unsuccessful in the four patients who were treated without cytoreduction prior to gene therapy, but was successful in half of the subsequent six patients who did receive cytoreductive conditioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link&amp;anchor=H3#H3\">",
"     \"Adenosine deaminase deficiency: Treatment\", section on 'Hematopoietic cell transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link&amp;anchor=H11#H11\">",
"     \"Adenosine deaminase deficiency: Treatment\", section on 'Gene therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RHINITIS AND RHINOSINUSITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acupuncture for allergic rhinitis",
"    </span>",
"   </p>",
"   <p>",
"    In&nbsp;a randomized trial of&nbsp;over 400&nbsp;patients with seasonal allergic rhinitis, subjects were treated with eight weeks of acupuncture, sham acupuncture, or no additional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/8\">",
"     8",
"    </a>",
"    ]. All had access to rescue medication with cetirizine and oral glucocorticoids if response was inadequate. Symptom reduction was statistically greater with acupuncture&nbsp;compared with sham or rescue medication alone,&nbsp;although of uncertain clinical importance and equivalent to somewhat less than the effectiveness of one cetirizine tablet daily.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6953?source=see_link&amp;anchor=H15106287#H15106287\">",
"     \"Complementary and alternative therapies for allergic rhinitis and conjunctivitis\", section on 'Acupuncture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anti-IgE therapy for nasal polyposis",
"    </span>",
"   </p>",
"   <p>",
"    Nasal polyposis is currently managed with intranasal and systemic glucocorticoids, although many patients require repeated sinonasal surgeries to debulk polyp tissue despite these therapies. The anti-IgE drug, omalizumab, is approved only for the treatment of moderate to severe allergic asthma by most regulatory agencies, but has been studied in the treatment of other related diseases. In a randomized trial, 24 patients with both nasal polyposis and asthma (with and without sensitization to environmental allergens, including eight patients with aspirin exacerbated respiratory disease [AERD]), were treated with omalizumab or placebo for 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/9\">",
"     9",
"    </a>",
"    ].&nbsp;Omalizumab resulted in significant reduction in polyp size and improvement in symptom scores, compared&nbsp;with placebo. Similar responses were seen in patients with and without allergy and in those with AERD. Thus, omalizumab&nbsp;is a potential&nbsp;therapy for patients with both nasal polyposis and moderate to severe asthma, although practical issues, such as cost&nbsp;effectiveness and duration of treatment require further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link&amp;anchor=H983890166#H983890166\">",
"     \"Management of chronic rhinosinusitis\", section on 'Omalizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     URTICARIA AND ANGIOEDEMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Omalizumab for refractory chronic idiopathic urticaria",
"    </span>",
"   </p>",
"   <p>",
"    Omalizumab, a monoclonal antibody to IgE, has shown promise in several types of chronic urticaria. In&nbsp;a large multicenter trial, 323 patients with moderate-to-severe&nbsp;chronic idiopathic urticaria&nbsp;refractory to cetirizine&nbsp;were randomized to three different doses of omalizumab or placebo, given monthly for&nbsp;12 weeks&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/10\">",
"     10",
"    </a>",
"    ]. Mean itch scores decreased significantly in patients receiving&nbsp;the higher doses, and 23 to 53 percent of patients had complete resolution of symptoms.&nbsp;Following the treatment period, urticaria gradually returned in most patients over four months of observation, although not to initial levels of severity. These results are encouraging, although omalizumab is costly and only approved for the treatment of asthma in most countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=see_link&amp;anchor=H19#H19\">",
"     \"Chronic urticaria: Treatment of refractory symptoms\", section on 'Omalizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER GENERAL ALLERGY AND IMMUNOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Identification of a new major allergen in dust mite",
"    </span>",
"   </p>",
"   <p>",
"    For years, there have been two&nbsp;recognized major allergens in dust mite, Der p 1 and Der p 2.&nbsp;A third major allergen, Der p 23, was recently identified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/11\">",
"     11",
"    </a>",
"    ]. It is a protein found in the gut lining and fecal pellets of the D. pteronyssinus species of mite, which can become airborne upon excretion.&nbsp;This&nbsp;finding also validated a newer technique for identifying novel allergens, which&nbsp;involves screening&nbsp;cDNA libraries of allergenic substances with serum IgE antibodies from&nbsp;sensitized patients.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33175?source=see_link&amp;anchor=H6881138#H6881138\">",
"     \"Allergen sampling in the environment\", section on 'Dust mites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Novel device for epinephrine self-injection",
"    </span>",
"   </p>",
"   <p>",
"    A novel device for epinephrine self-injection is available in North America that is called Auvi-Q in US and Allerject in Canada. It is a rectangular cartridge, approximately the size and shape of a mobile phone and has audible instructions to guide the user through the self-injection process. Each device contains a single pediatric (0.15 mg) or adult (0.3 mg) dose of epinephrine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link&amp;anchor=H8#H8\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\", section on 'Available autoinjectors'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=see_link\">",
"     \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Proactive, intermittent therapy for long-term control of atopic dermatitis",
"    </span>",
"   </p>",
"   <p>",
"    The long-term control of skin inflammation is a major challenge in the management of patients with atopic dermatitis. The 2012 European and American guidelines&nbsp;for the treatment of atopic dermatitis recommend proactive, intermittent topical&nbsp;therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. After induction of remission with continuous topical therapy, twice weekly&nbsp;application of topical&nbsp;corticosteroids&nbsp;to eczema-prone areas may prevent relapses in both adults and children with atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H41442152#H41442152\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Prevention of relapses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Timing of venom immunotherapy injections",
"    </span>",
"   </p>",
"   <p>",
"    Venom immunotherapy (VIT) is highly effective for preventing recurrent",
"    <span class=\"nowrap\">",
"     anaphylaxis/systemic",
"    </span>",
"    allergic reactions to stings from bees, wasps, and other Hymenoptera insects. Following initial desensitization, VIT maintenance injections are given for a three to five year period in many cases. Most clinicians give maintenance injections at four to eight week intervals, although there is increasing evidence that the time between injections can be lengthened further in patients who have not had allergic reactions to the injections or anaphylaxis to subsequent stings. In an observational study, 186 patients meeting these criteria were given the choice of four to six weeks between injections or extended intervals (up to 12 to 16 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/14\">",
"     14",
"    </a>",
"    ]. In the group receiving injections at 12-week intervals, there was no increase in anaphylaxis with subsequent stings, while there were too few stings in the 16-week group to assess protection adequately. Thus, for patients who reach maintenance doses of VIT without systemic reactions to either the injections or to subsequent stings, the interval between maintenance injections can be extended to as long as 12 weeks, at the discretion of the allergist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H14#H14\">",
"     \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Interval between maintenance injections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mechanisms of drug hypersensitivity",
"    </span>",
"   </p>",
"   <p>",
"    The first unequivocal example of a type of drug hypersensitivity reaction described as &ldquo;pharmacologic interaction of drugs with immune receptors&rdquo; or the &ldquo;p-i concept&rdquo; has been described. The mechanism of abacavir hypersensitivity has been determined to involve binding of the drug to the antigen binding site of the HLA-B*57:01 molecule, which results in alteration of that site such that a different set of peptides is presented to T cells (",
"    <a class=\"graphic graphic_figure graphicRef66704 \" href=\"UTD.htm?13/57/14228\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24949/abstract/15\">",
"     15",
"    </a>",
"    ]. Since T cells are tolerant only to those MHC-restricted peptides to which they were exposed during development in the thymus, the presentation of alternate peptides is interpreted as foreign and can result in an allo- or autoimmune like T cell reaction. This explains the strong association between this HLA allele and abacavir hypersensitivity. The p-i concept was first proposed in the 1990s to explain T cell mediated reactions with strong HLA associations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link&amp;anchor=H7#H7\">",
"     \"Drug allergy: Pathogenesis\", section on 'Pharmacological interaction of drugs with immune receptors (the p-i concept)'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/1\">",
"      Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/2\">",
"      Vo TH, Le NH, Patel MS, et al. Acute allergic reactions in Vietnamese children after drinking a new milk product. Foodborne Pathog Dis 2012; 9:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/3\">",
"      Chiang WC, Huang CH, Llanora GV, et al. Anaphylaxis to cow's milk formula containing short-chain galacto-oligosaccharide. J Allergy Clin Immunol 2012; 130:1361.",
"     </a>",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/6\">",
"      Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood 2012; 120:3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/7\">",
"      Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012; 120:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/8\">",
"      Brinkhaus B, Ortiz M, Witt CM, et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med 2013; 158:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/9\">",
"      Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/10\">",
"      Maurer M, Ros&eacute;n K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/11\">",
"      Weghofer M, Grote M, Resch Y, et al. Identification of Der p 23, a Peritrophin-like Protein, as a New Major Dermatophagoides pteronyssinus Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. J Immunol 2013; 190:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/12\">",
"      Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/13\">",
"      Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/14\">",
"      Simioni L, Vianello A, Bonadonna P, et al. Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimen. Ann Allergy Asthma Immunol 2013; 110:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24949/abstract/15\">",
"      Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8363 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24949=[""].join("\n");
var outline_f24_23_24949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ASTHMA AND COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Mepolizumab in eosinophilic asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FOOD ALLERGY AND INTOLERANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      A second carbohydrate food allergen identified",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Egg-free influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMMUNODEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transplantation and gene therapy for adenosine deaminase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RHINITIS AND RHINOSINUSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acupuncture for allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anti-IgE therapy for nasal polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      URTICARIA AND ANGIOEDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Omalizumab for refractory chronic idiopathic urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER GENERAL ALLERGY AND IMMUNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Identification of a new major allergen in dust mite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Novel device for epinephrine self-injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Proactive, intermittent therapy for long-term control of atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Timing of venom immunotherapy injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mechanisms of drug hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8363\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8363|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/57/14228\" title=\"figure 1\">",
"      p i concept",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8363|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 1\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=related_link\">",
"      Adenosine deaminase deficiency: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33175?source=related_link\">",
"      Allergen sampling in the environment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=related_link\">",
"      Chronic urticaria: Treatment of refractory symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6953?source=related_link\">",
"      Complementary and alternative therapies for allergic rhinitis and conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_23_24950="Melomental folds";
var content_f24_23_24950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55290%7EDERM%2F80633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55290%7EDERM%2F80633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Melomental folds (marionette lines)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The facial lines extending from the corners of the mouth to the mandible are melomental folds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mental crease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A horizontal groove is present on the chin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24950=[""].join("\n");
var outline_f24_23_24950=null;
var title_f24_23_24951="Enalapril and hydrochlorothiazide: Drug information";
var content_f24_23_24951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enalapril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/51/27445?source=see_link\">",
"    see \"Enalapril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6156445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vaseretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F164890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vaseretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral: Enalapril 5-10 mg and hydrochlorothiazide 12.5-25 mg once daily (maximum: 40 mg/day [enalapril]; 50 mg/day [hydrochlorothiazide])",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to dosing in individual monographs; adjust for renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F164893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe renal failure: Avoid; loop diuretics are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5/12.5: Enalapril maleate 5 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10/25: Enalapril maleate 10 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaseretic&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10/25: Enalapril maleate 10 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9884439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Norpramin: Brand name for enalapril/hydrochlorothiazide [Portugal], but also the brand name for desipramine [U.S., Canada]; omeprazole [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6156447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enalapril, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; patients with hereditary or idiopathic angioedema; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2529336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use enalapril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use enalapril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use ACE inhibitors with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective). Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F164895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13829684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enalapril, enalaprilat, and hydrochlorothiazide can be detected in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F164885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Enalapril-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-12.5 mg (100): $107.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-25 mg (100): $119.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vaseretic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-25 mg (100): $375.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6156448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F164887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acesistem (IT);",
"     </li>",
"     <li>",
"      Actensil Plus (ES);",
"     </li>",
"     <li>",
"      Angiozide (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Biocronil (CO);",
"     </li>",
"     <li>",
"      Co-Hypace (PH);",
"     </li>",
"     <li>",
"      Co-Renitec (AE, AT, BE, BF, BG, BH, BJ, BR, CI, CY, CZ, EG, ET, FR, GH, GM, GN, GR, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NZ, OM, PE, PH, PK, QA, RU, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Co-Reniten (CH);",
"     </li>",
"     <li>",
"      Corenitec (AR, NL);",
"     </li>",
"     <li>",
"      Duopril (BR);",
"     </li>",
"     <li>",
"      Ecaprinil-D (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Enace-D (IN);",
"     </li>",
"     <li>",
"      Enalten-D (EC);",
"     </li>",
"     <li>",
"      Enap H (PL);",
"     </li>",
"     <li>",
"      Enap HL (SG);",
"     </li>",
"     <li>",
"      Esalfon-D (CN);",
"     </li>",
"     <li>",
"      Gliotenzide (SG);",
"     </li>",
"     <li>",
"      Innozide (GB, IE);",
"     </li>",
"     <li>",
"      Invozide (IN);",
"     </li>",
"     <li>",
"      Jiu Bao Ke (CL);",
"     </li>",
"     <li>",
"      Konveril Plus (TR);",
"     </li>",
"     <li>",
"      Landuet (TW);",
"     </li>",
"     <li>",
"      Lotrial D (AR, PY, UY);",
"     </li>",
"     <li>",
"      Naprizide (IL);",
"     </li>",
"     <li>",
"      Nariplus (KP);",
"     </li>",
"     <li>",
"      Presopril-D (DO);",
"     </li>",
"     <li>",
"      Renacor (DE);",
"     </li>",
"     <li>",
"      Renidur (PT);",
"     </li>",
"     <li>",
"      Renitec Comp (FI, NO);",
"     </li>",
"     <li>",
"      Renitec Plus (EE);",
"     </li>",
"     <li>",
"      Renitec Plus 20/6 (AU);",
"     </li>",
"     <li>",
"      Tenazide (ID);",
"     </li>",
"     <li>",
"      Vaseretic (CO);",
"     </li>",
"     <li>",
"      Vasetic (KP);",
"     </li>",
"     <li>",
"      Vasoretic (IT);",
"     </li>",
"     <li>",
"      Yi Shuang (CL);",
"     </li>",
"     <li>",
"      Zanipress (DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24951/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24951/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24951/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterens Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2008, 51(6):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24951/abstract-text/18413488/pubmed\" id=\"18413488\" target=\"_blank\">",
"        18413488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24951/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8734 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24951=[""].join("\n");
var outline_f24_23_24951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6156445\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164889\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164890\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164905\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164891\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164892\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164893\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822421\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164879\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164869\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164881\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9884439\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164903\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6156447\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529336\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164899\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164875\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164876\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164886\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164895\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13829684\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164885\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6156448\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164887\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164883\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/51/27445?source=related_link\">",
"      Enalapril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_23_24952="Omeprazole: Pediatric drug information";
var content_f24_23_24952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Omeprazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"    see \"Omeprazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/61/32725?source=see_link\">",
"    see \"Omeprazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      First&reg;-Omeprazole;",
"     </li>",
"     <li>",
"      PriLOSEC OTC&reg; [OTC];",
"     </li>",
"     <li>",
"      PriLOSEC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Omeprazole&reg;;",
"     </li>",
"     <li>",
"      Losec&reg;;",
"     </li>",
"     <li>",
"      Mylan-Omeprazole;",
"     </li>",
"     <li>",
"      PMS-Omeprazole;",
"     </li>",
"     <li>",
"      PMS-Omeprazole DR;",
"     </li>",
"     <li>",
"      ratio-Omeprazole;",
"     </li>",
"     <li>",
"      Sandoz-Omeprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastric Acid Secretion Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Proton Pump Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"      see \"Omeprazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants: GERD: 0.7 mg/kg/dose once daily reduced the percentage of time gastric and esophageal pH &lt;4, as well as the number of reflux episodes in 10 neonates [mean PMA: 36.1 weeks, (34-40 weeks)] in a double-blind, placebo-controlled trial (Omari, 2007); higher doses of 1-1.5 mg/kg/day have been reported (Gibbons, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents &le;16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GERD, ulcers, esophagitis: Manufacturer's recommendations: Children 1-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5 kg to &lt;10 kg: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10 kg to &le;20 kg: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;20 kg: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing: 1 mg/kg/dose once or twice daily; range of effective dosages in the literature: 0.2-3.5 mg/kg/day (Hassall, 2000; Zimmermann, 2001). Higher doses may be necessary in children between 1-6 years of age due to increased metabolic clearance (Andersson, 2000). In critically ill children to maintain gastric pH &gt;5, administration every 6-8 hours may be necessary (1.5-2 mg/kg/day) (Kaufman, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjunctive therapy of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     (in combination with antibiotic therapy either clarithromycin or clarithromycin and amoxicillin) in children (Gottrand, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15-30 kg: 10 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;30 kg: 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &gt;16 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Active duodenal ulcer: 20 mg/day for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastric ulcers: 40 mg/day for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GERD or severe erosive esophagitis: 20 mg/day for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance of healing of erosive esophagitis: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pathological hypersecretory conditions: 60 mg/day to start; doses up to 120 mg 3 times/day have been administered; administer daily doses &gt;80 mg in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Frequent heartburn (&ge;2 times/week): 20 mg/day for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjunctive therapy of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     (in combination with antibiotic therapy either clarithromycin or clarithromycin and amoxicillin): 20 mg twice daily for 10 days (in combination with two antibiotics) or 40 mg once daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If an ulcer is present at the time of initial therapy, the recommended duration of treatment should be extended an additional 18 days (dual therapy) or 14 days (triple therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Bioavailability is increased with chronic liver disease. Consider dosage adjustment, especially for maintenance healing of erosive esophagitis. Specific guidelines are not available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PriLOSEC&reg;: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PriLOSEC&reg;: 2.5 mg/packet (30s); 10 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&reg;-Omeprazole: 2 mg/mL (90 mL, 150 mL, 300 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PriLOSEC OTC&reg;: 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes granules for suspension",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15241703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Prilosec&reg; capsules, granules for oral suspension:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322359.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322359.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsule: Should be swallowed whole; do not chew or crush. Delayed release capsule may be opened and contents added to 1 tablespoon of applesauce and pellets swallowed whole (use immediately after adding to applesauce). Follow with a cool glass of water. Applesauce should not be heated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral suspension: Empty the contents of the 2.5 mg packet or 10 mg packet into 5 mL or 15 mL of water, respectively; stir, the suspension should be left to thicken for 2-3 minutes and administered within 30 minutes. If any material remains after administration, add more water, stir, and administer immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet: Should be swallowed whole; do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nasogastric tube administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsule: When using capsules to extemporaneously prepare a solution for NG administration, the manufacturers of Prilosec&reg; recommend the use of an acidic juice for preparation and administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral suspension: Add 5 mL of water to a catheter-tipped syringe and then add the contents of a 2.5 mg packet (or 15 mL of water for the 10 mg packet), shake the suspension well and leave to thicken for 2-3 minutes. Administer within 30 minutes of reconstitution. Use an NG or gastric tube that is a French size 6 or larger; flush the syringe and tube with water.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Omeprazole stability is a function of pH; it is rapidly degraded in acidic media but has acceptable stability under alkaline conditions. Each capsule of omeprazole contains enteric-coated granules to prevent omeprazole degradation by gastric acidity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delayed release capsules: Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from moisture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and maintenance of healing of severe erosive esophagitis (grade 2 or above) (FDA approved for children &ge;1 year and adults); treatment of symptomatic gastroesophageal reflux disease (GERD) (FDA approved for children &ge;1 year and adults); treatment  of duodenal and gastric ulcers including active duodenal ulcer, active benign gastric ulcers, peptic ulcer disease, and adjunctive treatment of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     (FDA approved in adults); treatment of pathological hypersecretory conditions; treatment of peptic ulcer disease; relief of frequent heartburn (OTC products)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Omeprazole may be confused with aripiprazole, fomepizole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PriLOSEC&reg; may be confused with Plendil&reg;, Prevacid&reg;, predniSONE, prilocaine, Prinivil&reg;, Proventil&reg;, PROzac&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Losec [multiple international markets] may be confused with Lasix brand name for furosemide [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Medral [Mexico] may be confused with Medrol brand name for methylprednisolone [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norpramin: Brand name for omeprazole [Spain], but also the brand name for desipramine [U.S., Canada] and enalapril/hydrochlorothiazide [Portugal]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F203613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, acid regurgitation, constipation, diarrhea, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal swelling, abnormal dreams, aggression, agitation, agranulocytosis, alkaline phosphatase increased, allergic reactions, alopecia, ALT increased, anaphylaxis, anemia, angina, angioedema, anorexia, anxiety, apathy, AST increased, atrophic gastritis, benign gastric polyps, bilirubin increased, blurred vision, bradycardia, bronchospasm, chest pain, cholestatic hepatitis,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), confusion, creatinine increased, depression, double vision, dry skin, epistaxis, erythema multiforme, esophageal candidiasis, fatigue, fecal discoloration, fever, fracture, gastroduodenal carcinoids, GGT increased, glycosuria, gynecomastia, hallucinations, hematuria, hemolytic anemia, hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatitis, hepatocellular hepatitis, hyperhidrosis, hypersensitivity, hypertension, hypoglycemia, hypomagnesemia, hyponatremia, insomnia, interstitial nephritis, irritable colon, jaundice, joint pain, leg pain, leukocytosis, leukopenia, liver disease (hepatocellular, cholestatic, mixed), malaise, microscopic colitis, microscopic pyuria, mucosal atrophy (tongue), muscle cramps, muscle weakness, myalgia, nervousness, neutropenia, ocular irritation, optic atrophy, optic neuritis, optic neuropathy (anterior ischemic), osteoporosis-related fracture, pain, palpitation, pancreatitis, pancytopenia, paresthesia, peripheral edema, petechiae, pharyngeal pain, photosensitivity, pneumonia, proteinuria, pruritus, psychiatric disturbance, purpura, skin inflammation, sleep disturbance, somnolence, Stevens-Johnson syndrome, stomatitis, tachycardia, taste perversion, testicular pain, thrombocytopenia, tinnitus, toxic epidermal necrolysis, tremor, urinary frequency, urinary tract infection, urticaria, vertigo, weight gain, xerophthalmia, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to omeprazole, substituted benzimidazole proton pump inhibitors (eg, esomeprazole, lansoprazole), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability may be increased in patients with hepatic dysfunction or patients of Asian descent; consider dosage reductions, especially for maintenance healing of erosive esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy. An increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy; patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk. Hypomagnesemia has been reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy), and may be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of omeprazole may be necessary; magnesium concentrations typically return to normal within 1 week of stopping. Atrophic gastritis has been reported occasionally in gastric corpus biopsies from patients treated long-term with omeprazole. Symptomatic response to therapy does not preclude the presence of GI malignancy. Use of gastric acid inhibitors, including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). Serum chromogranin A (CgA) levels may be falsely elevated if assessed while on omeprazole causing diagnostic misinterpretation if a neuroendocrine tumor suspected.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     First&reg;-Omeprazole powder for oral suspension contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; use oral suspension containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F203601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2A6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C19 (moderate), CYP2C9 (moderate), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Proton Pump Inhibitors may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Omeprazole may enhance the adverse/toxic effect of Cilostazol. Omeprazole may increase the serum concentration of Cilostazol. Omeprazole may increase the serum concentration of  OPC-13015, an active metabolite of Cilostazol.  Management: Monitor for increased effects of cilostazol when coadministered with omeprazole. Consider a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Omeprazole may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Escitalopram: Omeprazole may increase the serum concentration of Escitalopram.  Management: Monitor for increased escitalopram toxicity with concomitant use of omeprazole. Escitalopram dosing recommendations may differ between international labelings in regards to concomitant use of omeprazole. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Proton Pump Inhibitors may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Proton Pump Inhibitors may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1060720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 25% reduction in peak plasma concentration was measured when the 20 mg capsule was mixed with applesauce; there was no change in AUC; the clinical significance is unknown. There was no change in peak plasma level or AUC when the 40 mg capsule was mixed with applesauce.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Based on data collected by the Teratogen Information System (TERIS), it was concluded that therapeutic doses used during pregnancy would be unlikely to pose a substantial teratogenic risk (quantity/quality of data: fair). Because the possibility of harm still exists, the manufacturer recommends use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses gastric acid secretion by inhibiting the parietal cell membrane enzyme (H",
"     <sup>",
"      +",
"     </sup>",
"     /K",
"     <sup>",
"      +",
"     </sup>",
"     )-ATPase or proton pump; demonstrates antimicrobial activity against",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 72 hours; 50% of maximum effect at 24 hours; after stopping treatment, secretory activity gradually returns over 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum secretory inhibition: 4 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C19 primarily and to a lesser extent via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive); saturable first pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 30% to 40%; improves slightly with repeated administration; increased in Asians and those with hepatic disease; excreted into breast milk (peak concentration in breast milk &lt;7% of corresponding peak plasma concentration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 0.5-1 hour; chronic hepatic disease: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 0.5-3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 500-600 mL/minute; chronic hepatic disease: 70 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Half-life and AUC were significantly reduced for omeprazole suspension when compared with an equivalent dose via the commercially available capsule in 7 adults (Song, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/61/32725?source=see_link\">",
"      see \"Omeprazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; do not chew or crush granules",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F203537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2 mg/mL oral omeprazole solution (Simplified Omeprazole Solution) may be made with five omeprazole 20 mg delayed release capsules and 50 mL sodium bicarbonate 8.4%. Empty capsules into beaker. Add sodium bicarbonate solution. Gently stir (about 15 minutes) until a white suspension forms. Transfer to amber-colored syringe or bottle. Stable for 14 days at room temperature or for 30 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     DiGiacinto JL, Olsen KM, Bergman KL, et al, &ldquo;Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes,&rdquo;",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 2000, 34(5):600-5.",
"     <span class=\"pubmed-id\">",
"      10852086",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Quercia R, Fan C, Liu X, et al, &ldquo;Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1997, 54(16):1833-6.",
"     <span class=\"pubmed-id\">",
"      9269520",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Sharma V, &ldquo;Comparison of 24-hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1999, 56(23 Suppl 4):18-21.",
"     <span class=\"pubmed-id\">",
"      10597120",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andersson T, Hassall E, Lundborg P, et al, &ldquo;Pharmacokinetics of Orally Administered Omeprazole in Children. International Pediatric Omeprazole Pharmacokinetic Group,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2000, 95(11):3101-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/11095324 /pubmed\" id=\"11095324 \" target=\"_blank\">",
"        11095324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons TE and Gold BD, &ldquo;The Use of Proton Pump Inhibitors in Children: A Comprehensive Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(1):25-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/12513104/pubmed\" id=\"12513104\" target=\"_blank\">",
"        12513104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gottrand F, Kalach N, Spyckerelle C, et al, &ldquo;Omeprazole Combined With Amoxicillin and Clarithromycin in the Eradication of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      in Children With Gastritis: A Prospective Randomized Double-Blind Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(5):664-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/11713443/pubmed\" id=\"11713443\" target=\"_blank\">",
"        11713443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gunasekaran TS and Hassall EG, &ldquo;Efficacy and Safety of Omeprazole for Severe Gastroesophageal Reflux in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(1):148-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/ 8320610 /pubmed\" id=\" 8320610 \" target=\"_blank\">",
"        8320610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hassall E, Israel D, Shepherd R, &ldquo;Omeprazole for Treatment of Chronic Erosive Esophagitis in Children: A Multicenter Study of Efficacy, Safety, Tolerability and Dose Requirements. International Pediatric Omeprazole Study Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2000, 137(6):800-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/11113836/pubmed\" id=\"11113836\" target=\"_blank\">",
"        11113836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane DL, &ldquo;Administration of Omeprazole (Prilosec&trade;) in the Atypical Patient,&rdquo;",
"      <i>",
"       Int J Pharm Compounding",
"      </i>",
"      , 1997, 1(1):13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kato S, Ebina K, Fujii K, et al, &ldquo;Effect of Omeprazole in the Treatment of Refractory Acid-Related Diseases in Childhood: Endoscopic Healing and Twenty-Four Hour Intragastric Acidity,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 128(3):415-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/8774516 /pubmed\" id=\"8774516 \" target=\"_blank\">",
"        8774516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman SS, Lyden ER, Brown CR, et al, &ldquo;Omeprazole Therapy in Pediatric Patients After Liver and Intestinal Transplantation,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2002, 34(2):194-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/11840039/pubmed\" id=\"11840039\" target=\"_blank\">",
"        11840039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Omari TI, Haslam RR, Lundborg P, et al, \"Effect of Omeprazole on Acid Gastroesophageal Reflux and Gastric Acidity in Preterm Infants With Pathological Acid Reflux,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2007, 44(1):41-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/17204951/pubmed\" id=\"17204951\" target=\"_blank\">",
"        17204951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Song JC, Quercia RA, Fan C, et al, &ldquo;Pharmacokinetic Comparison of Omeprazole Capsules and a Simplified Omeprazole Suspension,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2001, 58(8):689-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/11329761/pubmed\" id=\"11329761\" target=\"_blank\">",
"        11329761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimmermann AE, Walters JK, Katona BG, et al, &ldquo;A Review of Omeprazole Use in the Treatment of Acid-Related Disorders in Children,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2001, 23(5):660-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/23/24952/abstract-text/11394727/pubmed\" id=\"11394727\" target=\"_blank\">",
"        11394727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12658 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24952=[""].join("\n");
var outline_f24_23_24952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572479\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203557\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203558\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060710\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060704\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203531\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203517\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241703\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060713\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060707\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060712\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203615\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203613\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060703\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060702\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203601\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203526\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060720\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203528\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203542\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060701\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060716\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060717\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060709\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203537\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12658|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=related_link\">",
"      Omeprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/61/32725?source=related_link\">",
"      Omeprazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_23_24953="Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment";
var content_f24_23_24953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/23/24953/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24953/contributors\">",
"     Matthew Tews, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24953/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/23/24953/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24953/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24953/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/23/24953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/23/24953/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/23/24953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanoposthitis describes inflammation of the glans penis and the foreskin (prepuce) in uncircumcised males (",
"    <a class=\"graphic graphic_picture graphicRef67724 \" href=\"UTD.htm?43/35/44606\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61240 \" href=\"UTD.htm?12/30/12772\">",
"     picture 2",
"    </a>",
"    ). Although the etiology is multifactorial in children, balanoposthitis typically results from poor hygiene that is sometimes complicated by secondary infection. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Irritant nonspecific balanoposthitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With general treatment, most patients with balanoposthitis have complete resolution of symptoms. In selected cases, topical or oral antibiotic therapy may be indicated. Pediatric urologic consultation is reserved for patients with acute urinary obstruction, prolonged and refractory disease course, recurrence, or development of pathologic phimosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410341#H172410341\">",
"     \"Care of the uncircumcised penis\", section on 'Pathologic phimosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Balanitis, inflammation of the glans penis only, often occurs in conjunction with diaper dermatitis in young boys, both circumcised and uncircumcised. Local care and topical treatment aimed at the most likely etiology is rapidly curative and similar to balanoposthitis.",
"   </p>",
"   <p>",
"    Balanitis and balanoposthitis must be differentiated from lesions that are sexually transmitted, indicative of systemic disease, or precancerous. These lesions are more common in adolescents and adults. However, vigilance is required to recognize sexually transmitted infection in prepubertal victims of child abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will address the clinical manifestations, diagnosis, and treatment of balanoposthitis in children. Epidemiology and pathogenesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=see_link\">",
"     \"Balanoposthitis in children: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal development of the uncircumcised penis and routine care in children is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link\">",
"     \"Care of the uncircumcised penis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common symptoms in patients with balanoposthitis include genital itching, genital irritation and pain, penile discharge, groin rash, and dysuria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In infants, penile inflammation may be the cause of excessive crying.",
"   </p>",
"   <p>",
"    In addition to the above, uncircumcised prepubertal boys with balanoposthitis may demonstrate relative phimosis, that is, inability to retract the foreskin to the extent possible prior to the illness.",
"   </p>",
"   <p>",
"    The patient or parents may note scarring or changed appearance when balanoposthitis is longstanding.",
"   </p>",
"   <p>",
"    Inability to void occurs rarely but warrants urgent attention. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Relief of urinary obstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several additional historical elements help identify the underlying cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circumcision &ndash; Circumcised patients are less likely to have genital inflammation, and, by definition do not have posthitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hygiene &ndash; Poor genital hygiene is associated with nonspecific balanoposthitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Irritant use &ndash; Overly aggressive cleaning with soap and water can lead to irritant contact balanoposthitis, especially in patients with atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/6\">",
"       6",
"      </a>",
"      ]. Sexually active adolescents may develop balanoposthitis caused by contact allergy to latex condoms, condom lubricants, or spermicides.",
"     </li>",
"     <li>",
"      Urethral drainage &ndash; In the uncircumcised male, differentiation of urethral drainage from preputial drainage on physical examination helps distinguish gonorrheal or chlamydial urethritis from balanoposthitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1\">",
"       1",
"      </a>",
"      ]. However, sexually active patients with balanoposthitis should undergo evaluation for sexually transmitted disease regardless of the source of drainage. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical examination'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H7#H7\">",
"       \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Evaluation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sexually transmitted diseases in a prepubertal child strongly indicate sexual abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of sexual abuse in children and adolescents\", section on 'Presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medication use &ndash; Patients with recent antibiotic use are at greater risk for Candidal balanoposthitis. Exposure to certain drugs, such as tetracyclines, salicylates, phenacetin, phenolphthalein, and some sedative hypnotic drugs, increases the risk of a fixed drug eruption [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recent or current Group A Streptococcal infection or exposure",
"     </li>",
"     <li>",
"      Past medical history &ndash; Several aspects of past medical history should be specifically sought:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adults with a history of diabetes,",
"      <span class=\"nowrap\">",
"       HIV/AIDS,",
"      </span>",
"      malignancy, or any other immunosuppressive states are at higher risk of infections, including balanoposthitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of arthritis, diarrhea or eye complaints may have penile inflammation as a component of reactive arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prior history of balanoposthitis increases the risk of inflammatory phimosis and the need for referral to a pediatric urologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family history &ndash; Eczema and psoriasis may predispose to balanoposthitis and represent skin conditions that can cause other genital lesions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Sexual history &ndash; A social history that covers sexual activity should be elicited from all adolescents with genital complaints. This history should cover sexual practices, symptoms in the sexual partner, and prior history of a sexually transmitted disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H8#H8\">",
"       \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Sexual history'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H9#H9\">",
"       \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Condom use raises the possibility of irritant penile inflammation from contact allergy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on examination of the genitalia include erythema, edema, preputial swelling, exudate, foul odor, scarring between the glans and prepuce, and phimosis (",
"    <a class=\"graphic graphic_picture graphicRef67724 \" href=\"UTD.htm?43/35/44606\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/2\">",
"     2",
"    </a>",
"    ]. These findings of inflammation differentiate pathologic preputial discharge from physiologic smegma secretion. In addition, inguinal lymphadenopathy or lymphadenitis may accompany balanoposthitis.",
"   </p>",
"   <p>",
"    Meatal stenosis and phimosis may accompany chronic balanoposthitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H172410341#H172410341\">",
"     \"Care of the uncircumcised penis\", section on 'Pathologic phimosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urethral discharge is assessed by milking the length of the urethra from the base to the tip and identifies a concomitant urethritis in sexually active patients or victims of sexual abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'History'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Genital ulcers suggest a sexually transmitted infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H11#H11\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'STD clinical patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital appearance may point toward the causative agent with certain types of infectious balanoposthitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptococcal balanoposthitis is characterized by a fiery red surface and a moist, glistening transudate or exudate under the prepuce in conjunction with an existing or recent Group A Streptococcal infection at another site, such as the pharynx (",
"      <a class=\"graphic graphic_picture graphicRef61240 \" href=\"UTD.htm?12/30/12772\">",
"       picture 2",
"      </a>",
"      ). Streptococcal balanoposthitis may also rarely accompany perianal streptococcal disease and guttate psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1,12-14\">",
"       1,12-14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H11#H11\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Guttate psoriasis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Group A streptococcus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Candidal balanoposthitis is associated with generalized erythema, fissuring, eroded papules, and a whitish discharge. General skin examination may reveal satellite lesions and other characteristics of Candidal infection. Occasionally there may be vesicular lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/7,15,16\">",
"       7,15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link\">",
"       \"Overview of diaper dermatitis in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anaerobic balanoposthitis presents with superficial erosions, foul smelling subpreputial discharge, preputial edema, and inguinal adenitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/7,17\">",
"       7,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A tender, palpable bladder indicates the complication of urinary retention caused by urinary obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ocular uveitis, oral ulceration, and arthritis in the context of balanoposthitis suggest reactive arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful history and physical examination often identify nonspecific balanoposthitis (eg, due to poor hygiene) or irritant contact balanoposthitis as the most likely etiology in young boys. In these patients, who usually do not have induration, exudate, or urethral discharge, further testing is unnecessary and empiric treatment based upon clinical diagnosis is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=see_link\">",
"     \"Balanoposthitis in children: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Virtually all other young boys, adolescents, and adults require laboratory testing prior to treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef76384 \" href=\"UTD.htm?23/41/24209\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for Group A Streptococcal disease and a preputial swab for KOH microscopy, Gram stain, and bacterial culture are typically done in adolescents and adults. In addition, children with possible Group A Streptococcal disease, sexually transmitted infection, or uncertain etiology should undergo appropriate diagnostic evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef76384 \" href=\"UTD.htm?23/41/24209\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1,2,4,5,19\">",
"     1,2,4,5,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young boys with GAS exposure, pharyngitis, impetigo, perianal redness, or guttate psoriasis accompanying balanoposthitis should have a culture sent for Group A, beta-hemolytic Streptococcus (GAS) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1,20,21\">",
"       1,20,21",
"      </a>",
"      ]. In this setting, pharyngeal culture is not always positive and culture of preputial drainage is recommended. In addition, we suggest GAS culture in young boys whose penile inflammation is not responding to general therapy.",
"      <br/>",
"      <br/>",
"      As mentioned, GAS culture should be obtained in most adolescents and adults because of possible acquisition during oral-genital contact [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Rapid antigen testing of foreskin drainage for GAS utilizing kits designed for pharyngeal testing has been proposed. However, no data exist concerning the reliability of this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1\">",
"       1",
"      </a>",
"      ]. A confirmatory preputial culture for GAS should always accompany a GAS rapid antigen test of the foreskin.",
"     </li>",
"     <li>",
"      Patients with balanoposthitis who are sexually active, have genital ulcers, or demonstrate urethral drainage should have appropriate specimens obtained to evaluate for the presence of sexually transmitted infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"       \"Genital Chlamydia trachomatis infections in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"       \"Approach to the patient with genital ulcers\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link\">",
"       \"Trichomonas vaginalis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"       \"Diagnosis of gonococcal infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of a sexually transmitted disease in a child or adolescent requires further evaluation for sexual abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"       \"Evaluation of sexual abuse in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urine dipstick for glucose and ketones should be performed in patients with clinical findings suggestive of diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=see_link\">",
"       \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4506?source=see_link\">",
"       \"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pathologic diagnosis is desirable in any patient who does not respond to appropriate therapy within four to six weeks. These patients warrant referral to a pediatric urologist.",
"   </p>",
"   <p>",
"    In pediatric patients, unresponsive or recurrent balanoposthitis is a potential indication for circumcision. Pathologic evaluation of the prepuce is important to look for balanitis xerotica obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/22\">",
"     22",
"    </a>",
"    ]. This entity may involve the urethral meatus, require reconstructive urologic surgery, and is considered precancerous in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=see_link\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older adolescents and adults, genital biopsy is an alternative to circumcision for establishing a diagnosis. [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/2,6,23,24\">",
"     2,6,23,24",
"    </a>",
"    ]. While safe, genital biopsy does not always establish a specific diagnosis; in one series from 14 genitourinary clinics in the United Kingdom, over 20 percent of genital biopsy specimens in men showed non-specific balanitis (balanoposthitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following genital dermatoses may masquerade as or coexist with balanoposthitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/7-9,19,22,25\">",
"     7-9,19,22,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psoriasis, especially inverse psoriasis, may affect intertriginous areas including the inguinal, perineal, and genital regions. This variant can easily be misdiagnosed as a fungal or bacterial infection since there is frequently no visible scaling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Inverse psoriasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nummular eczema consists of intensely pruritic patches of eczematous dermatitis, each showing evidence of papules, scaling, slight crusting, and some serous oozing on close inspection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of dermatitis\", section on 'Nummular dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genital lichen planus in males presents with violaceous papules on the glans penis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link&amp;anchor=H12#H12\">",
"       \"Lichen planus\", section on 'Genital lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Circinate erosive balanitis appears as a circular plaque that extends onto the edge of the penis and foreskin but may be indistinguishable from other forms of balanoposthitis (",
"      <a class=\"graphic graphic_picture graphicRef62093 \" href=\"UTD.htm?5/9/5267\">",
"       picture 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Balanitis xerotica obliterans is the male analog of lichen sclerosus et atrophicus, and is characterized by white atrophic plaques on the glans and prepuce [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/22,27\">",
"       22,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=see_link\">",
"       \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fixed drug eruption is characterized acutely by erythematous and edematous plaques with a grayish center or frank bullae, and chronically by a dark postinflammatory pigmentation. The defining features of this eruption include the postinflammatory hyperpigmentation and the recurrence of lesions at exactly the same site with drug reexposure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H11#H11\">",
"       \"Drug eruptions\", section on 'Fixed drug eruption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human papillomavirus infection occurs as single or multiple papules on the preputial cavity (glans penis, coronal sulcus, frenulum, and inner aspect of the foreskin) in uncircumcised males.",
"     </li>",
"     <li>",
"      Scabies is suggested by a small, erythematous, nondescript papule, often excoriated and tipped with blood crusts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"       \"Scabies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few randomized controlled trials that evaluate the treatment of balanoposthitis. Thus, therapeutic recommendations are made by consensus and by clinical experience as reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/2\">",
"     2",
"    </a>",
"    ]. Proper management depends upon addressing the most likely underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Relief of urinary obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are unable to void because of severe penile and preputial edema require urgent bladder catheterization and pediatric urology consultation. If obstruction recurs or if initial bladder catheterization is unsuccessful, then the patient may undergo dorsal slit procedure or incision of the constricting band of phimotic foreskin (",
"    <a class=\"graphic graphic_figure graphicRef61427 \" href=\"UTD.htm?40/31/41458\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/28\">",
"     28",
"    </a>",
"    ]. Circumcision usually follows this emergency surgery once inflammation has subsided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should receive local care instructions that will reestablish physiologic function of the foreskin and help prevent future occurrences. These instructions consist of reinforcement of proper hygiene, avoidance of forced retraction of the foreskin in the young boy, and avoidance of irritants. In children, balanoposthitis typically resolves in three to five days after institution of proper hygiene (",
"    <a class=\"graphic graphic_picture graphicRef61428 \" href=\"UTD.htm?39/30/40416\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link\">",
"     \"Care of the uncircumcised penis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H9377172#H9377172\">",
"     \"Care of the uncircumcised penis\", section on 'Routine care and hygiene'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H86213584#H86213584\">",
"     \"Care of the uncircumcised penis\", section on 'Foreskin retraction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Irritant nonspecific balanoposthitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sitz baths &ndash; Soaking of the penis in warm water containing a weak salt solution two to three times per day is advised while inflammation persists.",
"     </li>",
"     <li>",
"      Reinforcement of proper hygiene &ndash; Parents should be instructed to clean between the foreskin and glans with a Q-tip and irrigate with clean water regularly until the inflammation resolves [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. For those patients with a tight foreskin or physiologic phimosis, irrigation can be demonstrated by medical personnel with the cut tubing of a butterfly device inserted gently into the preputial sulcus. Alternatively, a 5 French or 8 French feeding tube may be used [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Once inflammation has resolved, regular bathing of the area in clean water should be sufficient. Parents should be advised to avoid soap and not to attempt to clean under the foreskin. They should also be counseled to avoid forceful retraction of the foreskin in young, uncircumcised boys.",
"     </li>",
"     <li>",
"      Older patients with a fully retractile foreskin should thoroughly but gently clean underneath the prepuce with water.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of irritants &ndash; Patients",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parents should not use soap to clean under the foreskin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, the medical provider should counsel the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parents to avoid exposure of the affected area to bubble bath oils, talc powder, and other irritants. Adolescents and adults should avoid sexual activity while receiving treatment for balanoposthitis.",
"     </li>",
"     <li>",
"      Antibiotic ointment &ndash; Empirical application of topical antibiotic ointment (eg, Polysporin,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33779?source=see_link\">",
"       Bacitracin",
"      </a>",
"      ) four times daily or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"       mupirocin",
"      </a>",
"      cream (Bactroban) twice a day helps reduce dysuria and may prevent secondary bacterial balanoposthitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/5\">",
"       5",
"      </a>",
"      ]. Ointments that contain",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"       neomycin",
"      </a>",
"      may cause contact dermatitis and should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Irritant contact balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This condition is marked by excessive cleansing of the penis and foreskin, often in a patient with atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/6\">",
"     6",
"    </a>",
"    ]. Occasionally, irritant contact balanoposthitis results from exposure to a specific allergen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of precipitants &ndash; Any identified precipitants should be avoided, especially soaps. Spermicides and condom lubricants are common culprits in older adolescents and adults.",
"     </li>",
"     <li>",
"      Application of emollients &ndash; Aqueous creams, such as Keri, Eucerin lotion, Aqueous cream, or BP (available in the United Kingdom) should be used as a soap substitute after gentle cleansing. Creams containing parabens preservatives are associated with sensitization and should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical corticosteroids &ndash; Low potency topical steroids, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      1 percent cream, may be applied sparingly twice daily for one week. Topical steroids are contraindicated in untreated infections or for continuous prophylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fixed drug eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;These penile lesions resolve once the offending medication (tetracyclines, salicylates, phenacetin, phenolphthalein, or sedative hypnotic agent) is discontinued. Topical steroids, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1 percent cream, applied sparingly twice a day for seven days speeds recovery. Severe cases may be treated with an oral course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    with a tapering dose over 10 to 14 days. Cases associated with Stevens-Johnson syndrome require an intensive approach that addresses the multisystem effects of this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H11#H11\">",
"     \"Drug eruptions\", section on 'Fixed drug eruption'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infectious balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper treatment depends on identifying the correct causative pathogen and institution of general treatment measures. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Irritant nonspecific balanoposthitis'",
"    </a>",
"    above.) In young children, presumptive topical antifungal therapy can be used in cases associated with diaper dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/5\">",
"     5",
"    </a>",
"    ]. Older children, adolescents, and adults should have therapy guided by appropriate laboratory studies. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Laboratory testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Candidal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with clinical evidence of concomitant Candidal infection, topical antifungal agents are applied to the affected area twice daily for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Parents should be advised to continue topical application for the full treatment course, even if the foreskin appears healed, to prevent recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link\">",
"     \"Overview of diaper dermatitis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Commonly used agents include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34720?source=see_link\">",
"     clotrimazole",
"    </a>",
"    1 percent cream, miconazole 2 percent cream,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"     nystatin",
"    </a>",
"    cream 100,000",
"    <span class=\"nowrap\">",
"     units/gm",
"    </span>",
"    if infection is resistant or if the patient has an allergy to imidazoles, and topical imidazole (clotrimazole or miconazole) combined with one percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    cream if marked inflammation is present [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single oral dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    may be used in patients with diabetes or with severe, recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A two week course of topical treatment is also appropriate for adolescents and adults with typical clinical findings and potassium hydroxide microscopy that shows hyphae and budding yeast. Sexual partners require evaluation and treatment to prevent recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young children, proper hygiene in conjunction with empirical application of topical antibiotic ointment (Polysporin,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33779?source=see_link\">",
"     Bacitracin",
"    </a>",
"    ) four times daily or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    cream (Bactroban) twice a day adequately treats most bacterial balanoposthitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/5\">",
"     5",
"    </a>",
"    ]. Ointments that contain",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"     neomycin",
"    </a>",
"    may cause contact dermatitis and should be avoided.",
"   </p>",
"   <p>",
"    Systemic antibiotics are employed to treat Group A Streptococcal infection, anaerobic infection, Staphylococcus aureus infection, and sexually transmitted infection.",
"   </p>",
"   <p>",
"    Sexually transmitted diseases in a prepubertal child strongly indicate sexual abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group A Streptococcal balanoposthitis &ndash; Treatment is the same as for Group A Streptococcal pharyngitis: oral antibiotics for ten days. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment and prevention of streptococcal tonsillopharyngitis\", section on 'Antibiotics for group A streptococcus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anaerobic balanoposthitis &ndash; Common isolates include Gardnerella vaginalis and Bacteroides species.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (15 to 35",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses) is the most effective treatment for anaerobic infections and should be given in the oral form for one week [",
"      <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/17\">",
"       17",
"      </a>",
"      ]. Oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      is an alternative. Ampicillin-clavulanate (Augmentin) 80",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose: 3 grams of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      ) in two to three divided doses for one week is an alternative for infections caused by Bacteroides species but not Gardnerella vaginalis infections. Clindamycin cream may be used for mild infections to be applied twice daily until resolved. If sexual transmission is suspected, then the patient's sexual partner(s) should be screened.",
"     </li>",
"     <li>",
"      Staphylococcal balanoposthitis &ndash; Children with Staphylococcus aureus balanoposthitis should receive oral antibiotics that will cover community acquired methicillin-resistant Staphylococcus aureus (MRSA) infection. Parenteral therapy is suggested if hospital acquired MRSA infection is suspected or if the patient is immunocompromised. Therapy should be tailored to pathogen sensitivities once they are available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Antimicrobial agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gonorrheal balanoposthitis &ndash; Therapy is the same as for gonococcal urethritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"       \"Treatment of uncomplicated gonococcal infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chlamydial balanoposthitis &ndash; Treatment mirrors that of non-gonococcal urethritis (NGU). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=see_link\">",
"       \"Treatment of Chlamydia trachomatis infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Syphilitic balanoposthitis &ndash; Management is based on the stage of syphilis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H26#H26\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Viral balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital herpes and genital human papillomavirus (Condylomata acuminata) infections may occur through self inoculation or sexual contact and are difficult to eradicate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=see_link\">",
"     \"Prevention of genital herpes virus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Protozoan balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichomonas vaginalis and Entamoeba histolytica balanoposthitis are treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=see_link&amp;anchor=H13#H13\">",
"     \"Trichomonas vaginalis\", section on 'Treatment'",
"    </a>",
"    .) Entamoeba histolytica balanoposthitis also requires treatment with a luminal amebicide such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/44/26306?source=see_link\">",
"     iodoquinol",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/55/9075?source=see_link\">",
"     paromomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients respond to general care augmented by appropriate topical therapy within seven days. Up to 10 percent of patients have recurrence of balanoposthitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute urinary obstruction, prolonged and refractory disease course, recurrence, or development of true phimosis require referral to a pediatric urologist for pathologic diagnosis and treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef76384 \" href=\"UTD.htm?23/41/24209\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In pediatric patients, unresponsive or recurrent balanoposthitis is a potential indication for circumcision. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathologic diagnosis'",
"    </a>",
"    above.) Pathologic evaluation of the prepuce is important to look for balanitis xerotica obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/22\">",
"     22",
"    </a>",
"    ]. This entity may involve the urethral meatus, require reconstructive urologic surgery, and is considered precancerous in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=see_link\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper hygiene and avoidance of forceful retraction are the most important interventions to prevent balanoposthitis in young uncircumcised boys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H86213584#H86213584\">",
"     \"Care of the uncircumcised penis\", section on 'Foreskin retraction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=see_link&amp;anchor=H9377172#H9377172\">",
"     \"Care of the uncircumcised penis\", section on 'Routine care and hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Circumcision in the neonatal or post-neonatal period as a preventative measure is a controversial topic. Historically, circumcision has been recommended thinking that it improves genital hygiene, but there are no trial data to support this belief. The presence of a foreskin predisposes to sexually acquired infection (herpes, candidiasis, gonorrhea, syphilis, and HPV infection) and circumcision reduces the chance of future balanoposthitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/32,34-36\">",
"     32,34-36",
"    </a>",
"    ]. Circumcision has therefore been used for the treatment as well as the prevention of balanoposthitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/32,35\">",
"     32,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study in Western Australian boys evaluated the most common reasons for circumcision and found that phimosis, balanoposthitis, and balanitis xerotica obliterans were the medical causes, in that order of frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The elective use of circumcision in a patient with recurrent balanoposthitis is reported to be curative, but only should be performed after the acute infection has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?24/23/24953/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/48/41729?source=see_link\">",
"       \"Patient information: Caring for an uncircumcised penis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/29/40401?source=see_link\">",
"       \"Patient information: Balanitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanoposthitis describes inflammation of the glans penis and the foreskin (prepuce) in uncircumcised males (",
"    <a class=\"graphic graphic_picture graphicRef67724 \" href=\"UTD.htm?43/35/44606\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61240 \" href=\"UTD.htm?12/30/12772\">",
"     picture 2",
"    </a>",
"    ). Although the etiology is multifactorial in children, balanoposthitis typically results from poor hygiene that is sometimes complicated by secondary infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful history and physical examination often diagnose irritant nonspecific balanoposthitis or irritant contact balanoposthitis in young boys. In these patients, further testing is unnecessary and empiric treatment based on clinical diagnosis is appropriate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually all other young boys, adolescents, and adults require laboratory testing prior to treatment (",
"      <a class=\"graphic graphic_algorithm graphicRef76384 \" href=\"UTD.htm?23/41/24209\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are unable to void because of severe penile and preputial edema require urgent bladder catheterization to relieve the obstruction and urologic consultation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pathologic diagnosis is desirable in any patient with balanoposthitis who does not respond to appropriate therapy within four to six weeks (",
"      <a class=\"graphic graphic_algorithm graphicRef76384 \" href=\"UTD.htm?23/41/24209\">",
"       algorithm 1",
"      </a>",
"      ). These patients warrant referral to a pediatric urologist for consideration of circumcision (children) or penile biopsy (older adolescents and adults). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathologic diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should receive local care instructions that will reestablish physiologic function of the foreskin and help prevent recurrence. These instructions consist of reinforcement of proper hygiene, avoidance of forced retraction of the foreskin in the young boy, and avoidance of irritants. In children, balanoposthitis typically resolves in three to five days after institution of proper hygiene. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'General treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irritant nonspecific balanoposthitis results from poor hygiene and should be treated with aqueous foreskin cleansing, soaking of the inflamed penis in warm, weakly saline water (salt water sitz baths), avoidance of irritants, especially soap, and empirical application of topical antibiotic ointment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Irritant nonspecific balanoposthitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of irritant contact balanoposthitis includes withdrawal of the precipitating agent (eg, soaps, detergents, spermicides, and condom lubricants), application of aqueous emollient cream, and topical low potency corticosteroid therapy, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      1 percent cream applied sparingly twice a day for seven days. Topical corticosteroids should only be initiated if the clinician is sure that no concomitant infection exists. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Irritant contact balanoposthitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of infectious balanoposthitis depends upon the underlying etiology. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Infectious balanoposthitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatric urologic consultation is reserved for children with acute urinary obstruction, prolonged and refractory disease course, recurrence, or development of true phimosis. Circumcision resolves the problem in these complicated cases. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/1\">",
"      Schwartz RH, Rushton HG. Acute balanoposthitis in young boys. Pediatr Infect Dis J 1996; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     2001 National guideline on the management of balanitis. Edwards S. file://www.bashh.org/guidelines/2002/balanitis_0901b.pdf (Accessed on February 14, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/3\">",
"      Escala JM, Rickwood AM. Balanitis. Br J Urol 1989; 63:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/4\">",
"      Mallon E, Hawkins D, Dinneen M, et al. Circumcision and genital dermatoses. Arch Dermatol 2000; 136:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/5\">",
"      Leslie JA, Cain MP. Pediatric urologic emergencies and urgencies. Pediatr Clin North Am 2006; 53:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/6\">",
"      Birley HD, Walker MM, Luzzi GA, et al. Clinical features and management of recurrent balanitis; association with atopy and genital washing. Genitourin Med 1993; 69:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/7\">",
"      Edwards S. Balanitis and balanoposthitis: a review. Genitourin Med 1996; 72:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/8\">",
"      Thankappan TP, Zachariah J. Drug-specific clinical pattern in fixed drug eruptions. Int J Dermatol 1991; 30:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/9\">",
"      Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol 2003; 49:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/10\">",
"      Manian FA, Alford RH. Nosocomial infectious balanoposthitis in neutropenic patients. South Med J 1987; 80:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/11\">",
"      Drivsholm T, de Fine Olivarius N, Nielsen AB, Siersma V. Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologia 2005; 48:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/12\">",
"      Wakatsuki A. [Clinical experience of streptococcal balanoposthitis in 47 healthy adult males]. Hinyokika Kiyo 2005; 51:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/13\">",
"      Sakuma S, Komiya H. Balanitis caused by Streptococcus pyogenes: a report of two cases. Int J STD AIDS 2005; 16:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/14\">",
"      Patrizi A, Costa AM, Fiorillo L, Neri I. Perianal streptococcal dermatitis associated with guttate psoriasis and/or balanoposthitis: a study of five cases. Pediatr Dermatol 1994; 11:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/15\">",
"      Davidson F. Yeasts and circumcision in the male. Br J Vener Dis 1977; 53:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/16\">",
"      Rodin P, Kolator B. Carriage of yeasts on the penis. Br Med J 1976; 1:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/17\">",
"      Cree GE, Willis AT, Phillips KD, Brazier JS. Anaerobic balanoposthitis. Br Med J (Clin Res Ed) 1982; 284:859.",
"     </a>",
"    </li>",
"    <li>",
"     Synder HM. Urologic emergencies. In: Textbook of Pediatric Emergencies, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1679.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/19\">",
"      Edwards SK, European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of balanoposthitis. Int J STD AIDS 2001; 12 Suppl 3:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/20\">",
"      Kyriazi NC, Costenbader CL. Group A beta-hemolytic streptococcal balanitis: it may be more common than you think. Pediatrics 1991; 88:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/21\">",
"      Orden B, Martin R, Franco A, et al. Balanitis caused by group A beta-hemolytic streptococci. Pediatr Infect Dis J 1996; 15:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/22\">",
"      Gargollo PC, Kozakewich HP, Bauer SB, et al. Balanitis xerotica obliterans in boys. J Urol 2005; 174:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/23\">",
"      Palamaras I, Hamill M, Sethi G, et al. The usefulness of a diagnostic biopsy clinic in a genitourinary medicine setting: recent experience and a review of the literature. J Eur Acad Dermatol Venereol 2006; 20:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/24\">",
"      David N, Tang A. Efficacy and safety of penile biopsy in a GUM clinic setting. Int J STD AIDS 2002; 13:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/25\">",
"      Buechner SA. Common skin disorders of the penis. BJU Int 2002; 90:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/26\">",
"      Keat A. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med 1983; 309:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/27\">",
"      Das S, Tunuguntla HS. Balanitis xerotica obliterans--a review. World J Urol 2000; 18:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/28\">",
"      Thiruchelvam N, Nayak P, Mostafid H. Emergency dorsal slit for balanitis with retention. J R Soc Med 2004; 97:205.",
"     </a>",
"    </li>",
"    <li>",
"     The use of aqueous cream in children with atopic eczema. file://www.eczema.org/aqueous.htm (Accessed on February 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/30\">",
"      Forster GE, Harris JRW. Double blind therapeutic trial in balanitis - miconazole and nystatin. Eur J Sex Transm Dis 1986; 3:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/31\">",
"      Kinghorn GR, Woolley PD. Single-dose fluconazole in the treatment of Candida albicans balanoposthitis. Int J STD AIDS 1990; 1:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/32\">",
"      Micali G, Nasca MR, Innocenzi D, Schwartz RA. Penile cancer. J Am Acad Dermatol 2006; 54:369.",
"     </a>",
"    </li>",
"    <li>",
"     Amebiasis. In: Red Book: 2003 Report of the Committee of infectious diseases, 26th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village 2003. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/34\">",
"      Schoen EJ, Colby CJ, To TT. Cost analysis of neonatal circumcision in a large health maintenance organization. J Urol 2006; 175:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/35\">",
"      Fakjian N, Hunter S, Cole GW, Miller J. An argument for circumcision. Prevention of balanitis in the adult. Arch Dermatol 1990; 126:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/36\">",
"      Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/37\">",
"      Fergusson DM, Lawton JM, Shannon FT. Neonatal circumcision and penile problems: an 8-year longitudinal study. Pediatrics 1988; 81:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/38\">",
"      Spilsbury K, Semmens JB, Wisniewski ZS, Holman CD. Circumcision for phimosis and other medical indications in Western Australian boys. Med J Aust 2003; 178:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/23/24953/abstract/39\">",
"      Wiswell TE, Tencer HL, Welch CA, Chamberlain JL. Circumcision in children beyond the neonatal period. Pediatrics 1993; 92:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6483 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24953=[""].join("\n");
var outline_f24_23_24953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Relief of urinary obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Irritant nonspecific balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Irritant contact balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fixed drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infectious balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Candidal infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Viral balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Protozoan balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6483|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/41/24209\" title=\"algorithm 1\">",
"      Balanoposthitis algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6483|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/31/41458\" title=\"figure 1\">",
"      Dorsal slit procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6483|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/35/44606\" title=\"picture 1\">",
"      Balanoposthitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/30/12772\" title=\"picture 2\">",
"      Group A streptococcal balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/9/5267\" title=\"picture 3\">",
"      Circinate balanitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/30/40416\" title=\"picture 4\">",
"      Infant prepuce",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=related_link\">",
"      Balanoposthitis in children: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=related_link\">",
"      Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11559?source=related_link\">",
"      Care of the uncircumcised penis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4506?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/29/40401?source=related_link\">",
"      Patient information: Balanitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/48/41729?source=related_link\">",
"      Patient information: Caring for an uncircumcised penis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21751?source=related_link\">",
"      Prevention of genital herpes virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_23_24954="Lichen planopilaris with erythema";
var content_f24_23_24954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86813%7EDERM%2F52848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86813%7EDERM%2F52848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lichen planopilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scarring alopecia due to lichen planopilaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Ginat Mirowski.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planopilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCS4s45pvLNtCbhhl41QkMP73HA/EVlRi7hmb7Pa3VqEG399B8ko/2sH8jWq7aW+Lb7bLEzkMFWRlKEejr/AFqy0UzxqouUwOUZMhvcN1rcZTX/AE2LZHm3uFGWjaEHP0J/lVRFe2uVm+2LaSoflmBKZP0zirssVxFKskzzRzAblkcqwI9toBxSXn2eY4nt45llGVYDIPt04oAtSa3ZXMIh1CeD7VIfn3kKJMdDjs3+0DWRqsZs5JJIoZxbXC7HMQDKPTep4+jcH3obSYpAFggjO352SWDfj6Ht+FWvMFlD5km3ysgEKC6kdxiluBm25sZUBLQO0Ywrudshz1B9qZeSiwx5luDBjaCSpAB9G9K0o7DTNQcz6e53g8wlztB+nUCqjXU9m4jubeVIoyQsrBXUD+6T3U/SpK30JNN1C0nj+yzi6EbEMGTLqcdMnsR+VOslWz1MRzXEcsbSDcrygbgehGehqndqEaG4NqJoch/k+WRMnAI/hZffj0NWjHZajetEXjN9b4Ko8exyM5xz6exoHHQnMj2F1KjykK25UmiYEqVOVJXv6HPaqdz9lOoGExQC6bDGGIeVnjO5PUewGfSk1AW7TXCutxCztiQDPyt2dPX+tH2aO7iS0unSSaI5gaQsr49Fb8yOfUdalspC6VqKvDcvZXlrmFcvHdZfDBv7xAI/KuospTcW0qXcKJEAQyq+6NkPIZWXp/SuaFrNNbXv2tSs/lDbcDbJ5nzcEgYz9cZ9ar2t1qGlvb3BhjWPHkyyxEgHH3WI+hPUUXBnV2G+FJIkjFxFyxXO5gPp0bPqOv14qS7t41sYjCgZ1GYJAeQndT6gf5FZslxOJFltEUbRlwvKkHvgchT6jv6UzStUFzI8F35qO+eM79p/vq38Q9QeR3oSEdDpFxFfaKrxZaS3LW5Ur86Buce4z0rJQtbzrKVjAA8uVecNjqPxHzDjrmtTw9aNHqLwzBdt1H5fmjg56rk9GA9+frWbdmOy89LxwrPKIHKAFSxPysAfQ027gTXdvbRNNpjs0vyi5gSQbi0R/unuB+dZlo39n3UaPIJbfaxVxnlO4+oraulN3pqeYiteacSVcH78Z64b0/l3rOjeO4uBCSGVgTGWGHDkHGD/ABZ9utIo53VLewOo3ttLYs2QJVEcgDMvB3rn+Qq7Z25uY4vKvFmtZoz5aT8Mren5j8Pxo1zS57uyju7Fw91YAfKThmTHP0I9DWRZXy3GnMs6bAh84OR1AJyc+o9R+NF9Rpdjs9AD2zPAysJZFLRxq/A2jlSD37e/HrVudWt0hv7acrAxEgAwQCTzn0rF0LV8vYxTv5u9ARKhB3An9W4/pXQwwkrfWbKdobeqMB90+nqKREkEIEdxfKbdF+0RllbdwTis3cIoHZgCYnWR88ZRvlYD26GtfT4xcafvwrGON89hx1/HHFcsL8WkdmLxBNZyOtvKW+8Ff5Qfw4oFFWJYAdIvpLS4JdSxWMnq6EdD+Hem2cQgtpLRcyfYZPMhbuYX7fgaf4v065sRYNKzbUdog5OcKR8pzTdBuo9RtbW9yEkZTaXHHQg8fnR1sUldXOjtrlDYxG6UqHRXHYI6N0rN8caa8sjz2mC06FoyvZwMqPzH61ct3K6nFaXBzBdIwUE52lT/AFFWLoja4b/l1JVlPGf7poM+pzmqqvk2M7Kklui5I9JAeenTn9KdbM82iu0b7jDJtVyBzHuDAH68irSWYm0xtNjYAzt+5kLcscElc++CBWf4YZjbz2EPz3FuglVJBw65JAPuAppp2LsQ+H82GuX0cm7yYZEePcTt2k859ga2dWh3ahO0aZjvbeQliPughT0+oHPtTrW3WWSa4i5NzE3lBv7q4b9eBU8gWG1t7u4b5Z7IxsE+byT14x2z+lICrcsdunvFL8uoWxDM3IjdAVOPTBAP41dSZbc2l3tx9qCJMOu0g4H8zx6Vmb2Oh3M4QN/Z149woHI2HCtx3GCD9a37Gw8u3t7JJRNLYspaSToW25Iz7ZxQQ9zlL+yk0iQyDAie6fe5GVRXI2sfYEAH6g10zMlnez3UChUDGdcjIxkBvzqskX9p21tDOoKeYI5k45aNsg/Qik8OZm0q/hud0ktpLPbowOcxHLKT7jpQI1rJDFqkltIRgk4B6FWBIA/SobgGHUYXbcsLxsjn0/8A1dasxmO4axvFJysKZ/2tpxg++Kfdx/aZF8xsI0jxP7N1X8waAH3aCS2SSVVLK4jc9cZ5B/MZrA1fz7QaXfWuPOstUETjafmVlyc+2cV0VoDdaXJDKjLM6/Z2PoQTzWZrGW0O5gCBXtJ41DL8xZBgbj6kZoAi1WO1+1CW2w1i7SK+4fegdNwGPXPAPas8Qzbo2b55ydm9Wx5e18j8lOPxrQs4vtvh2K3jG6O3lFtLID9xSPlbHf5uPxqCyY3DzW1wAfLZiT/dI2kfkGxQO+hoRoJ9Rv7ZQVgMZYOi42sADgemdx5pdOidL26nA/1p3unbf0OfwFTaUsv2udwhMpVo2+buBxx3BDVNZ5SKSOXbueNWcDjDg4Jz3oBvQjXFnZzIjBssTJnqpHRh7HPPuKrpCJrucPs8mLYrc/MeAevuRiteSNVZGZcgY3KBksM54/KsewlaLVVhTYY542Z1XB2NgtGCf4RuI49SM8UCRUtZIyZJ5Gjbzm2sM/e3PjgdgMVfUu2qxokTnESW0UZ427jukcn0AwfXnFVLp5LO8luYYzPqDGG38qTlIeckr2LYB59cY4Fbek2o065SWTc62UXmNI75MsrZJGe+Dkk+woAq61G1zqcKsiFkiwqYwApDDbj39T0yaxdLdpph+9E1yIJ5DJkBIyOMKegA9fbitC3uHnvYh5uXV41eRQSGDJJkewHGTS2UCxXUltHGVtlVhLIDnfkcKB2GWPHsc0ALoIih0147ZWMc0Dld64Msi/MD6hM8AemSetZtxMzxNIz7EgBP2iYAAZPL+mS2ffAFW4bm3SBJL6f571JfJ2ckIinIQfh9PrxWHPci4iBS2mLqqyxxEkhACBvY4A3c9T79AKaVx2ZSim02cKtrC5AHziKZXYe/WnQziCUPZSTeYpHycnd9RgiszN46OLSOKXj5beWJ/M3d8EABh9RVAaiihYZr6eEr96FLLAB9Mk8fhV8wjurO+stTicXljc6fMBgFWBjPqQM9fUcfjVG9sZIw8TCOWIkOhwYyR9T3rl/tjXLIY9YnLKw6xMg+hbbjHvW3p9/c26tZalqls0YG8BW3Sp6YB4I9jTUkwGWrSQzDbM7FclWRi5T8c81andJYzI8Ak8z5WcRjORzkiob+0tVPmm2gKMM/aEi9e5AxiprBRdR3EDBUI/erIvTI7A0wM8wwmSKRRKrRYKZZSOe3qPpmtNJPMUJLLhiCvmjAIP6/rkVmvYSrcPLHFHtyNi7clxjkggjjJPB9Kr3FqbhQNs0cgG0EBUOR/eB6j6c1I0a5gmtsI9x5lvg7iqhCAepwPlPuOhqjrmlywyQX1vcJcRLGCHCZCgdNpHIH48VmJqd3o2yC4VlgYZKtudX9w46GtzRdZtLlXhs5FkK/OItoimX1x2akyypPeAXYinuoJbS5RXWKVgrKT3R/rURjdzJCl5l1YFN5UtGfTPcGtTUbT7XaRzqEfJKjKjIYdRt6g/SqGqQyS2VvI1jDJPEvlXDpGCSB91vWoGRk3DBoLrKS5ABHAfnscYz7dD7Gqka3kQmQyqpZcqxLcMOQCMcHqOamt7tzGYv3UrowxGxKE+x9/TtTYruOSdTJCPlbgFTke2c/jgig0iXNHnhvbJ9sixahZgyxyKpCsn8SEdx3xVbWbaSAre2oLRTASFVG4BvUf41FLaWdneRX9rL5MmfNVGmKq3Zh83HX+H3rXvoWsrUzWMFwbCVd/kfKVXdncgyQQepBBqWyrK4mh6zBqMC2c07Wt9HnybhDggjnp/TpW7rwluLy0uL+1t3tb5BG0qg7PPHZh23YyDXGwWrLdQ3VnN9ot1O4LLHmdFznn+9j1BrrNO1JVW+0vUTtgY+ZGQMeWw5UgHqPp0pRk2tRyhFaopG4utFu/MkObdmBchwyOMY+m7HXHJ64zRcr9kvFa0ZDAHWSPpmIk5HHofUdD2q/EVcSwXTq0Fym6SFl6+jr9Kzbi18hJd4mZYBmNlG8rGTyMdTg/wAP4irMmrMSe4Om37XaM0kT/Jcxr84PYsB1GRzn2rF1gnSdTzFu+yOvmkYBV1P8Q4x9a1zIpjglkcOCpAmj+cSLkrg+/seRSS2ct3bfYZFxJECYJN+5Cp/hJ6j8aCrdjO068WW5htFW1l8xBJCqoELdTgY7nH5iuy0rUI727s5F3L5kbQuhO75l/wDrdq81fS7iCOCWOOVTbzAyQlvlA353Iw6jPaul8OuG1S/td3yTf6bCcg7mBww9jjg+uKlN3CUep2WgG0RtUhupNsAjkeZpAflx3xXHPapPpktlcja0qHYSCCRjMbEHp2OO2K62KaL+0rWWZMxSph8fKWGOPzxis7xRZr/b2oxogSIMJogQRhW+br7cirTS3M7F66me90TT4LmOMzTRKpcrnDjAwf0/OuS8NW8VlrWpWkmY7e56qefKkB4rqmZJTPGZv3yxJcJGOM9mx+hrnLiG4h8TPKVhlkMZlidSPnB55x7jml5lLax0M6xSQWs5+WSNiRjJAycrn3zkVYvgLl4rtiALmP7HKvYN1U/mAKp6jbxz28KyqWtrrbMm1ivlt1GTn16VPp0YE1/ZiR5CQLmAvISM98+vIoMramNJBKILVtvloHjeNpOiSK3X6HkflVDWYZNO8WR6raHyYJJS8yP8uw9G/n0966WZ1/f7EL27utwq7eQsnUD6MD+dY1w+65FjeRKYVfMLKctIoPTJ6nDA/wD6qC0aqSLp+p3IkXbZRhfLJXgpL0I/4ENtE0aQtpsfmHcDLHkdGQ5/lgUqot/oFp+8YtMHjXcuMSI5YZx9MfhSQML3SYHjO94WdWG3buwcEeo+YZoJb7FDRYEt9blsiA1vcLnaOBhh0A+oH61r6Qsi65dxSq+LiFpOTxvDHj61j2ki/bovMYyzkkhg3VwCdv8AOtuxYvqqSwESBo1uYw393bhgT6hgfyoII9NH2bcXGB56kALyVfjcfbNYvhl5NP8AEb2U/wC8h1Cd4t38LEA5IH4j8q6qNP8AiYOwyySH5GHQqQWH5HcK4lZTJPa37ZBRvtMKg527iVKD3+U/nTQHYWRe1S2s3jwyTNE47A46/nir+oozafeEYEQiSZuMlSh5x74p9+sfnLOeYbuVFbBzsJX/AOsKt2qrIrIybvPjZJM9MEcGkBLpkiXsU9yCWI8t9q9Rx39BWMJobWXUvLMTtbyoJURhxnbwR2yrZ/Ct/wANzok93bCPbIttsHqeep/WsXW4lgTXJoliEn2BJZQF+Z3B4LeuVAA+lAGX4cT+wL2+tZiWsTAEVm5JG4nPuc4/Kn2to1rrVxDI20TEugbun8efU55/Kn2ZjvFjE0jokpjkjweI2dPunueO341ppDKgspT88qLsKSYJ2mQbT7jrQBmTulsmpRy/60L9oVVB+aJcKgBHQliK1ZYxFc3IZVwkYPA+6xxn9c1l2UezULq8WPcxiEY2/wDLSIEkbR2Of/Qa0bsiFNru5Uzwo5HQqWxgH8j+NIGaEMTBAAQziNo9zDjO3k1zmm20cc6tgf6a/nEsu0AYJbOf4RgHHoa6q/iaPT1WH5HBddyfeUlccVzd6sLL8gbyoj5yYyRKCRlB6rng+uPrTBDbcRzXVvIGc2gRpowRjgDbuJ9T0BNVNQuprmyiVHEUMw+VWYqDGD8x5OQCdo98mt02zSrbCEny1kcO2c7Il+c8dCSMgD/arI1wRX2oM12iiKMh1BztTaMgEd/mOB9OnekNblS1jW+hWfe62SKZGc5QyAI2AFGO5q5qyyLfMhSSSIQRKkCjaoYkZ3Hv7+mKVZIt0LxkRKloGXzFwQmOcelLfz7pLdrgkpPPtDZ42hPMPPoOppjabehTW2kfX4ZWcn94fLwMKCc4/IYAHArPjtYlhkE0rGNkBZF3MxbIIy3QentVPR76W91aKdf9WjFyzDKrjoCfyqheX8kkV1b6bDcKiOsYlaPDSfOdwUZGBxyep+lCaLs+o4aZbMEjvLvyTj5ZH3eTu9ucofcHFJeQRxzmOe0eeQj71xtDHH9yQ/eHswP1q9btGlqINSgn+zNyr3OCRn+5wOPWmXBS3s1hQQXNi+WS2lAZT2zGT0b2qrGRkvp37oS6Zu+UE+XcTFSpPGAmNv5c1CsV7EgE2m2x2/8ALOLfk+/NXY2kuUdbCf8AeL/yxeDypAB6ZI3Yp63V1NCkd/BLMBkYwSVGeSFBJFPYBml6jd2k3lkW9taOdhilLKWB+vFW44WtLkXKvA0JOd0UmwqPcZIasqTTxcFhaXaDPSOdPlJ/324/A4qrZtqGmXBhmimjtx1RLfEY9w2SpH0oTuB013a28pzZvAVPz7BuGfcYPB+lVmdpg0TOZWQcLLGVc/rg/hS/2bNPCRazs1oV3IqYJjPqv+z2rn/7Vntt0OoeZMinaBPFtKf7sgpvQpRubInTPkLJJGWODb3UaFXA7LuGD+dNgewivUQyy6ddK3yp0Rx3ABGPyNRWl4kqmNUmuImOQuMTR/QdHH0/KrKm7to9jW0V7YkFhkFXj9th6GpZaVjYltZTZTW86m6hf94skbAyrjoRkZz7is43slvArzPJe22BFIXO047ZOAVb2PHvV/RZrW4t0itH2ovKw7SOe6jP/wBaob6Q2lyfNtpmgPDbkEiFD/eGc4qQMm7s7aSAvbSXEjKQCoUBgP8AaDEEj8aoTM8kLJJtmYfxGA7h7MM5rp5IdL1CGJbC58nUEUiIcYeL0yfQ9qoy6W9wuGeN5Ys+ZEecY7gdfwzn0NTLVG0dDDt0EyS2XlQJISGRWiLAPjp1zgjitHw9duIGsSYFMOZPJRWHyfxqAe46j8aqPpYdVEpkmQDCyOPM8o9sPkMPofwq0lptvEvhNOjxEGXBDo3+0O4z3FZ+ZpoQXgvNPvd1rPBcWr4kXarKxB75HDVrRoL+2ivElKXEJxKqgEMvqV/z7U+Cwjkie0DoYWcy2zbs+W/dCMfdPUVRsx9jnIJVZf8AnjIDhue3PFUk73HZPTqbX7rULVUlcKysfs0u77rY4AP6Y96WHVBZIr3sBAjbZOy8gA8Bh7evpWfb3G24dB+7SU5G9crn3Pr/ALVXEBuS0ltvN7H8tzZM2TIh4Jz3PoR1qrk8vcrXlp9ie4tYgfskziWJ1YHKN/F+FZUV9cWj5mAe5gYAsoKs8WcBsYwQDWtMsU1v9igl3SQndCZPvBDyQc9eayHl3TiK8SR1ALDPLKDwdrelA1BGy19Ha6hGo2qlycKQBtc5wVIPGQe/FMOn2djrUGo6Q7JcRSOk9nKMb93UxHpnuVrMtRJPcHTpn3EOk9tJgcsp559xiodMvZLy8a3lJ3Fn2Fjw4B4wfUc+9Fxcr1Ow1OBreCzktvnihudrAN/yxfp17q1aOrA3/h+G/QMbq2YJIh4JU5U5rM0qVtQ017Ryhknh+SVxyJU6Aj1rY8PTwPBJDcM0fnKPMXOSrH5SAPY4P40zCSsZGn3ESahpsmM2zMYwQBlNw5BzVfxNpoGrafLBnfbSqrqOoRzwfpxUDI0OryQoU8qR23ICAVYHg7evPQ+mRW1re2+sdL1W2/dXCR+XOmOHVW5B+hoFsN8NSJLYWyug8sM8EiOMgYbKkZ6VSu2/srWraVtx2hw4x1Vj6e1XNMkjN/c28Y2yTIJRjleCen15NTeMYBLFbXMi+YpUxMo4yD/k0yXuXre2W0ayQsRbzTeVE2OAHG5AfbORXGeJILi31CWGDYbmO6SORSfurn5T9fT6V0lg0t14Nu9Och7i0j3wnGMhDujOfbGDVfUUt9U1Wx1i2YoGjSJ0YZDPtzuHqV657CgFq7DpmuGsZYYvLzEqzrtztdlYhlAHfknim7VtbazMc0SKLvLRgdS5OCfYkVU8L3RltpLW8EzzrdSQQ45KJIhAJ9uKn1a3ltJgigTQiwgijKqRtZT94+jZ7UXFazMGbMep3kLr9nFsDOhzyHU5PI6//XrqoJJTrEMyLmISmJsDAQyDOD7HNc1q0kM+rxCKNWW9863nYcDjOP1rY01/s0usx3YCQs0c8e48qVRBkD65oE0dLZ2zi3EO8GayLsUHAKhj39ua4Oz0/GoQoqOYIrrcxHURliwIH14Fdxf3q6drlrPHHvicskqp1YuOQfxOaxri0kt7i2VBiHbLE7HkHH+rP0Ix+tBKNWwVdQ04SrgY2sMHkhXP+GK0LWZy6BRtG5d/PCjJBz+Yqj4aaQabJA4w6xsA23h2GGP8zVxPKfTJiGOY5AJSpx1IOffBxQBoW6JB4jjKYEokMcuP4gyDBrP1y3Jt70sdjSweRJkc5UNjn1wfyFbN8jT+fJEAshiSTIGD8uP5c1S1lQ6FbTE0VwHZMnITCn+eaQjmLOJ4NrSBSTcRtFj0zjjPXpx+NbqK0MlnI5/cYuIpR/sFgevbBOfzrn2k3X06rEw+xbPLAH3ecL174BP410Go+Za6SiWybpnkT5WGc73BYD2xu/IUF22M7SLeez1Syt52RnUtE7j7oABOR9citq7tgIbokKhDE/MfvBduTj09KpryZ2AcmztxFgnG7AJQ+5I4P0rQuA21reNg80xaYkkHYMDc3Pp29zQEoiT7pra5XEkcHmhpJFJG0AD5FI7nqfQe9ZP7uWeQOqQyyxCNCgOI0jY449h+Zrfu38rw1HHaxNuZRtG7J5bG73OTXM6eu+/tWUh7a3z5jv0c7sEjHU54/XmncILQu3Myx2x8htkIdJACMEqVIUH3yK5HXLjydQFtbW++baodmyBGAqliT/ESSePbmusEfm2Rj4Lg7SwGSQkoGPYEk49q5G/EM9/L9rnt1VmbCA5/dpnOe56HgcetIuMepPOHktRcYjMsmnog29AdwXOR0HoK0b5Y7ZWmbDpcXciqu7OUCBSRx1GMY68/WmWc0YgKwRLvZYQscoyuCyBVIHQ9SO+ar+J8y3QgQkxW900TySYLK5jLOAOmSWPze3rmlcdtTEubm6mV4YSY7dUBUo4O4dQDgcEjGfQZ71LcXCxyTH7RFtnn3RxQZYsuM4JPJ5boOPWqNxBCLS0jA8y38rDxJGPnG4gEnI9OlGq2zQtCkFvGEigSMMoO5MjLAHJIOe49Kd2XyInuhamEW19cyLCzZVSzBseqtzj6ZGaguNFa2s2SxvrC+06cYwDjac9G3H5X+nWt54RCGM1vDNbqBkRPyB9CKnWKC3Mk9oYZIpUx5bJ8rA9M7eh9jmrujmvY4eCxvLVN1vLbOqn/AFbSOcH3znH4VMryTiT7RbxXExGQsR2yqfUE/Kw9q6DUNPvDN52lXFtIuMiKVCCPUK4bkemRmsj7PNMRDe6fFEclUaJ92Dk9uCKL9AK62U3lGWJr5EJ5y+1lPuh6/rSwS6lbtsazW7thwGjkXJHfjpVuCKZBua6Rozx5qplh7OM8/WrC2+wDaIIHPKvHyGHqaVmNFGyurbTp5XS2FupbJMfDJxn5lBx+IrW1rSLTVYk1S1liQkATCNAwcY4b/GqS6cIZPOihtC7gt5kSMp+vORVqKSztf3zXH2WdDlvLjaNGB/vDoRQ2UmYcWhWhfMcW+Qn/AFtrIqsR6AHmr8d5NFOLe6SaZt2EupUKliOzdCWHrird1pVleJJeafImGG4hADHnPfg4qjPPBBEyahok6RHjzJW3xk+xBOPWkWieQzQ3ayXdk9wdwKS25+ZfqM4YVdaNJLUywma6tCS0QZ2jkhP8SKw5H0IIrMstaS1byVlkCMwCsYl2t2ww459xW5aXkF1FIikN/EVmdl/FSf61NzRqxnw2P2l/LhENxMg8yONyqTKcd/UEcdPwp4bzQpe4+zxk5hmRSHhb+64/iXP5U3UtKtsh41NnKSSrBw0bHrkehoeUXMAF9DI1zyEkUhSxHcDkMf1oY0F9JewsrzXBlcKCTGoMcn+0p/mp5qpHcrwYikE5PG8ZR/bgg4+tXWuha2zGZ0axOCzH5cn69mHTB60ybR4NRtBdaVPDcrn96hwrqfdCRz9Dg9qDaFrakxEk8PmpOFThGV/laFx0ORwVPalnuWdI2vNoLHYxZMeXIP6HrWXEl9bvIjLIJIW2ndEAVHQjGSCMdjxUrxyPi5s0DRsAs0cZJPpvUHB/qKCuVIk1B2jmiM6rJbDIWRcYH+NSNOwRLmKEO8QAYxPhtvqvofUVQvHntF8ua58+I4LMcYIzwy46HFSCWSzuSI7jzgRuMUmFyp7rjilcfKzWneHW3XNwINSgwYpHTazrnuR15qrrmmK+nfaRmGHcPMKNkRSeoI/hPcUv2N2WJt4YEfKp4yD1H17/AIVJ4c1SU3klvMQlyAVJdBsmHQqw6buOKG7E8j3TM7SY5UuLN5CnmQSGQFTuDqRnAHv29xWRLbmy1KSR1d7eeTeqqMlOc8+4JzkfQ11UFrDHrMalFt5iT5GQdrDBOCO3P4VmTQXBt5PPVo2ibfsB3FsdQPYj+VAN3dzQ8OzyzieAOEeV2mj44VwCpwe24YP4Vrac51R4yXZbua1aOTKjPmIeo/ECuW8PaiYdXilmIVWcbuPur0H5Z/nW9chtM1uw8rktcPJG69HyQcfzpp3MZ07OxD4pglh8RWd7EEBlG/Kp8zMF5X6HFa+jTfb9IiadWjRJB5gPeOQYP4g/0pdZX7XDMitkQs7RMOxIPSs74ezif7bA0m+MwbZgeSrDlfpmmZ2vAfp6xWeuXz26nz7e1MIhc4JwSQT9QTWxdRNe6LsuBkwnzU+bqvHJ/Pn61DqtvHexXmoEv+9tlhcL1z/eHuOlWPDe6YwMrAh4XjkRlIDfKM8fhQZ76mRod2IJrgyZeW3UnanUo3UfhzUtzLCl42mxoBb7op7NlGdrY+fn0IBBqK+ijtZLTVIifsrkwzIOqhgV6/XFPv1e0+xj7kMkIlJPcA5wP5fSmOK1IPC6xzaobq3YO27yLgdfKdGzHn9ee4qe5mC3outoBu8wssjYGFLHPt8uT+FZWgmPTdbe6O9bLU/3cgB+UPjcCp77ccn3roNatAZI4QQSHnu0IPIBjP6ctiktglucivk3sGkahG4EKzvDtfho0cgxlvUkjH45ro7s7NWtmmJb7TaQ785ONvy4/EkEn6VyWm3cUq3ccYCrLbxygOACY1f9CRkiux1Ly4tbvZGLAxaZHJHgEYVCdxP14/Ee1CG0aOuRJJrlvE+d4dZht43yKCpT8ufwqlosj654L80yH7RCQ8iDkYilJ5+gI49BUGv3e3WprxyVfSp1mVeu5ZYR09TuP61L4XhGh3Oq2RKzrNNLNJHzgo5AKg/TJpsixraLOwulnjZWgnKSRnPB3gjp6VLBGklvfB8LHJapKqg52kNyP51BpbpaI0LYJspkswSOoG4qR+H8qulPLsjC7ESTRSSpsXPGQCp9+4FIS3NuwmeWysZmdfLmhLFdvORyR/Wql1CYhFIroscUgLOFz8pJxkHqeQPxFTaaB/ZGmkkqY12gdMkgg/j7Vn3dz5OiWX2td4Z0tZj06ycE/wDfIFArNs5vR7RmzdSFBczZlnXOEZ8kYz6DaB+BrfeeaTX9OgEZIa2ZWGc/O4GMD1HB+lQpE0WpXEGwnBaJVHAK8nIH1NJBct/wkEkkfzBWkwMHACoB9769fSjoatXegW8Yj1OeISKYpPkDKMEnaPnI7Y+6PcmtTSN1xb213LGqGWB1diOQA5/TaDxWTqB+06nPcFSLSOOSVstgPJkAYHp8ufxzWuVJsSYzhxbEqxJ43Ajp9cfnQE1ZFi5kjfTL6WGIb9iQW7kEZBb5W9uTn8K5Im2iuYLG14g4lkOOCqng57Fmx+Qrp9RAfQnV8qZIVywbJUA8/wDAiFrznWpL+61GeDTysaSSx/NGASqoFCKB25yfrSClG7Orin+zrfMdkeIJJidvC4k7e/ArjNTEceo6gyWhSaef7Ou7G9485Zs87V5Hvya7DUysX9oy5OUtnHz8gM0gLED2APNceZoJtRN7O+4RwpIVDHBZk3HP0ApN2NqUbtm94Wkh+2JPIw8iC88zAOcLBEznOOByV45J4rMspL27ELSxRRi7lleQSA5OQMHHqCc/hViyKWXhGW8kZkkvd0XCkkbiGYgD2Cj8aJmFrp1s7eYZpI9qDYxY7jk5HXpgfjTDkWpn7GjmZ5IJHjhxHHtYDcy+i8Ec5PP071BcvbM0HmK8chQE+cu05545OP8A9dWbmQyXMzO22NW7bume2BUd0yoQv7x1VVAZI+OnuaVwce5ZlDQNw1zd444T51+qntRY3h01m8yG4WFjlZFIyue3Xt6EU2G9uJHA/syaNC3DrcBkJ9Tk/wD66deXkCTq0Uey6TI2Snb5q47Afy/L0rVo4yCa/tmucSMfMySzMDGxHr6EfrVy2nje3bbKjorEMVjLFR6//XqnLqFvKSjWkwV8OGjk+Q+pGTmq6mNbmQxtcBBkrmYtlT3GBkfrUgXJl6LGImMn3GPGfxzzWePtlu5W3iRyWw0Bk+8fUY6VI18sZ2y/a4hgEElNrfmMH9Kv28iyxuyySlmH3doJH+7/APWNU2BWglE+SgkjkX78U7En8MHkVe08WklzGlzGzQsSrfJgEfjzVR4FvJF/eDzE+6CQG/AY4/OlaWUyeTdvJDz8twgxg+hBBzUlJCjTTpWoyvaKoJJxiQgyD0IPFMW2uIGJiDrDIPmQYKg+hHQ1aubiayt1+0uDC3yl5rcsr+67ev5UyC9s9Qj8u1mG1SFZZo2QfVWJx+BoLTKEkEyuEe3Z7c/J5ccoxj1Ct/IGq+mzR2crNDLEYx8pR4ysiD6d/wADmr97p8CyvIY5GKAZUOGkXPQYP8+BUHnRyvtjtL2Nx8rSMFyPqfSptbU2hrqWAxsM4ki8qT5g7Aorg9MY7+9NiuRJK0duomDZYiEEAkdOnf3qCOFYoFiWZraRcmOM5VZc+hBGT7YqS0YIEIaMiNsM7RkOvsBjjPqeKL3NFG6ATwSuY4zAWc4jLqxw2OY3XPIPY9qqJpUMUomhtILSaT/ln5rNHJ7KcgE57du1as8JLShQnlkD51chiO27FV2tI7VHmSQANgTxTgMn12kCguKaVmQyF5HPmBmMZIMmA0kQJxtfn9e/HQ1FHFq8Ev7ue3u4ujqkhLEfTqG6GpZViuYla1mMMqgKpP3W9QTzx9c/Wo5rNmfMUjwnhHb5Rtx3Un+E+vXtQWrC3Vr5tvLbSJHBOOQ+3MZJ5ycYKk96oWti09ssUyOZogTGynPAPI6dK0bfdKRFLKXmIPlu5Bz/AHhwOmeaowXIWKS1mAnjifI3xnOTznIP/wBalbqOzSLVtcNbskTbpFY/JGRkhh1GegpdUMUkazsNrN837s5ETZ7jv9aq3zx3SFIbhlO3Bt2G3I65GP8APtU9mjrgT/vIXBSUDPJIxkfUY/KlIaXU3xF/a+mWohVJLmB/klVjknGSp98fyrIt7sw3rq/zwS5DwnDMrDrg+p9D61DbLcafdSxxMVLYZJOQCy8qw9+34mrXigQyzWt5JGvlXa+YzIMtFKMbxn9aTYuTWy1Ri6vaHTbwDaZIX/1bqvBU9vqP6V0njWAw2WnSROWkgCyCTdg8hTnH41ULG60/7K0mVU5g2MfunqM/Xv2zWhrVw9xo1gVBZktY1wD97AKnOe/AqlsRL4kdBoxR7aQoVaV1LKrAfN/eH154rG8MhtD8aNEmDBeoSvygbjnJBPc1PZJNbWWnS7wjq2cHrhgCD+dSQh7i506+hXMsFwDIgH3X6OPpzkVRzpb9maOp5gglQ7GhilkDKrYyrn5fy4rP0uUoJo1U+bCzDg525X17/wD16t+LreY22oruzusgwKr9xwxwff0rH0CUtbaiWUktZrPDJkZV+mD/AD/GhmaV0yaeWF7V4mRZLS4+YIeuD9/8R1FaC6bnw7cQI6FrIPtIGTgDPfvVPER0+0vHARYGjkYg9842ge+cfjWpZz+bY61bxIGmVGy4/izxn64/lQTtqcnFDb6tosenxufOhUTK20ZjkbkLjpjjr2rbOp/2pZSWpVTqEEBeJ9pweoZSRzxyeO1c7ZS7b6TzEQ/a8R/K23dH0LfXsffFa17ELO4k1jTz+4S2GyQnhvmBB9eRkH6Gmga1OcsdNit55YjdJJLtABYfeKjp7KBmuiaORrgXMku5biwMSgHurH+gxWVq8SXev2OpWTq1peKJWgwMIdrbgfUhu3+NX7EiDQdAuzu/duyuc8szhl/LnikN7XF1WBbrXr1PMjEdzpqwopB+V8nDL+Ix/wABrashvTzQAZorcICvVx3/ABBBH0rH1eNzrWgQqQjqG84+hAcr0/Gtnw5NHK8Th9rlWnd3xgeZ8si/8Bkxx70yS0yRLpWsTxyKss80TMzLjZsxFj9D+Jq5q9tcf27p3kzogNvJHHHkfKxIyx+nT86pQp5jXVlMMweem0j+LCLMVH/AlPXsacG866uZsHNpcNEztxyLfecevJpCS6m/p8SmyjVRHsMoMODkYPH881nX1q0lrcwPIrr54y68hepzj61DoERh0+La4JieMKX7gJnp65pszL/YdzLEdskkoV8HhWLjk+wJP6UeQ0nckiUTauJbgriF3nRBzkkDoPQcke5qK1VYyyo4M0cTxnaCQJJMHHHXH9Kdrd4bTfLAqmUqiRlzyxI5Y/kfzpkIEE8KqpDXAZ3A4CsQOfbj9TU31NlG0bk9vEl1DdI7bcwhhxnIwCyj8Bn8KuXAZdOtgm03FwYlSQfxHcGJ+mOKihiEdjFE45OUURcEcEH8gauK0UbQ2vDm3iGw4z8wG0c/z96ZjJ9TNlZ4n1G6aQIjGF4lHA2oAGOO2S1ed6OGmvmnkA/cysUUcbpM4z+HX8q7We7ebU47N2XYLcNK/TeXkVRx7dfxFcjY3MUBkmCHyrSRyqNz5jBs9fQuVqHI7aUbJo6bWVja0ubSQ+aPsDiWRQAxJlCDBP8Auk/hWFLCbqa3SAnF1IkMZTtnaADjvgD8q1Ut4YftttNNG0ojgtfMwTt2hmkP1+9UHhWXZPeakoYRWSBIo+BvkYsI09fU/hRuTFcqLesTia4mgs4gYbJxa25znLd2P44/KszUZQb132lhEBHEQTgkYGTjqc5J7dKvRRGzeNY0V44y0xfOS2FJIPqd2BiscQM77pISzYG55XUDJ9sjim3YdNFWL7RNcBSNwyMuwP8AOp5pI5HfeY2JY/L2+hzVpbd3m3NcRJ5SMQC+FU4wBhTjr3qFNPlkiSQyoyk4GRnPvzikmOUk9tDKn1uG8bypIoriVcK8mSrE9iVPUfrnNIDcxRu9taQSR7ipkt5T+bBiD/OoJ7VzO8VrLbyOCZYg+4ZBPK7vukbsnrxmkispPN/fu1tcdPL8wgn3HJyPcVtc89K5JLqerybYkityy/xqwIkGOA4J4b/a79/WoprjVpG23NtHbOoOzYqyFD7r6VZY2VvbzG9uoTJ0byjub8e351Xj16BI/wDQV+2BTtOxMMMenY/gaLFJCx2GqSxItzMku4cAQBOPp3+tE2m6dZIWv1toHXkBboxZ/AHg0yMT6rbGO5W4toWPySRzKhGecFeoH1qnBp+i6dcj7S5kuFJys67iD6def0qWUjSsryIZnt5Ipo0zudmZ3QdhgDcT9c/hWjHqqSQjckjRnqjICSPdfvCqETxyosi3M4QD920tuUUf7qgj+tOT7NIWWCd/PjG5kituR6kDOBQXyo19Nu7FJCEvHtYnYDbNKSPw/u0s9vJOxihkDRx52rkSrJnucnj9ayxHC4DziR2HVkdFwP8Aa6j8q0hGLu2mNqLfdb/KylmPHqRjOR6YpXDl7D4QIUELCPdGNpiMZyB1xx04qDeNThY2c8iAceXOzRufQqOMj3NFvqLLH+8uPMiA+WdI+VIHQg89KS5feguQ0ciDrJbqQc+re3saTbNYJp6GddQCFhva6Zg3zeYxKD0PILZ+nFWHe1vE86CXEsYw0YTG4dySOSPpU0c9rKgC5ldeFAl2jOO3dfx4qGS2idk8uFo7nqFZdpz6gjg/WobXQ3Ue4v26wu41kghCBQFdHBYD+pFSwyxFY/sr4dWP7kHqPYkcj2qlDCl1NMnliG/Xja3RvfB9aY3mLMIlt0NwmQUJKsFx94fjVJMr3dmTalH8yzw+e8Tt83zHKt/d47elFtcSxhhGxmXHKsSc89Px/pU9tdAgxz7Vk6MVG0N7egNR3kZtZgJAT5h3RSEn5h2GfX2pspfysHuITcBjCiurA4Cjk5x1BHr0IqO7ht47/cGkiE0e7LJldw7E1FcLNGqYlUB1JIYdMH25qDUZze2cUyoWgyH3DvjgjH90jr9Kkt07aopNYCNoZZWjUZLISCNxI5Oeh+nvV+1wG+VkYuNrhHGCPX6ioIppYnw0Z8tTkxldytnpkdBx6cintaC5y1gpSXORbO3J/wBxv4vp1qXfdFxhctrNcJiOTzFeEj5gp5XP8sVKv7wPp0hxHOS8WOglXpx7jiqqO91arJCv+kwcEbiN6jnGPX2qTzXmjhUTlVnAeOTaD5cinjk9u1A/ZtMi0i6a1vIwQRG+Vb19CR6H/CukubWRtVtIsDy5IvlIGBuX5jke9YupWEU99HPGrNBckNvj3fK4OGDDtyP1romkK2c1yvFyCXhOeiZAP5Yq4mFZK6aC5uGvlsngZUaOYQgpyGU9PwyDUel3/wDZ/i69gnUfYpmQygYBPq31HFVkZYkCAIArhlAHc85P6VXv7sjxI4Y4dSN44GUYZB+mD+lWcyV9H2PQ/Ewja7h8pAY7jdACvuNwI/WuB0a4MFzqJhjLReYbMKq9gvT06iu61rDWlt1b7Giyktg8qp6etee3EuzzY9zMbq93Rp0RRswW98c4B70Mxp7WOh0y2W60ue0dtzNCrogzhQrd/U5HSjwncwGWSaUqRcPIjEMPvBjyR9Ki8KtHHMJZRuJt2tpFB5LDHA/E5qHw7aCE6l8ySGK5RVfpvfBJI/Digl7mfdI0JmeOIPPaXphYL2jYZGSe/IOKt6fHLf6dqNhuQBGKPJG26No2XsP4WzyR0p8qM+sTJcTBLWeBZCo6u64fPsAF5NY/gvUPO8RTRQHbDcZi3n7uCjMFC9OCOM9c5NK4+XS5D4aiC6VeaYY287S5NoaRcNJFIuGz+XBGDxWppgMHh+ISPmKKRLpWIxgKScDHTJGPoag8N6otzdWMtzCtvfTN5DiP7rFclVb1G3PPY1oujW3iObToyhC2rtGuCP4ieR3I3H8hTE3ZWI9Tn8i+0SSSNxPM3QLyfMIITPryfoAaZ4RuJbaz1N5rcCO3RkjHCtJ5jBW2++ec9zT720a88YeHILiSX9zaxuA47ktgnHfI5HoKm8NeXNFqDuMRGaK081iAVQsSZP8AfJGQOwxR1D7J12m2kCX32e1VxbxqBF8vJ3Agk5/2Bj6mqoPlS2zYCu8sxO9SRtJVGY/8BBrRgUvFb9ROqqsnIyWLcfX5agECzz3EZiLussKuBy3lqwzz9QaGQtCUqB5wU+XtukQgjBICE4qukB/sIQNGY3vGA2A8RkLkhj6Zq1kvYSXTuUP2iS7DH5cLu2KTVe/kfyn3NmOWWURbRwOAF/HOelIora4/maniRECxthpMfIoAzhR3NU7LzGubcyqSk29inoAV+cntgVdu2HmXCSIuZIY5zvbHCjBBPYfMf8iqFs2+4Y/ME275W6cE/KFHZRjj8KhOx0Rjpqbt0j3CItuoU+YU3KMYQkFmP5HpS6jItvc3moER7EViyA85Awo98k0zSpJBAZduwksYUA+6OmPxINV5k821fDIWNyhnjP3RGoJOB2+Yg81VzFxu7HP2khN5en5g7mKM+uFcZ/l09zVCwtVfV7GGRYxHATe3Ck/KAuXUH167vqw9Kn062NnaNLcuUeZzJzgARgEkn3bA/MetUlaWa0vJhJi61CX7MrHoik5c8+gB/KsLt7no8t27Fg3Bj05JpGJkuy0u456uxHb2z+lT3l6+l2ltp3mFJ4S0j7UJPmNnLHHcLhR+JqeaCSys4tVkQCGKMCygI6yDhM+oUfMffFcpbRTXUzTEyeezEs7ZBcnr1659qpsFGMteiNewCDTrq2VdzTlQrNGdo2/MepzkjHT0pkVrbzRfv3jJxw5Jb88DP4HNXjZTobKMbi0IDv8AKACSQTn8CBUCRESyRr5ZZCVATavHbiqRhK19CCPS0t7WZ4oEcykJmJ+Sq89Dz1xUZtbnaDGJFwcEFgpHtya1W82KQGUR7Yxg5AA9yrdevH4U17cSbGglO5l4QsGR/wAs/oRTSuQ5NHGm51ad4bpJrYWzMyCVHATkZBORkDgdcVXe6u5pGiz9piwR/ooPB9c8Ifyq7LaQXBlmNy9zNEuQIQY14we/UdRmtDNzIoeOx8tGGY2eUNtB5z2A49K1OS1jJOlxkpJNo0twQOFuWyEbH9wHaPwANPMN/sTN8UOP+Pa1gWJUHpgZY/QfnWpc2smwfaLqSOJR9wMMY/3upFNto7NIARF58ZOCQhZc+54/rSGisLaOVoxNeyyYHzqYcA/oNv1JzVtrbTru2R45Vt72MEI0Eu4so7kdsVFJcEnfbQPOUTyxuOFRc54x0GfWnLKiFXuZ2gl/ucSKfpuzk/7tNDSuVlsJnLSy+XMqqT5kJyfqy8E1YMcVrCjO6Ou4MqqxABHfA4/A0k5lkRXiKRDBIdsxsfXbGeTWVcPep926it1bDGGaHLSH+8wwAo9uM96TZoi9eakvkN9m2Wlu6FlaNRvZx8xVB7gHmq2l3N6LqG7T/QrVBw0rfNL7AdTU+htPMZHk02AozDdcx43xsBwwUjbx9eh71ceWCK8kUXUiyjhUZdqLjqC5Bz+nXNQ2WiQzJHPFMsBdCd4kIwye+KrJaT2WpO9ux3qcs7Ptyh5AI75B609bWe4Z31WUHT2TIUPggHoSTyB60t3p88ip+5knSMBVSFgEZe3OcnHt61F3c6I6Fe9kRpQzBiGJIlij2sB3UhuD6HoTUaXkG1oEeNhuyEnJUL788D8OKtwJeRI8U9tLJEx5hiQsEYdwfWqsthI0uye3KqTkBWBLD1OcgDHc9KLGyjZFu1W/ZGLAPGpJQSMJI89trA7hU17Eb+JVkQRTDhD5mGJ9Ae49jWaw0e1DRW10ImXjYpJLNnk4BPapp7ddixtPLNkbgrQKeP7zk4x7c5rRbGbjd3J2tpIE2ywtKsZA28ZJ9ifer8Z82D7Nds5sc/691GY3/wBo+nrWLaJNK7kyoyxg7ZTkKSP4cA4PPft05q1ayFGmg1R2k81NjMuePR9pOMg96V+5Si5aEV3p8yTNDMp+zjgRhvvD13f3fbv3olnSaznjgHMa/MMfd9j6n0A9q13sJfIFtPNNd+TyJElxkH6AY68Z61SWAJcRi3Z5oFXcOeh5wOORgZ6UWNUny2ZT06zCWMckmS8hMjZOcE9Rms66mUT/AC5AB+Qjgk+o9MetasEcy2qqyB/lOB0YDP61ny+RGhmkIDjqDwR+Fc1Zy2iddBLZl22uluZFaeQrcj5VmPHmeze/+1+dS3ls7W81uYys0beb06g9cVTi2yoGC9eSndvoK6LT/KdI7Up/pkSEpuPHstXC/UzrLkd0Racjy2hQkrebd8RBwSv8X44qeWaONoXZsrgxKvUnLZJPoMUafu/tAyufnQ7TuG3Pr9DioNWWKWKNMcxybVXHOCRj8ccmt0cU7N6jr1VN5cKuz5DF8v8As/5FZWuQhvFMcrSYWRFgfC548wAHj0OPzrakVhrd3GjKQYSuW4xjoajvGkN8GjkPkQ7gR3kchWHPXjk49uab2OaN7o7C2uEvLS6ldGAG+LYepU5H9K4LVlaObTIVCvIF8wnOCq9dzegwDk+3HWuo8M3JuLG5D/I87vGNzZDbXyD04JyRWT4kgNz51naFlIKM5VeZIiwLLn6EgCmzNe7IdojqsFtFFKu83HmMMH+POSQfqCB9KsoiW8mpAERkXC7ewLAgYz74NUYJosxXAJR7gFEVcYVwzEcd8AHv2p93cecJGkLLDGxuMheQdwYE+5/Kghr3i/qzpbXSxZSTfabo2AGNpypz6kZxXn2iSpZXNnLG2/7NdPIxA/iROnoepz+Fdk8sV1YeFr4xhReRPE53fdw+4DH4/jXJadBI86oqNEsFtcSBOp3Ox68csQvWkXHY2LWxSx8YXNtKWMMzvNvxwqD58599xHFdPFepfeKbWQ+Yh8qMbyuGKtn5P++h17cVz2tNLMtg9uoUGKKLc38cznYFHrhNzH6j0rYjUW0ujwuFlllszCsidC24Fv1K4+tApa6kdwgaIyw7hcFJLWIgc7yQCx9dofA9yTxil0vTYb1LbTII0FnBe/vLgE4J2nefXAUhF7csa1hJNcSTNtRDHdsqOSDsiUbmdh23NgVW8O/LM0CRSiWO88+VD97aYiUB54yc/L24z1pmepvQyN5Et1ESJLidFcBgQmBsVQOw5FWtkVqdSulwZ5QgwGx2KoB6dSfc1BZRPZ6dGJlQCGM3F0QMgMecg+uScfhir2mTRfZbIvEYmukSRyw5U7cqCO5CKfpmgl7Gf4gWR9Ot2jZVDvbwsVBOxVYs31JPb3qVZFc2cQRCqOcruzjEjdKS9m824a0ZhiJwNpGN7FtykH/dIoMSi7iRATvlTG0Z5DNkcdBhc0i4q+hjKfP0a1kLjcFdHMgzll5JPsMfSooUBme0tXYTzRoZJZBubnJ3AdCcfQD3q5oyefoqi5h+SOVmVG6OxJxlfTkHn0qlZPIjX3llZpWYo0zZAO1duFz2znJ9j3NZnTGTs4s3YZ1OkC7to2EERKwE9GIG1W57Yzj161WgikFxsDfvEiZsZ3AyEZKn1AY5/Kq80zJG0rIpS2VoYR0BlI5x2GOmasWIjSaR1+Z4IGJ+bgNkE49eSaYKDWpieIFW4me2hRTc43yqJC27oDtz6HGR9MVCmnC6v49OttzLDF5DuBkZPMrD+VRaPHKAmsTMu6AMIh0LOwwv1A+Y1uRw/wBmaUoUFb29+dyD8yZ+6n8ial6nQm6cbIz/ABFO82ovBFh4bVPLjBOcnA3HH4YrLiS4kmRbnLRJmZ9zDG1ewA7k4H40OUW6mWR5GGWVtwAH0J9KuecllZx7bYyTzlZPL8xTsT+FiGxnPUD2BpG1uSNrFcNdbTJKXF3M24iXkKG78cj2z/hSiYrcu9wrqyuREsqjDN2IPXgc8e1WLeJpZ9xTy2PzkSxcsRzk8n881YdmjXy3CyD+GNlAGPXHUc1RzSKt0zoiRQzeUVOXDxBwT74waVN5iP2yyQLkfvLZztYdjz/jmklNrCAvlWsYduRIxw+ew5yPwqSJmWMSJtjXJGzJYfgy/wBRRchogdLtXH3W6NtfP1x06fWqCQzW7tavLJEgGVCt/Ae4OMjB4Iz6VVN/YSNKkWo3E0h/htvmH5OMfkaW4sb144jaXkTfMGjeaAoyn+7hThs9OOK2PPTbJY7bSxJuiaS5nDYYujEH8TS6gIkcyXYt41HTcxc/gO2fYCs2TVLpJDFPNcRXTZGyCNXUkDnABzmoI3nN05SW4abbkg7Uc+zA8Y+pNK5aLj3nnKPLV5E/uOpxj12Ac/jVW7vEKlJpo41I4wyoSe3B6Y/P2pLuJXAeZ5QAPmSGNpGYk8bfUfn9Kjjw8g+z2I2D5c3HzbiOxCr69efalc0iZ6TxyzJJAx8tWJF1MGYg+788fQZP0retW8+Jfs0VxfufmZ1iYRD3CHlh70+zgu5yrNd3jKCGYRRiNBj0z0+nH41Fc3NtAzEIbsx/LiWdn8ok4yxX5VH+yMmoLLy2c8xaW9RnnUAxiACKNB/tktz7ccetTy3dtGy2lxaSTsi7sbEaOL0K9CwzjNR29hd+TvnuV021Y/KqRhWlPoseCSfrn8Khu7K087Ag8udvmUlt0hx7jO0/T86VzSMLkWpWIuo3kjW4VeDJPP8AIEz1HlDOB7N602ODzPLU6nGwUZTbbEllJ+6T0AxVNorpJ0MkxjbGEZScqO5YLnOfWt+ARyQ+dNCojxlWchGI7fKOv5ZpJ3OmNJLqZFvpEMbmN764mjGdoaMIqjOcgDrj3rQS1tktRbMGeBzkySnLMc/y9qulVu+FL7gOsiY3AdMc9B78VRvrxo/3cIWWUAkYYKPoCeT+H6UzTTaxHItvpkbKUjjK87goGPcDoT6f41Ui0+6vI1muwYYjjMOcu57Bj2/yT6Vo6Rp91LGDfbjKxygROIV7Bc/mSfwrU1K0EJZZZ4FSNSCQxOQMZ/yaAdkzFuHCKAB8iYUY6Fu34DtVUbZFHnYEKdGbsfQjuKvSw211FG0PmGHJCuRsLDPJxycZpxtDL5YwNi8gDkD3rPU2ilYjWS4kaGRmfzYk8pm6Egcr9eKmmZHczMWiL4WR0HAPY47Z9RU8ESRRSROPlGG5NRsqwOfMGUYYIzkY9q1TstSmoy0G6jDtJI2qzDIIbKkduaxry18yVBcDMUYyAWyCfXNdANqwPGcSRghgMYIHqD61TuIY/IJOWtjzn+KI+4/yDUOCeo6dVx0MgKqTxHh0LqCGPIGfWrVtdyi+yZirpNtYHrndjv7VSuAsHyyOcEZDf3h61bkSOR7e7dMSzcorDHlYHz7vp94DrzWcWx1PPW5u3t5Gmm/b1BYSqMgHg9t30qhcxl9S08bCRKVuHbdt52+n4D86ktLhJ9OlmSKSVImBVGPyqh4KgAegzj1qOZnt5LYzkmRYWjBIDNjJJY+nA/WulbHC4taWLVxJHHrquZFQMYVAxnLc8dfU0rzIL66UWz7ILjaWAJyxULwO/XH51X0ctc3FtMhUqZ4/OYqMrhWG38wKkBzqcTGIkJcSTMVBwuxchiSenSmYJW3Nfw1K1tb3UlxBHG8OXjTO/GHUE8dzk/nVfxawguWniVm/e7BFnaoDEElz2UDP51d0+ZPt1/bxxqVNoXGT8zFnBGPbv+NZmuK11FfpcDFsiRkP1BkD5A/PHFFzFq8irFIkkEdzaANBFLKUVUySdpGxfTk/0qrr8oxePsYr9hEjru43MgUKMdea0NFKQabdKcpBBgBi2Cruqk7j1Gc9MVDrmmGW9khTIWW0t41GQDneWP6JQiXuSXUB2eG4oU3SRO+wA8YUIW49hmsOF4v+EjvoY5I90dpJiHflmXbwzY+6M9Bnnk1v3cvlFGAeSKzjuyIxwNqoqgHucsDWRb2DRWOq3jJH581uru4QKrynG2JR3AJyT36dKAjcfptyG0zQrdXF5qBnXz5V55ZCCQB04QZ6YzXUzRO7yxSxRGa1mFvE2OVZ0U59hnJP0FZOh6fb2GiSqHLXEgxLIeOr849icjitfUgytqEjzM04uXkWIZ2j5DGnAxnnk80FOPQmnuxZTwQN5Zhmt9mwr81yTgLnHQFjnj2pdAtDptzdR3UzSzvtuZnAAHDFVH/j3T2pNQt1v7zKXG2NlSFZosAiNEXeq+gJxk1sNh3toRANt4p8x1HQL90c9BwD69KBOOgl6wntJlbObj52BHCqhDcD8ufy6VobVkluphIpJUWkQz9xgo81j7j1PQCsKykH2OWWdiHk2yFiSFILAhM/QZP0rWVxawXnnS/uoo2iMzKCfObJdsegHHvQQ42djNt7iK58SWc6MWe5K7Ni8MuMbvQDCgZ69KmeR57i5FsGj2RuAS2CP4QfbqTxSaJbwQT263Uj77aJ4mYtt5yuCQO5z+tZWozS+XA0apAryyNNKQchPujaP4s44PQcUm7G0Ur2LGlyJDawQ2QV7mSJ8OSQQuWwST0U7Rz3NQaDbm0s0mnEZbmW6mY5BbGdqjGcDgY9yetP0mI2uhtKzeW8m3EjfMxBPBI9stgVPqLPGsYt4i3nTEWsYGcBeQx/mc1JrFczKlxLc3moJGY4MBiWUkgpn5iBjjp1z3NXNdhlXS5EgkXfNPsLKN28sc7Vyf1qMeXaXMFtBLHJeSsHmmPG1RyQPY+p64JqNpjdGAWjRSbSQpGSpdjtGPXCgn6mkaKOqsSadaRxXcUExaa2tFOS3/LVvTjgDgDHoPekhmM+o7rjLZBkJB4G3JAH4gCpLiVbG0e2hnV5WyJJWz94YyRjsOgArK052lkuTbgvgCMN0Ayck5PsP1qW7GtON05sjtCrzHzLfKRDc7kknk9B2yelNvRLK8jpgSMAxYDoO39ABUwiMs8cNvvK7t+VBO4+/wBOw/GrkjGKMCI75ScAxEM2729/ft2oTuby30IYLcxII9/lqgDTP0OccD264wadOsjosjxxOgOEJUdPQMP8ah+WJDFAvmqWDSAthpCB1z0OO341GZVhRmjzHz8u1iCP95aEzmcbt3EmjtJP+PqP5B1+Xep/LBrNEE0Jknt5Clmx2x4fzYmHsRhgfVTUU900OsXE9zHNMskapHJEu7YMcrtHGc88jmrHhy2jjS5McdxAkkvyRkFJETHdM4xnJ6U0zGWhQlu7TYw+120I3Y2JAHYj9T+lZd3Y292xS3Ek8rgHdvCkDPAIIJ/QYrSgsmgkaSeOOJN3yxwbnkPuxHSnLbX87skc4s7PpIIGAZh33SNkj6cVscCSRXisRFEiXdrDcEDakSfvJP8AgUpOVH1P4VG9lNK6x220xxkMtqx2pGf94f6xvds+wqK61GwtIhbZe6xhhbQEsSe2SOTTd+qXqqsBj0uLkeRtyyL6tJ0H0HOaRVh8myzuN979pW56Su2WABHCjHOT9BgVcGowIRGsbZGFjhUhWYYzkg8ge5xTbOC6xDH9oENrGCB5il5pM9WP93PqTnpV6G1tIpT5EGWVePMIZznr97gexPPpQUtCGOzvrzc2qGOGxB3CAcRsev3+pPsua0baC3tBDJZwxmOHJRjtCgEdk5C/U5Y1miK1TEzW0/qqrK65Pfrzj9KkYzMuXhRMf8s3UnaDnJbb/wDrPtSNIq7HT6jDAWw4aM4zM3O0j+DceSPQZwO9ZS6jc3D7YIvItGBYnHzy47knovvwKuRWsl1IsZWG6YAhV+zDp6BQdoHuTxWlZ209pIqSQ2hUDeYoR5zQejyMeNo9OT+FTJOWx0Qko6FXTbW6ISW+kdonGUhyI/MHqem1Pfv0FJLMiTl7QbcNlpkGYyw42qh6n6VZnWC6DzmMXsbsW3PISJe2XbjCj8PQYqCWUMykSQyNwAkaBI0HYKByan4UbKLm7kQhneRZbuMso52FtpHoSuevsTx6VqQ3cD5YQeSUX53eH5mx6cH8hTLe0aJYp71toflFZSzsfQKOas4YspklkhPaMAeYmO2OQv1OTTWo5RSdlqynLfxSLuaRnTOAoOST264x+OKbFcRN/wAfU0Mikj9wmWjXH97j5m9+lXpGt2hb7MFjkJJdM7i3+0T1J+tQ7meFWETHLcH7ufzquU0jF/aJQu+Ga4iSSSFCC+1PmXPt6e4qPzgIiUt7gk9vLwP1pC1ygKoI43A4Zzx+OBVsNK0GZGiZ+jbX/wDrU7Dv0M0faJ2mGFgG3HXcw5/KmC1aOIpLLOe4wQSn04rRdxGwLBtpGN2Ac/lUcskJLIAz4HKs20//AKqhx6lp6lCKKeNwpZJouxVDuGexAqO4stSSf9223ByF8kEMD2OeSKtec6lVEixLn7kfHH4cn8TTJmeUBVlYMOQS2SfxqW9BOMkZ1zaSCJphawxmMbWieRWaJ884OeUxyPfjtUVmpihuhcNlJm2HayMwOMl+T9AR3B+lJYQrLNcQMQEkleNsjnJOQfwJFRyQrJKn7oDy+Ai/wnvj8ajbY0hBtWbNuwtpIIWZj5wKuyFcKjjH51VlhllinEQXzZJzGWcgKqqgLMc9Aoz+tLokTfbDcyeaVhUkL2Y9lz0H+HPFPuoIv7L8yZxMjyedKmNnygZIHfaTk5PXHpW8WrHJUUufQi8OyKumX13bN5ds0v7qSbJLbf48e+f1q1cpE1vJBEDcSSFmO47VUE8jB7Zx61Vso1/4RqOKYyQtPJuXByyqSSoGOgwO9XpEEs8McUu5RDtIA3FQCD+Z9TTTuc8odWaOkzKZb6TIeSKMQEKMjapHPvkjH4VXBe5sHBJM5KzKMDJZDlh6en4mm6VJb29lrUqSoygLGW9WAJ2j8ATgepNRabO1jo1jP5LvdTSMY1bAESddxHfGQB6k+1Mlx3ZRm5029gMmyee7ImZlLDdtG/nuFJUc9M1tWo82SyuLhcS2kAnR1PDhgBt+oJzVCKJLaYTK6G2CPFCzyZLtJy5A9d2D7Ae9aNozQ6xHHIVZUjSBm3Z8wBdxP0BwKZEosRrQWmjF7nyUnmYYaQ4B56evX8yay2uIpbe8tALiQ26BZZWBXzhu52D+FSRjPUjvV7WkklW3Zp28m0R5AzrgbmJO4kdlGelUNJjji0qa6cRh5WVsyMV2Iq5XtgdvlH971qG9SoxutDUt7d3S2+3AltsR8ggALj59uB2HyjPtVmQSXNrEUzKkk4k2dCwjjJGO7fOR+PNM0uea4OpyPbxsUKW8chUA5Ay/PdcgfhW3YwNb+Qyt522FmjyNpbkAE+gAHB79KYN8pDDFGkYeWNUgSBVlVP8AZXBA+pA5qmbqaKwnkumcOZI5ViQgBB/dHt0z3P41JZHzrKd3Ym3BSISMw2qwBcv7jnH/AOqodJtZUkum1HE905H7rHHmHlEB9wOB6cmi4JXTubd3y8ZbkBvOOByz43bcdwqjPpyKzJp5J72OGNt0qW8l2zE/u0kkbOT2YgYHtipbq5WG5BDRyxLHtaQdC2f3pHtu2rx1x6CqtwVk1W+hLKoNujySr8oVPl2qB2LnBx9KTYqcLalyOGWLRIVDMTI8ag8szgZJYnrjJ/Eiquoyxy3Nz5TebHtKQRxjcQccY9MdT7mrM0spW4a2+SeRFgiIbcFOT/D7c/j1qncxf2fpwij3Df8ALLNjJ2ry7FjwCSMc4qbmkY3Jr1lWazspGjVLdPMdk+6DjGSep/ixTPEE1wZLVLWd7WF4EZ9ow8g67fbPHA6DmsC7vUeETvM7NITtitzkADgAHjJA+vU1tapbzahPsnjkFvFtCxrgeZlFOWJ+9jB46Ur3VjaMVGz3KFlE73BeR5A7g7p1+6iYP7uPHU+rfz61fvGuLWLbpsAW78tY0+XKWq45J9Wxzj146mrYtljMcUY2k/vJNuOFz8q+2ev4VBqMMnlr9qLJAG+7Gmdx+vf6nii2haam9diq9tI6KmVVtuFE8gBI7k+56k1FeQQ2EIga4Zo3XzpUgj+d2JHBPULt59TUyXHzeSuyG3b53OcsQByWP9BgVVuv9IeRiqNlslScFR9fpUNWNuWWz2Io9Sa7zb2x/cgbD5ZIcc8hh1Hb6+pqYE2wIO5nbAz6DuB/I1hm1jhuBHO80vdd2Gdc9RvXDE49egre0y3kNtEbe8UwjCYlUyKQOoyOV/E1EZXdglaGyFeZkd1fPBwdq5Cn6VDcNFLFtlDe+3IJ/OrTWqCJyI5g7ElmguDJn1IUnP6U17d2gKR3kq7h8okjJIPY4PX9K01M3KEjmZDZT6vPHf6k1ttCGIM5QDjnLL3z61q2RX7NIIJ2uLffzIxaZd2Bxu6+nSoJtO1AlSbu1mXP3o7Zc/jg1NaJdWsZZpXuSCCfKwjKB0G08N9DTRg4O5z51VJ7ry445JCvzEA+cw9yMgAfhTJ5/OZlNpdBwcg3Dgx4I6hAcD6DJroY/s32TzTIsce4hvJJiJPoxPNVzcKHEenwTNIwG0LAoyMZ+8RnH+0a3PMuZ620tsYMxh5Jh8qRwlEPue+B1xgU4RLHcF2N5NcdWf7Pwi9gq/dX9TU8UNvNM63V7PPdEDzFtzhV+rAdPb1pP7JjdB9sv5jHj/VxudoHue1A0ypLqqq5it2vFYnPlRR/MSO7HBJ/DAqbTYppo/PayYiJjhXhMcak/wAbuSN59hW1aQR20arYwKihRlvLwF9CxIyfXBqJ7dJr7ff3TXFwBuCM/wB0eyDgD60GlyOaaZ4vMAVJwPnlZN5ceqgkKp9jmnW1o0sSSTRXzqOR50eSfcLkKPyxVmFrdWjMLQguS6SMRIxx1K/jSXc7yWz+bfBbUgJJOXLO5zkqoGPyFA79h7SRwYjiP70nO0MHcHHGAOOPX7v86VJJbnzNttM0e8kqJFCP/tHHX602D7PZwOtnbwrE/LOQWmlJ7uD0+hzUNzcu0e95lVVPzAqSv4DjcfrwKmTsbU1d2QS2b39wWZRDHuBYREszY/vHhP0NWlikhjUwzwNnPIhVmAz6jgflVTebuExxzuWccgjkjHvQJY7TZaxKhfgMTznA/ICoudqpK1rhHNdvvkaSONdxBcDcfzPX8KcIlcnMkrr/ABkNgkfQUqLKJNjlWYDIBP6VNGqQH/SCQMZWEcFj6n0H60GkYxitB0Ma2/75E8pCx2qvBOOwPf3p9wwm3OIyDnJA4BNVpWe5YFsSN6dAo9B7U9CwAViAQd2M5x65p3ZrbqTxhWBYZzjP0pxQbf4ST7804sSGCAk84MY6j0pLME581o4wDjDOM5+gyaq5N9BuQF2soIIxyM1DdoDEwYZGOferkixHP7w8f3V/xqldzeUrBCwbGAW/+tUzdlqNNMyocMzKkbZHBaLt9e1OaJ4WxKQnGdxxgZ9cE0yUyCYZZPJxnaD39celRx2+YNyKSDknPoTXKpXZq432ITbSTG4ubcF18xmIRwDuwMEZxx0qS7tYY724kmSW4LYkSGE4QbgD8zemSelSWQdJ7gQsPMWbap6ggrwCPT/GnXgeaSE26RxSLCm6J+o46qB94VtZMhXVk3oP057gt5t1IBKqlILfcwjjB6sR1wB36n6VFey/vHuDvdZv3ca53CRRx+Xc/lTjHIVuPNYvHwXAXbkdlxzwe49KWOCGeWORpJC3llZDGRHEn+yuckD6c1T20M3HV9jShj+1CImLYzncdwwgADevbFUryTz3m/swuyO4h86HHKKp3AexJrTuykNjBFbKqROCo3sTuXPOWPJHXpzWaqmS6AhlZYLUFBGq5BBHGcfTOKpHLy316GjYaaLfR4rcRCB5JfPcJt3ZxgAcfeI4z9aPEamaxiWxiAT5oTh9u3OAwDHnk9x/CDS6hc3Nra2wtZTA0sZ3zuoPlAA7nx1zjgD61QgYyQWUoLssqNI7Pncq5+U9MAjGaq+hCi27mhHp8iWcZupoY5ImG3Z8qFT1UDspwPc+wp+uXlvBYSyCTzi0oBMH7szSbVIXJ/hGc8VW0y1mN1JDdOjRMj4jD7nfA++x6KO3frUG1tSvr0yMWWCRJYkA+QPgIwUegyACevXtSuyXC7fkS6+8t2JI7YFHtWBlQYBlX2z2zximAXO2G1O2OSfDSo/zMVPRSoyQcdenb0rWsrFVv5ZTZzfvCRJciULgE8hQc/mPwq1bRw2momK1g825mYK2DmOFfdu5x1qWXF8qskPktFht4raJN0bSvM7StwCxAwTj0AHrgYAyc1FqepmOG8ktIyjXG2GMZ3SSMeFzz8oAydvQd+9V9Ule4P2geYFCubck8EkkByDx04Hqazbq3jbUxpVl5jxQyfvZGyGVmGNmR1YLwce9O9iYUlLWR0FrH9r02K2g8qMiZ2k2DKSOABkduMHA56VPE0dtF5iAhYR+5c/M3zdS3fkhiW64HGBVbzra3lisbSJEZVMaIGJCLnp9SeSByfwqa7tVeCzuJ1ea8jkExjVN2ZSpVHOOwBY49TRcmS5dyjc+da6a4uHj82OaRIIjtHy9VY542KpJ9KsSyiH7S80bNIdkoZn+8xwEJx2GCRnnJzirk8FtHBbwNmeSNgwkdQW7bv6YA6Vzl7cs1veuoPmsVZnZtxyX6fUDgY7VlKXLdmlKPPoXrea8UIiiCFDIsO2Ng3UnO0/xHjGfXNU5bSK+uxG2ZPMxGGJLbYlOC2OgLEbRx61Z0+bNosMTxeaI/PRsFVjBbaCfQYDcdasrIIJJzbrIJnYhWb5G2+oA6Z7dwPxpwfNG5ai0+VbkkkcXm/PG11KnyqzocJ6jIH4bfarmutIrXBjkjMqqAsOC2zAH8IHJ56du9Z87bG8l5JHutpAijOTGCPrwT6npVr7G5uridH/flAB5bZ8vIHT1PHWqsDhdrUh023ntUl3jzZTgySODlj9D2HTNQ3jGJpXHnDdywP8AD+tX7u2lliY+aPl5YzDG4nuM1DDYtEUbfCzuMqqISo9SSO1MfOlqzHku0RQs0KyTSD5vmCOBnhcjqc84+lE09uZkF2k4ulG77NLjK+mWA5P0yfpW0NGSESSWlxO5bJMrHeIvYA+vPzHmqxs2EB5uJQhxhkDY9+Sf0NKwnVV9GZ0VrBIElUxf3uEUEH2YZyavJFCW8xmEMnTfH8rn6jGG+p/OmSrKgQx3TQT54MsZVWPoxHP+e9MuJ5Y49upBbJm+VJlbdFJn3XCn6jBFJJIbnfqK1mTtdQrCTP7yMcMc9geh9aLlLjyAkkaSxAk/vSD/APXpDbXCq8RcSmZchWfKOByNpPX+YqCNroxl7VldR9+CRtssfrg9xx1PPrRohNvrqIcxhWWXypSMhwPMTHod3Kn8akNzcb1a4s7d4GGUaJ9z49Srcfk1ZWqWt3cahMkaylL3y0SRmG1Ihy6kf3s/nmpNHhmiF2lzZNZ2kkjPBb/eKoOCT2APBwOmeaq5i99ClFZmSRFj1Ke4cNyvVWPfI5z/AJ6VYGjWMDtHcJIpb5WjEx2nuPlX+XSrEmtw20pitrOMtjCwW4Z2OO2FAUfiaYNRu/LYLpr2KS/89WRSM+wG6trHnXZOtpdgqsdlBDAuCjTMAvA4x/8AqzRIl0iNm/iUtxiAA4/mSfYCqUuopZxliXkLcbVADv2ySzDA9zUTBdTt2aI262rEK6YIJPoGQ4f6d+9A0SPcW64kuJmuXyY1jVgzbh14+6mPoTVeSWO8V4orZEjA3SqJMRqPWVhgvn+736AVat9MhXHleXaQxqFw8OCoznAx+PbrV11VIFhtTaxRjJV5CHZv9vBGMj36e1IpW2MwwG6tyIUKW7Y3YQx+Yo6biOQvoi/jUsccFq6uzK90E2o0qjIHoifwj26nuajaaeRiLZ7iV3zm5Mi7n/3ck/oKS1sUSY7VQ3BHzlp8sp9CR3qWzohFBd3qQB1wzXTE4AYEge56D8KZZWt1cK0t4UjhY9WHt0HdvrUkNtawXchCB5EGWmkLbB9T3HsBV1roz/8AHsis2MI7J1+gPSpbudMWr6IqRT7m8mzjMcanJdv4vUk9/p0pYo4pGZlKrBG23zpGAVz6KP4se3GaL67khkjt7dvPvJQd8pjGyFAee3zHsB0781L5VzLDukZY41GMFVG0D+HOMfgKjY2u5baFmGeFJCYQQzcea7/P9OBx+FQEx+Yy+U0iKfvByM/nSRLOioZ5TIADhVO1V+p71LLPIVGHjcH/AJZ8FfxHWjzNIq2wsc2wHMSYzjawLfmakkuPK5j+UFum0A+9Ui8TgB3aM9MAbkP9R+tJfSIkb5nWFFXmQAuRjknp7GqUi76k13dM6bIv3kuD8oOdpAz+dR2lx+5Af5gMc7ulZ5uEYAwhtsgyJGxu/AD7tT2qMS24naT3x0qXLU1tGxsKfNQFW39x6is+/dxncPmbjI4wPWpouFIUsAOvoakuZ2UnLnHbjNDXMrkJNMzbryxHkqBlcY9vU+gqvb/aidqr+7K7tzEgYx0NXJJyEO1lxkrkIBz37VA0e9JJWuGDpyke7Ic8Z47cVk9GbptIfY3KCW58jDqZW3Db984GAM9OnX61MYjPDBIFYjykYICcgc/MKzbRJSk5fcv76RdwGFJz0z68VakucLF5NwysihDjILYJ4/WrjIXLdKxNFfeVMFmwinKiTOMe7D1qxHHLLMI5LhlgU4lc5+VfYd6hhupLiN2uIA25doBAxt+mKuWj/a8Ws7yfaI0zbOSPnH9xj6jt61adzOcORXEmha9iRWVlhU7I03H5QDxz1HQZPvU9nbQ2Vu/lksQ+55FYhQxHI9TxjrViwQSSPFPI6biFKSHbgerN9QO1MmkQk/ZSC0WcDH7tGzgt/tY96q9jklreKRT1eYxSKiNO1zNyVZuinBwfTOAPbNR3PmzXUiqLV4U2wMZJCzfKPmbBGAM5+b2qxY2sUctxeTLLJKMYIOSWxkcdz3/Coo9PW6t1iSZ47RFLyOcqT/tMOp5zjqMmle41FLTqPLiGC0gibe126xvIAN8qoR94/wAI5xtHp3qKMJbwb5pFCuJJ3A52xqSF/Nj0/wBmrUbRRRmdrcfZ41bYv8ShUwD7knr9ahtEafypbmHy4n2jYEIL7R8q7e2OpoEo9COe5khzHAxEkgDMoXBwBxxW1ZQSMZpFj2TKVi3btojjYZZs8gELwB70xbCOW7F5eyNHCeOR5anHJGepPpVy+vx5cUEEBQyRg5HCruyc+pbGMn+VJJ7inrZRRmTu1v8AvF/4+p2/cqrZ8lAPlAHbAA5PTrjpSWtjBptnc3v2uV7jPlxNu2CJ3GGK57gZ556+tOWyMQdmkHmuCGdhjaoxyfQfzIq60aTWaeQyxwfd3MdxGOh/3iSeBQncGox0bINDS2t2L7uQcbgh3YPA5Y5LE+w9amfUZZrwhvlgVCroh+VSRhVznsOSe2agjSO1eGGBG8wvvZ25Zn6FiOygfjVuFbW3l8iKBpHJILygE7vYdM/hTE49UjO1jUf7PSG3O7zZIwJHVeI1IHygnjJ9+g+tZscSiyQiYJmc5cZkCjYevGGbBPA710MtoZ5JPLSPzZX3ZCgsT6k9uKo3sDG6a3VgI0jBVx0PODjHQnj6AfWs5R6lQvZRQ6CNntmMtrOFebJVnVC6qvVjzwMgAfyrWM7s6gSpGrAAiAfvOMceY3I/ACqaKILaziV5N53McAAElscj8KtQ2xUgzRLuZ87gdvb0qoqysVOEd2WoI0t4WWPaoY9AA3Pck9Sa0UPmmRBjJIAHUZx0Hp+PrVWJojKkSyNy2DtIPy988cCpPtkLW8flcM24grnHXGSev5VRyvyJmit2yzEnadu0dR7Z7/rUE1svMfmiPdnPyksee571bSRcjCoMKflAxnvmnPbKYmnmlEMAALPnGcjpiq6GfNZ7mUIzG2c+ZIDwVbB/CkcF5lGAk+MLuQFSfQEdDVO6njWQ+UkjKMZYkcD2H/1qZZyxtO3luS7Y46ADp34zWTmr2N+W6uSzXF5BvWYR3AB4inQK2PZgMN9SKZbXVuCd9rPah1J2pjyz6gjLK3rir+5WQeYjOEPPmdDjocev5VHcW7Ou6ML8wOQQBz9farI5YvR6FCKGwdZRZMI43LHygzGDPf8AdnBRvpgUxIpnlCzBkm/gePLqG77sgEduufrRctNbxbGd3XABHXA9KkNxun8tHXzY4xgOcFuQQAeo46HnmloS4NbM5DxA5GqsL1I0dJYTbl2JCx5+Zgg4J9eQcVa0yyRUnZp55rOSZjbLdKwidM5LADBXnPXPFX1nn1LWLu0OotYiIIVgdFJJI5ZS3T8DzUNvfXFvPGl1epfW73j2pZowUYBc71I5BHQjkU7GN2nqZ/2+5hUR2v2hUYHctvsjB9Tv7VXtW1CZ3NvDGgJH7+RmfHqNzEA/lWqWFtFGhjmj3nrOhfn8MgUgu0aYl4vOCj55XlG1fQAc4rY5UZ9xDa2u1JomubluFWK3DM5+pGAPc1dAu5xkNHZoAAyxt5kij0GeAane6leJjAqQQA/NLt3M5/uqGP6np6VQvZGm3S6jP5Vsoz5C/Mox1JyPmP4H8aC0h0t2yuP+PaK2jyI0dy7EnuWHQn261nXbW8wdAbu9Bb50ZgrSEdiFHK+wx71dt4zeBLmOK5itWXjzgsYCg8HGCQfar9tFDDEwtYpng6GWX90HPoB1NItJIz0ikkIt1tHiRvlcRsMr7Fvb6j3z0okEUOLe0cAIuCse0jPpnjJPtj3NXp3MkhV0SCHH3iccnnAReT9TjNQ+ellHvsokK5x5oAJBz6dvxzUs1g2NbTpLlhJeO6RgbkhIClh6jn9aszmKKESCByV5POOnsO3tnmqiEyq1xeymQAFzu5z7flWfJeCZiSGZ2/1KjjOOrHPQAevT9Kyk7HT01ZD/AGvdMJ3iHltJIMJCNjuM9AT0+tUmvVinl8y4bzychAWfyxz0HQY71bANvbkwSOXfOXVmBfPUqCeB2z+NV4LiUgWsDkwDlpDg856Ank/WudKTe5vTstLG9plwbiyG3LIB3Pep3UKFDNxjPHGarQXUkEP7xy0f8I+X/Cpbe4DwFpFUFgfkYgE/h2H866fh0Ohd0QKyoWmZcKisw+brg9cdhngeprPgtWhgKysz+Z0T69fwrSSczwx7wglc5bKDG1f4QOo5/Raa1+Ey8snlQRg7iwwSAOvvUtIXPIqMEgCQscOyZA56A4OKuRz7QyqpYYAVkHI+vrWdcXdwtiz3ZdJZyGABIKKBkJx1bGPxamaTcvIAlw+yY/MuHJAHYZzyfenbUz9o5bm/AGYlUO/1+Ug59yRxS3XmKOEcgc896qFvlEbGQyEenB+lRXk0NuPOl8p41OSzKFVaTlbQuD1uNMbxQyPJKEBIDc7i564AHfioreR7iF3cLHgDao+7gsM5Pfgc1Fc5nu/tQlQvGuxGHI56gdgMelaNiEmgeNyFO9VGOhAyenpWMXzSszrUrK8iGwLJbuFQlHkkLAEkfePRvXHeiQ+U8qeWPMyD5o5O3rkf49au6PHu0mKONiRgscn7xJOP8mopnQRo8a/cYoc9eef8a2aSVmELGbHNIkw2lg2c4bnJJ7elXV80zErBcFs5Ty3yM5x/KnxeVImHjO7dksRyD/hWhLcx4CPG0rk4BUfN+PtxTjHRiqLokW4poLmJVnljW4Q7Axyj4/2s9frViO3McoldUYuOeTgerZzjBFZd5Oq7TLcqylcqhUH6cngGrVrbtLGkSwBo87mUxbgM9CW9fpxT8jkknFFu4+zxr5ETBIT/ALfJB53HrzQ9xPJCkUUkoMQ+TzEwWx7DoPQHH60TBLYCGM7tpO4R4BbuAzdFxnvUbTbfv7Wnk4S3j4UY9Sefqx/CmZ2TWhWaEvcPLdXCs6qCVEZO3PA3evOcYx0J5qdS1ukUod5FA2ysQXz24wcgDjtSyxiK2WJnDSufOnkZMDpgfQAcAVSL+Zcq1vuWKPGJJMbEUf3iaGVGDatc1SzfbYri+lkuLhUJQyfdiQdSoxgdMD61XldZm3zF2nYBiFfaASc8nr3NWLfVVLPBcXbzynazOIyAinoAT274+lWme2uIiJ4lMqjJdBkntycDp1oJi+R7Fe+aEJGgjRkHOD9xTj82P14p7wItnAZJJmdEO0E4PJ9hxVhbKAt5kcsg3EMoePocdSfSrFxN5h2Ksc7ADJMeOnf6UthOSulExrRZZDuWIwwLzktySP1zWlb2qQkTOyIoOd5GST7AcmmW7rGC926QMCAqBQGP55xUUspDh5FkaNsFc4//AF1KfcuXM27aItw3Uflt9nQoz/KzZG5j/Qe1U5FffthYqzdWPGDT7dEnUlfM+UZyuPyp1soWYs+3KfMVJyeO/wCdUEYqA2WGTzGLhfkUIshPp3PqOtODSRMPIZmGNzADOR0yoP8A+umlZ23AklsbmXPA/wAKsQXUQYxsNsmVDsV2fQ49/UUEzlokyS0RsSSxQxybk2xlVG7J4JwcZ4z0NWJbm3trwQyr5TBQFLZCn8TxUxeRU82KMbhnA/vk9Tn19+maWC7iVCSdgHVWHI7cg0zk1buidP3cYe3aGct1YkOPqMelUNSuLnzS8bl5OuN4II9MHip5IrKQ7fKiwfmDJ8rA9P4cZqpd/OgCM6BACp4bj/geaYQTTu0ZE4cyZuIEYSE8bcc9xnuPetHT4EBSdYVDN91gclx/d6cUMl40bN58ZQAgI1sM8e4Ip0clzFDtzaBgQuPmQbfQdeazUNbs0c21bqWcgSY2NsTqx/vZyBTm/fSHa3kyL0+bAJ96zXupVeNBaOhUFsI6n8VBxmoZ71ojsUuJW6rJ8pJ9BnvVk8pbe2aRiQhAT+LJx/n6VUlhDFk3yO6nKLt6Y5xk9fY1pRtvtDArAk4YDGPn/wAcfyqjNam5tyrvlwBgZ28k9PTafwwfY0mJbWkc3r073rz+Zp1hJHaNHHIbwZky5+8NuMAcZH6Vq6DcxRM63VpAt3ZM8CxwKAIo8ZOA3UHOTWY6ST3l4kWnC+IRYZ5/N2EA8gEDOSMfe6jFTWlu9jAqXlq8TtKX89ZvNLHHBZvXtg4+tNbGfKpS1ehQ2yPIGEk5dxgyFiFUdeTxgfzpktvA7iVLd7gLz5m3aFPqvYH35+tTi2e4gJlCmNATsMuAfrz3/E1VSaLyDGrmaVeFhgQJFGPqfvVscVhtw159sTB33BHyoyknA5wG6KPUmiEIsj3V1byL/F83zo5B4+Y/njA9TVmGJvKQMdiE5EYJZnPqew/z2qDUNTht7wOq770Lww+eVQT2J+WPPr1NBoti22dzS3oiYqfMWMbT5fuzY4x/+qq0+oXN3IjWzMiIBh84Xb7DsPc9azWi+0P/AKY2Tydi9E9yepP9addkxW2ILtxCeodN7yt6cc9fy7UjVJLVj7i4WGCR3l3Lnh2GN30Hp7d6htDPPMl1cHyQqnykB4UAZLHHp/8AWqkbK4E0dzdrHMdwEVvE5yT3/wDrntV+7kuoECvGEdyBIEcEAZ+VB3Zj1PbpnpUs15kWLm7e7dAsKM7rmGOUY2AdZHI7e3QcCqc1zZxxjmd1kOSA4JlAPU5xhcn1/wAaju5ZrazaJlTzZOZGZwflAyN3+yOyjnvWPfSzoY402q0hGd+Wc/7RH8l/wNQ9So26l25ljaPzmuyiN/rG8oliM8KCDwP5/Sp4Lm2gWFJTIfN+6iIFCKO7HJwKzF0+Yfv53wuSEjdhGOONzEdfwrXtUgtmWFUE0jDBVAUVSPXv+FRa2qNIu9i6L+N2iSELCWyq7vmYL6+xPtUjWqwxMRhWK5JYfNzwPrVGFGdpDAI0O4lzGuAx+vU1peV5dt87jGQDvJ5bjA464pLme523tGyM+4mMcix+W7MyKmWb7qgY3H6nNNBLXFuNoeN2LQoRuYhRyx/QAepyela+oaeiuFdR5jlWmLfw98MfXHOOw/CuXurxRbTPboI1lAhWRvvbDli3sMAnH0z6VSVtzGU1y2G3kpu70xW87SyTHa0g+6iD7+3HXnjPrwPWnQO+6SXaN64hjA4IGeg9eT+lUrBhFA06ARswCj5gMZ5AHsMD681p211bz6pZ2cKhTk4G7J4HBP6nH1p7mSlbU0rdfsEfks3zONzB+dmeQPqep+oFV5wLxdSRJCchGAYZXBXr+ea00mWdJTKiByGIyfvdOR6ccCs17XN1fpBuWKKCBQC3O7cSc/8AATis5xua81rCzp9jtSoACnIKdicjBFaELRx2qsQSCT5gHThen4c0S26yW7RSFVKysqsOhOOx9eao3EXk6Vsz8kfmjcT09M1EE0zqvzIvacGjt7VUUNC8YHIz1HQ46Edc/jVm4Zdk8cmAyqm4gcA5wT+tYVjeJDMY4QRGYsSZ6yEY6+2D0/Guisl3bLjHMkTZ5DYwOwxyMgVva4czjqym7xxRRkSITnC4+tVvt0ReRnJVu3GQef0q3PZ2skgSKJY51cOxQnHXIXB7f1rMvI44lYAHdkkhuM/WpbuawmpOxPa30nmj7EXMrZKlRkgewp5vL+eeCGRpJGmOFZpMZA6jHY84rNjCwuScorcrtPT3HtWlbMWY7Y0kRlwZNpJA9PeiDdtRVdC/baiba5Nm0TM5ALwg/wCrU8BuegHPucVoWdtKkzPMWccMzY2hh0VQP7pP/wBes6K0hUSkzQRtIAZpApbGOF3Z/QflmrV9d20IgiVLiRVQHIPysf72O59B2qzjcrtJbk08vmTq0rrK6nIQHCA+p9fpSXKbIt1w4DYG2Mr09PkHbv71nQapCsiCAOjsOAyEsP6D/PNTQSQukpkmYsrcCTI3n8OfzNBoovQkso5ndzDnccHdIQcn1K/5xW7bQqJiJWlkcxt5YYgdgDux3BPUDGKyHBMMbXUaeUQQkCjAY+p/+vUxvCFEssZMkZJDLIRgAcgZ6DH8qAqpy1Rup+8b94y7eCw3Z5+tQXkxjO5WYADgnn9aZbzqFUBhs4J3pjmop53DNtIK7ecOMYzxn0FBktyhePEmx5ZGCuwyXXkH0JFauWkCjaxGAfvZBPsazw8kkwLSKHYYXDqAV9OuKilsntbgzwCTacEK2SjnPIIz2HfrSSsaqSlpc3oVeO3KcLGeWCDn6UM0MSgE75Cdpz271iC4ErBmDW8iKAVkkUD35z098U9LgGUO9yJQDysK7/1PT61POKye7NQXPRCjSSOcZBzx6AetW8/PkkO+7Ii4+X1J7H6VjS3Spa7VRog3PyDLEfUc/lir4KxQtlQu8fQBSewpp3MpxJDdJKzbGaKVRt2gjamf9k8U2eRpSmx4ndBh1DbCfTaeQAfeqrTmCTiQOjYJKuAyj6nqPb9aCIrTEglzbkn5/wC6D94evvT5kyHTUXoOe5kjK75EGcKEkOG79hwT9KjGoyPMVcoBjO9QzYHvkdKq3fkArBdGQncCVC5WQHODuPb3HINTW1xAjCNW2vjavnklh7Fu9Mdny7XNiyeLCPNL5pJyR5e0BfX9e9I7205ZhMrkAkAoflUcE49AayobloZV88vbuwwSWPOOg9D+H5VrXd9JI0bbD5LZ3SL/AHgfWi5i73ujMaWEQeUJImTOSjPkfh3B/Kksw0rFNyyIQF2uM/mDwx9+tWNQaGZGW8RcHkHYMAY6+9c+9p5D74MI6/ddC2G7gH0OOlDsikmzYO62nZIy1sQPMML5Mbdtw7gj2/Kr0kyTEuoB8z5WThhk98jqp/OsqG8nMdvBMwDynEYdcq568t2bnGO/UVciVBHM0cb27kEMzjdGCBgZI6evY0k7szk7bnN+IJrf+3biaS7nBiSNUELNGZExzl1B+bPc5Faeg3dtc24FrdXFyGGWivWPnAgYIGe30yKe9trUAVZNTtJLZxhpDaZI9Qy5+nzDj1pqWV1bW3lajjUIQWfIjx5SnBDKOSR16cimZxaZzN1czXUscUSQCMHJVmb5fXhep+ppZJ7awhMDIoZxlUVdruc9wMnb7556VFuZI8WDCEEc3b84HTEQ7k9MnpViy0/Zhghwxw0s7EsePQcn6CtjkjZ6sqzy3U4HnlkiP+qgj+VpPXP91aWwtZVk37DJcv8AMdq5CcdQe59zWnPcLZhfs6q07AL51woGT7L6D8ap3lxcW8avLOXDEkDblpGPZVXjn0/Og0T0IruaC1gd7uVk3DCRR/M7kn1FR2kXmOs8zOkf8IOEVB2AAySfc0R2s3n/AGm8x57DAhBDvnH3dw4Udtqc+prQSykuZY4ZlCluPL6bR/tdgP1pDb6sht9lw88+2OO3jXDzscHA7Z7L3IHX3zVJbxPMeXLNK5wvmpjyxnrjsx/TpUGr61FNI1tZr/oVvJ5cRB+WeYdxnqF/Ide1ZyxtcQi4nmaK3PRujze6D+Ff9o8nnApAlcu3c0j5WOKIiPnqSgbrk85OPTqep7VFZQzw3HmRw4u5jvnmdcFRjoi9AT/KpRZzCKEogjZhuSHG0Rp1GSfzPc+tWwWihSLzQzFdzynufRf1ye4FTY016FNmm86aQsftBXqTkwpn8tx/Ie9LbiOGdbWIGSaRTkjsOwz7nueTUUN1ISrBnKmT5IywzK/95j7Dk+mAKuaVJO918024H5jJ1LHPI49OmBU9bnTTTbL9nAiMsY5bPQc7mPbFakkLQTxoAvmREuWbDBDjHIPBc5OB0AGTnpVV5fsicENdscqrLhYl7yNjnA6Y7/rT9PuofLa5u0VbcKXXcMEqBwfy549aaLlNv0KEvL/Y9rIkyNLIxkJIjHJy3qx4J9M+1c9qi5mdIxumIweOAW6KB6DqfoB3NdBqGJ7lUR5ra7uGLuThxEFXJBHogxn/AGiB61nyWER2HzNjsPMYOp3LGVwB9TkknuSfSk1Yhy5mYNxGHgnZRhRsWPA5+8ASPyxWjpxikvLi+RCdoEMb52jcSASPbAIJ9Wqa6so7gMUnhgyUUltwIGei8ck9B7/jTdHCNp6O8ieVNMVjWKMkRwrlUUZ+hJPc5PeklZBOTlOy2OkUT+XFbtAFkeVVXYcjpknJyccVBAIbiG/uvN2CRikUjEDMYbZk/iGx9azbq/hhlXyZJ3ljTMTbwnzPn5fYALn8asCW3g0uytLa3jJiNvEqsWYghsnjPXIzTC7vYvuzSzpGYtmCRtIyT83+Apt+qy2BVQEjYqSobrlsfn3qaXUom1ERywRsyx+c0m8njHAzmpJktooLCFIYyjSoH5OCQCeD9MflUWOhSstTMvLIw3AnXhYwJHVRncoba344YH8K6CxIEiKAmep2j5V5Iz9D/OsiQob2K3VCfOLwkySHABGM4FS6NeSPNZytEvlCIiY9gAMHnvzT5iql5KyLr2xuGmDfu5ExyVxuI7Ef1qtd6dcSSI7MwgOAVdgSSfTPOelWDPcaeWS9V50gYYlK7iuT8u09x7Hjr3p95JiQxXPzqyB0cHgr3Izzxx+tCSEpyTsigLZYHIjjili5ci52oVPcj1o89o03iaWSEnAjiQIp9iccH6CpYbOZ9jFeIzlnlIVHB7bzTBFbWdzIrsZSD5ckKthJD7sRxnOcj8DT16FNrqQbrprhGUsdPAJIU7s/7BU8lzj39eKlYI0zy+bEYpgsohkOwqegIzz7fzqe8DzxkoqRWBICQqAFgPqOuWHcnO6ppbiGKNIpFV1ACLPIN2Pz6d+tBGvQx5beSOWN1EsdxGuQUwZEB747j2NaFncRyygalaRRXC4OYE2ebn+LHT8OvUUyS2D3cjIoUwqj7wcMrNnJ3fQD2qK4eYTlLsFkUb1l29+eD6//AF+1Bpzto11hR5CLabzmI4Enytj1XsfwNRpEfPaMq4dgylSDgHBweaQwmSARK0bXBPmRlRjd34B6Z9D3qykyyKhB3qqjLYORjr+HY0DUm4iQyqkKOzyEso3bxlWz9OR9arOV82Pc8kY52SZBOe4z/TpU0pxBt2EoWKKRzjB6fyqlbStDciF9qWsmRhiMH0YZ4zmlcIpyjzGjFBFlnUxMX/gl+TP1H3SfcYqxFaxmJ1ljO1sfu5BuB+jVRkhkgj+XMiMfmSPgj1O05HfkflTTfRQxPDI8lunQjado44bHp6ihmLd9YsL7TgswQRIrhiYmQhXAxzgHr6YNVtOjKyrBL+5uYQTFlCpA6Ej1XnkZ4q0t4k0aW148TkthHZCV56Yzn5W9aWeyuF3EuqRqm4GNgyEnhcE8qD78fSsWlq0aRqP4ZPUmhnYXK28jKZ8ACVRtDjuVPY+orQieC7UtvLEZBDHtnisfTpnZJ47tUEgOAUztbI5ZQeeBnPPGauWtuIPLQuXQsMMf5MP6/SiLB67mjJblIYnK7jnhmP3vY+3TikCYdkOTbyjB44YD+LHp2q/L89vHHj/U43PjOB6D1PvSKhedDHGRjjY3BreyRk56amc8H2m2aMAjau35zgLjlenUEZGeo4rOkSSFxFcjO3hJQc7c/wB4e/rW/wCWUnLsZPJ3BG5Gc+vtVWeFbm0KR7o3jY7kAILD0Pc+uKCFNr0KNkJ4bVYb/fcQsQDGVyR6Y9R+tayI8UaxRbYo1GRGV3Y/DOSPpzWDNAIk3xxkqvzBMA+WB3UntnNXoXXyxJGxkAO4gDkE+g7HHp1ouZ1Iu9ya5u2SN5NqbihVVXlT7j0+hrnd9xbSl1zcWx5IXl48dQV/i/Ct9ooXkMglaM7sNgZEg/2lPBPXng1QawkVnTAZC2PMiyVGDkFh95T7jPWlJXCnOytcs2sVveQFreRJIWGSD8y+h/D1HBFX43mWGSNJh9sRAqh16jIAY46gdD68HvWXZMvnM9qY7e6zna2MXA9Mjhj79R3BqzdLLNp8xiO28jCsqk8cMMqx7g98fUdKaJnK/Uqy3V7YzSQXl5olq7gEbjIDjs6jPIH5jmn2FxdpZyFri3ukilYubJyVAOOhOSCOT3HPasiS2k1O4u7mKJZJXEU0TsRwYzhosHoeo9Pzro9CgmFncvJbCzRpjJbRMASI2AJ+7x1yfxqlqYSTWxy9zdRQzrGpTzcFYlEeVjx3VcfM314FMuZ7jy3kmmePP3ySGlY9hnoD7DNN06O2sYGLBUfBLsX37cdAT3OOvaqU1yNSlSKyT9zGOZJHwM59ug9hye+K1OeIlnbq8hdEHm9fn3Pz792PsP0qeWKO2UyT+Y0rZDNv+eTH8JP8K+u36U+1kVEaG03TDJEk5XCsfRR2HvUbERyCeY7pWYxxIo3M3cbV/qeABmgtskg+0yMzblibGdv3UjHq2OfovU1U8R3skFo2nacd1zIn72aVtuxe+T3dvQdBxV0Ry2drLe3JgW1h5SFicSyDkl2HOB6DrwO9YkbzxmO+ukabUpOR5ibApbuq9gBwPz60hblXTtNitjHHMPtV6qAMAMRwKf4ce/fue/pV43WyR5IF86RWEKIF+/IeignrwMk9hT/ss+8R7vIMi437fujHRV7nqSWqVY4oESGyQSqi/u3kJJZmAyxx0H6mg02Kk80Vi22WTz7pxkqMkSP6seuwHgAdT+lWZmi8yLezyFgkzEDcZMfcHbvjjgdO1TTvEsgFvI0jq+HnI5d/VR6joMcDP1NXrKzeIiWaIJJIWSFM8RKepH95j0/PtUu/Q1irblXyvJT+Avbx+WpjydzEdB6kk/lzWxa20eleVGmGvAu05GRCOmB7k5yaW3jGnxooVJL+UM8ao+VhAPJz69AW79FpA5tkVlZSzElXxlmfHLn0AwQBSSNea+iGXtuQpglISS44lnkY46ZY+uFX9SBRrdwn7lIYnjs7cBpJCASvPyKB/fJ5A9gTUH2hmRlgkM85Ajkk+8A5YHy1PdycZ7DHPTFJHHsgtBGqmJJXaEH5/MmJ+ec9yAflXPU59qdiXO+g+2inkl4G24IxKjH5R3SDPooO9z3Y+9TO3lXxEI3lo8SMQASxcZ+nAOPapLWMIkxDEGNCFy3Oc5OT3b1Pc+wqr5RuZrpsFkL7JSO2F6e3VifbHrRYV7GX4huPMVI7UjbvEgYc5JBVf58fn3qxZW6QmCGDKxRjyIwOhRR1/Qn8ajuYP30bSuiSXFx5qKxJbYvHAHoqgDtljV2SRVjtrW3UrPcoyIzDKoCeWx7DJ546CoKg7JtlXTYTcyG4IDQoxjTdwGbbkk/3sYA/OrMm2SGMxblWOVVDtgM5CsT9M8VcFtm9+RyyWkYiALclm5J/ID86h0+JQmnp94onmyL23Nkgfrj8KBxl3KqoIoJ55Qu2UiBWz3HA/wDQQPzqe3vPM+xRZ/1SGVlIznAKgfmSKsRWaf2d5UcbNM6tMRnAJbIP+NU1EcUkToFaZrbcT1C/MM/U5zSs76mnPdampNEifZb2UFQkoYL3Y4wOPyqC3WWWG4gVlijV3hCgZUDfuzjqTj+dVo55BYQFpQd0nnbWHKjnI/mf0rYmiTY8CsIisSPIOdwLqCFz+RxTsNS1uPn2JMovGdvM+X5MfIR7nggjHA/xqxFMVQWy28McUXzB4V5GOThjz6Hb3561QUlzcRt8xUq8Yz1BXBX+VRRS7drxPtaPoGOFkX0P0o2LsmvQmvYiHlh3eYdmQDzuQjORzzUE7RSJGu+OWIQriRhtZO2CewyODzitGEwXVtuEYjmiP3V6oSTx/unt9ap3lrut4ZIHJAzhlGJAc/dIPp79e9A4zvoxVZ4JFZfnxgOhH7xBjkMP4h3z75qxOsaj7XHnyxHmXdgjbjncPp3qqXUkKJzFKvETMu1kI7emOeR2+hosfOuXd9imG3fBTg7nHVfdMjI9fqKBObTutyzpQWSMsy+TM+SynI4P3F/AcU8Isf7vKgLhwrAkg9yPapJYjMpntQ3PylQcn3wehx1x9fpUck8kexlOSfl2nBHXoMjn/wCtQEWnsVJUaCfzF3NayN8205aI9mT/AGM8FT0yMVLG0VzMt1ZOx3MSWCHbIQQGDr1Vv19asKYZYCJVSKOTgbCSmCOD6rnp9aZZw83BcNHdqwS4yTywxtk/EY/WgpvlZLaSRstwr8RM+4g8/N0Jx68ciqd4TDLsKhgTlSed3+fWpC8kV8uZAQ6bC3Qhl5yR05GR71LtS5tmib5JFwYy2UAY9AP9lvXoDxSsEanKxYrtlYKm4ptCENgNg/dIPT1HvinyyLMnzRwjnaCwKKD6Ejof0rMnleJlR7eVoJcj50491P49KSWeazhQR7Z4ouJN8nzbT0zkc+nzfnSkQ1Z6Ega3M/lOkwmX5VhlI2ycZwCO46jp+NXzOZCzGd4I0O6RjkFc/wARBwGHYjvweDUIMVzaxNhGRj+5JySjjnaSP0xUqjdbmW2aOVEG8xqRyCcMFz/CePoanlJmy3xexHz4mhKHKzQtyvoVI4YH1/A1Itw6zPvQrMhG75OCuOGXnBX+VZklkfNV4YykgQPbzou0Ff7jKOCRnp359Kt2TmMg73KK3zockocZz26+45p8q6jU2kacStbKWg/exjkoDgbiP4Cf5Hg1pwTR3IElsd+4YZ2zuJJ5+hHoazY545XUBmWc4PlHjjHVR0YcdQc093lCI0TP5xyWyPlbkEZ9eOhq7i3Vy9foSsYCr8vCDHLDkc1WuColhwSI3JUndyG/xpk0rzvsEhKKTuB6g9+nNJJOEuWLoQDxxgq3oR6kE0EPRISdFMRkljTezfcJ/j9vXpWb9kPmyXMMmJTwT/QjuP1FXLvlAt0uU3DkDkZ6H296imjdnWWBvmjOREwxv9CPekIgNyqqs5U7Hby5UYZI98+v+TUytidZYZVEedu7kHjsccH602GYPOFljwr8rnjjuD70yMfY7lnlRntWJEqgDKHrkj+f50zO1tS4zwTvJHdKFYAM+7pjtu7j/eFVCJIJ8+ZJKsqmME8y56gA/wAQyBjPrwankgjljRZJOpJQxnDKP76t6cjj25qC9DJF9nuIzcWrDcsyHa3A9uVYe3H86Cbp6MybOeC2166vXtrt4p0Gya2QtsP8alf4TnB/zmtzRPMh0u7WSF7WAz+bbRNnKxkEYx/DkgnHY1zOqRRy6g/9mQajcMscbCSO42grj7jc4JxnrzVzw9qiwuLNLW9hWVmEYun3qZVG4qGzkHA+6eDTM+az1KH2A30aT6m3k28a/JbKdzSfUDqf0HvUc7ySQDyvKhRwPLBONvbnHX8OM1Yu5ASyyHfkZZmkCrH7s3qewGapI6SHzXQPFkoGK4Vhn+8eSOO3b61qYJ2HvIttCEt8MSoUE9Wx69lH6/yqpaLqN7eGa4P2S3jBM9y+FIj7Ki9VXsM8k8ntUbRG7nhDy3NxJvLRRoqqm/pu9AFAPXgD3rbmltbKxjsbQPIu4MXkQbZHIOB79z7DmgOpjXQhubuMXEbC0hx5VnAC7Y6oCT0P8R7nirFoJZGDxW5hDnDDl5M/3dx4HqcdOlWLeCe8svKg8xI3O2S6DeQHJ+95eBk9OvpUN9dxRyRWlnG1xM6lVDkiNF7lupIH3if60M0A2M0swt0jL+ZuaYj+PuEPOdpOM926dKiuoLq3TyMM+/5pZ2KIXbvjPQDnCj8as3UbWtqtvG7CS6w7si7X2AdB6FvX+EdOapiEW8m8xiW6kHyIoBYjsBn7qjGcnrjNIcU3uOt7UW8sFvbxRC5Zcplw7LntjPLHPJ/wrUMAS5mjtts9ygI3mTKwjvk/nk+9U9PxbAx2bRm5kJElwoOwMOWGe4UfTJPOKhkk+zaa0NmwWV2Eau3OGP3pWI64HIA9vUUjZa77Fu1VHea5EiTB32bwuDMVzgH/AGRzgDgDPeq8rq9qWLzfMNpuYwFIH8TL9cBRgdenrU32SCKzje6V0sLaPy7a2Y/NKO7Se5PJHbp61ly3Uckcl9eSstnC+CyDt2VB3diep6DJ7UDlotCyyJ5bwRQiPCl8CTHlp0dgR0yf3anv8xq9cRNaWFu8SJ9tlKQRqFJVSxwAM/3VDHFQaZE907Xk0awbyohgzntgO/4YCjoBz1Oau6pPFbxxIkgN1BETESMlC+SX+pX8gfemZt2sN3CJpI4cGNCDuXje2cYA9O1Vdk0lnZwxSjzp4mllcDA+c/eI/EfgtF8RaQP5echSPlOcSlen/AVyfqwp+ryw2qxRLmNFj/fSHoFVQoH4c4HrSbsDkYySLPcyXCMVs4SI40Vcu65AX81Un6tWtbLLb6nPczL+8W3VFiJyASd236IvzMfVvpVHQg32aNIopHubib9xb5AboMs3YYHXsBwMnNa/mxzRSyyyeel3NIvmgbQ6Jx8o7L1+oxUpXNb9O5VKC2sJZ3dhKFeU714YucZx9CMf/WpYo2Jt4o5tzJjJIxjC9fw4qXWE+3QXX74DEgR5WGAoBHX+VTXpWCa+khUeXAC2F9SMj+hosF9bFpCyaZC8bjylxHJJ3PGBj6nBrJMEtjI8DDZNBbJGFPOBnr+fP41LCUm0PBmcRtF5W/vhsDA9+w9zVWwuDqN5dyXEbj5Fj2A52qDkDP0pN6FJaklgFXV4rMkBIogxV+pTb83PcnOfrkU55n+3aqWh8qV/KmyTk7SCMgdh2NXF2xsLoB2MpjtSRwMZyc57ZGDWddxiSRZYZS0ojMJ7sCpJGR7YPHtQ1oP7RcG6OSBSR8yBGJ7Bl6g+xxVWSUw3W1grI/QYzn1GPX/9XpSJITHCrFFbYBkYPGTg/T+mafdJ50DyKu7B+dM84x1z9DU2OiEtSVZvsVwm0l7aQYyQcrzgH6dK1lm+2RNJbZ+0DIlDruBxwT7EY5x25rnftMc9jLBdSFY4xvinVyNuPvBvwxn6ZpIpX+2q8iPEssWWbdtE7AH8gcfeHXPvQmKav6mnIU1AGL96kSNieY/M0e3jHqR1G7BwODVu2C28IiwGSJAm5G3CSIHoPUD16gY9OYp4lMdpc2sRa3kG6Fl4dOOYww4yOcZyCBjripLC9guAUhVTcnBEQGwMpPJA6E/T6GmY8raukWrZpYbgebIjyyMfLZjgSrjKhj/C47N3NTalZiazBXBjYk5PDCQHIB9O4qBbIr+6SUqobCCSMk5PPluOwPUH16d6uHiSTEoZEZVmj2k7fRhnv/MU0rkynqnEzbYOkogVJfLbLADkg45+oPJx9e9TO8dtLBPvDRSgQyE+/wB05Pvxz61KlrJFcNGJN6I2Ufady88cflz6Uy6VLiOVWiIWTKSR7cKSeQw/EdaRtOSkVtejEcK3EQIIbAY/yx9cVRS4uFhWaFUlgnXckTE5X+8gPpn+laNj/penPBclsyIw3ejqOn14qrHAkP2q3BLBnWaPJwV3Dp+dJii+jLKPFe2SyWKSyw5Mc0Eg+fPdlHf3A9M0wQLujeItv/1bE/pn8P8A0Gm2XySypMEGdp8wDJ/2W/PirEMEqSm3nZ7nTZwsOeskLEg/e7r0IJ5FJq6BycXYp2CRW9/I7QmNpeJDEcbx6svQkEAgjn3rUgheNorhEgmZQSzRLglDwWXPIz0IqkkTyx7kZLmPceWGHUD1xweR1GKhivoklEd1JLbsWyGfIVv9pT/T8xVJD+JGrFY26yNGloVmBLqgLL5gzz3/AP1Gs5I5tOusPLcTxyA+W7yHLcZ24PRx27VqTNK9vBJEwuY/vYRsv/vpnqfUdamusXEUZTY3mOoUgkDOfvD0b2oMrooMws90t0Hmsjh3d0AaE/3uOfrge4rQS5ZZ44Jfm8wjy5upxjoT0z3B/i+tVHTJUK6ZJK5Jxg9OB/MHio45Rah0mUmxYEHjAj9Qe2z37ewpBKXVGpeSpD5civlwCJCBjcvfj1HUD6ilV/NVuEYbQVJH8PoPY1mTTSwEifbLDgOsz8svcBsdQP7w5HelidnjKrN04Ic8/T3x2PcUFJo0ZpQlmjwI0kSjy8bvT3/xqMyO0nyyONgD9eSuOh9/pVe1uM2FyCCske2UjquO5B78UiruVMgH7xQZz35TPp3FBna1xbkyLvcnckqhGU9MdQadblAHQRsJFA35f51zjGD3/Gk2BYvMUE7WLbcZLD0qOQb51RSeCVftwRwfbnn8KY73J4j5JCx/PGG3YXse5X+6fWiOdlLLKC0bcjaMAkdxjoR6fl6Vmm6ddrqihm4YHuR79j3q3FMJ490JJUH95GF+Ye4HqP1FMycWjN1iVbK8nk06eVjchZbiBLbzlXsJD0xkfn6VDoNtG0cMkNybhoZzMVdcGSUD5dw/gwvT1xVpPttvqU1xp4tp/tIHEjlBJgYyp7+6nkEfjTrCzUy3F28kS33nESrFnYuQMRnPUcAg9jn3FBi+xnC2kVw975MXkg/LE24Qbh0GRguehPUe1V5l867SI3AiKjld4JBboO5LcEfjntT9QuHkeOK3jZtjMkUa9HkHc+qr3J6mrWj2SWUcrMFmndi6sxyeeC/tk8Lj69q3bMh9tbw6ZaXBuSv2p1w6Q5YIg42DIGF9T3Oap2s5nZbsxGJWVvLD8uwJ5Zj0GRgDHRasXO66TYVC2wbEki5Pmsv8PqQDwfXGPWqNzB/aDyxfOsQGZAjFXK9lJHC5PUDnj8KkFoxLu4uJ76QRZdo1EZuJGJCZGSEHdjwMdhySOlSadax6erXTCSWeXorngDPGT/d7+/AFRrATCthaBAnW4weEXqQT1yeBjvzVqUqgRJckRqJJBgbiT0GB37AemaDRO5HcNv3s5eRmO+V0yWkyflRfQf41WtYpbq5ePzVj3kyXV2Puoo/hU/3R0yOp6VaWGa4nS38stM2S6B8KgPJ3N644wOB61JI0cVqZZWLQIymVwMmR+kcaDuM9B7ZNIpEV3LHb27JFCQ2zKxAfNHF157Asfmb8MmptMt3Fu0l0MbG2OR1QjB8tT3bn5m9eOi02ygkjja7u2CyORIEyGCc8Mx/jOfzbGOFqe82RRxIwYQoCqITgnuxJ9Tnk9hSNU76dDO1i6BgV5wmZCBFATgORwFz/AAqOSx9M+tZ1rZtftHfXIL2kSuYEKbPtEneXb2XOAB6D60ltaHWtVWdsi3A+8vyhUH3segJ7n2966JEje5QiMiMqSqdFVFx1/QAd+TTE5636D7e3kjEcILS3QAdlbu2MAce/P4VTv5Ikv3nQI7BFWDK4AGceY/4gY9cCrME02y8nhKu8hMcKvkea2Pnb1CjON3YKaqxRr50LJ5VxJv3KCSq3Mv3VCj+4gPbjOO9Bm2Nu5BaxW8s0jRRSArCWXL4PzPIR3LYxj0zWBqdyZmndlCXEgWK2SRsiGEH5mOO5yR39q19Unto57p7i5ll8qM2zSnHHz/NjPA3HKDjorGpdK02P7PaPtkae5f7SQ+MhRnaxA7ZPA/oKQJ9yxbhtE0B5pC8txcLukDNtfO3aFJ7DJxtH972pZrbYrDCpHaIkGIuAGVQ7kegBG38Kj1KOO82ybJzbRXqnO8btkYLHPqC5znrk1PqLRSNMkaSGKGNfNdmH7wq26Rs/jQaRT5hl0wuNPsrQfJDcXAMu77zliM7j9SKa8b3dvdPG+yDUZnXdIm3ChfLVgO/Rj+VWpCbWBHWEbtgUbvvbmOSMngHJAz/hQcfZk8w75QWjVm6bV4Yr+DdfehiT94xBcB9PtY7ct5MUqvHxgkDf8ze5IH04qzoAina8tywSWR12AH7y9evr836VDZx/ZWnimDKsTbGQj5tm/IyP+BCr6iLSZrq8mRDJEkUIAPJeTlmPsoABPvUWZ0Nrlv3LF2qrZeTKH2x5iJBG7I5D59SefxxVXUk8uUTqoUyOjK5GAHJBBJ9OqH/eFLe3SmOGcyJID/rIYxkuMHsO4IB/GnWoOpWuoWsiBoxvDNKcAjI6Dr0IP4VTE/dWpA1uWj8u2jKXce+aFc/eAOWT8M5x9agN35rJcWaNMzph1+6E9iR+I49ahmjeOGO4mLTJG5aT/ZPGXIHJU4IPpnPrWjDMsU0excQzglZkG5UJwVJA6gjuPQ1NgUrO6MqKFkuEup2aRw4kR1X92x/2l7HqCfzFXQkMJWGR3NksgmtJOvkLzvjH95QccdQOR0q3dqDDM8lq727LvkVWDDPdh7dww/EVJY25ns5BLP8AabIKiqwwcITwf9llbGfZuKlRsaOV9epDpxutEluIAC8D7p40xlWxyQPQ7f1ANWr2yguxLPa/LJJGsy4Hyvk/MwHVT/eX15pqecCkiRK0kTbXg3/LMoB4B6g7eh/A1PpkTWUjWgfzLdS3kTYw0bLyUYDpx1z9RVWtoVz/AGluS27STQxzXCmWaFdjkNnz0JBAJHUg556j8asO29kngKu3HzqD88ee4/MEdj9ac0bod8cai4yzvHj/AFrAdQemR1x3FVIlCywTWyh484kCk5CN0Pvg9D1AJHIqkrGE9HzIntsXFuio4KoMrtOWaM8qPcqcj16fSmXRVgkF87qAf3M4yGTj749fcY+tVYgdPDyqQ9hcSExyRnHlvnDZ9OcHH496tzSebbH7QWfbJkbkyysDzgY4GOo/mMVLQRk0ijbyyWGpOLlFQzHJdGBjkPQEHsWGKkk2i4iLCRMKUYqM7QDlcg/iDTtSEotg4VLlIWLBsZ3L/Ep/4CT/APrqSR2RZZIwfI8k85+bHGcn6YOe9Iq9ncbJGWWNGnxOqkKSuEcDnBPepUneJwk27yduQoHzhD0K+vIPHeoWDgLNby8oQHC8q3oSOx96twIty4jCkMwOYzjC567fTnnHag0dmtSvqsCx3LMD5a3JWWN1JBVj1I7EdMqaSGdruN4ZQjzL8sluTkEDjK55H6/lVj7LHPphgnQFIGZQTnhev8ielZNu0Lym1lMv2y1G6KbO0yJ2IPfjnn0NJ7ijGL+RpWFqE3LbzMkEpzKioFeNx0Yds+/QipistreTrcFJLa4XYSQRhvTjoMAkEc9j0qsv7iLzDG+4Zd9oywHQsB1K9Mj9K1rWSDUbdldlliZeChBww6D/AOt6/WqMpS1u0UJJJYWa2aFzPHj94erjtv8AYjo446ZxRujurdrm1fDjIkLDkMB0K/oR6etWNXEqWSF2d1t12tKnDQp2kX1weqnjGe4rJigdLuOWVlEkibZvLH7u4H94EdGHB+h70NWHG0kWLKRreJlfCQqNyAnPlHP3VbHMZHQ9uh4qG6WW2QSxcxgb9pXmInnqOqHuO2cjirAkZD5kbmGYNtyw4bHYjofT9akIj0+4dJmaO3dDJCeTtxyUA6EDng8gdMikiHo9CxZMros8Efy7SJFZs8e47jqM0z7NHBdKiOHQ4KyHq4P3T9exqtpkqxXeIt4KgzRSEhhyfmX3X2PTODyBV6WNWiGws1tMu5QpyEPQgeh7fgKCXKw8RrNC65AUcgg4J9j7jFUlunWVluhGzDlHONsg9j2b1X6kVKsjCN3LFnT/AFgUc8cb8fz+nvRcLFNESq5VyGUjBBYnkf1FOw+ZEV1CmyVJIySEDMofB65yPTrVRJCI3aESPKgJG5sNnqMYGP8AP4Veul2hJEQkRqQHjX51PHGD1zyPyqlMYJ4PtDSERgE+YgI2euV9v0pPQIz6EEN9qMkyqdIDSOMsguF2yY5yvo386uaQJmjvftkfl/aZidrkOSCoBDHoenpWXFqlhGBuvLV8nIKsQPr7Gte0vItSQzWlxvmXgyJyr98EdzTTM5pLYxYPK+xWrLEzJIzR2trnH2g5/wBY567c8nPGKv24e6jljiuFO2TynmiX77D7+z2HIGOlR2bNfItxHM1qz5CvGvztEePkz91T0BxzyeOKkeWRIJYrELDHDF5KogI25H3c+uOuOmfU1qcyIH/02ZrSycJbwAJIY88f7CY/VvwFQapeWunWxEcq29rESHlT5tz/AN1fVv0H1pYjFZ6akUlw6lyRIw+XzG9EPZe2R24HNVbS1/tvV0We3aHS9P8A4tpXzJeyp6Y7nqKBmjCG06xVVizdzEYgbqjN8wVsZ5A685znNTeXFpy3Nw4DTHMkkhHUjso7Dtil2qGLwqq5OyFt2Rj+JgPc+vJxUD75pAlnhmZsmRhkIP7xHf2H0oKiMtrV4LZkcu8shEk2WAdyTkJ6Ae386uy20clxEk5jJtB+82N8qMeSq57noW7LnGKSEJaNc+ShJtsF3PzMZWGVGe7DOT9R7VQ1aeG3hS2Z8qpBmC8l5OpQf3ucAn29BQWtRJrlbzU0jIYLHhhGRjfIx2px+JwvYCs28WfVr653lodPtCsLgD55Wz8sQ7ZJGT+FS6V59zcln3JeO7QwDgi3B4Z8+uN+Prxjk1qWqW4VVWQxWNplQcZLu3DFQOrH7vH+0aRblfRC6bai3t7h5CmxuAA3DY5wPbPGfQe9NguRPaTXG2WfLBisRAwg6ZboCx5PcCpLp57+ZY3QxLKViitg33h1yzf3QBuIHHGCavXNubvy9Os0ljsYVDytsCjb+HHPZfQUClorGXcQOrLJcsH87LS7DtjijB+WNF/iPHVugUnFL50KxT61eABLZS6IDjAxiNB+LZ45JNNuz9vvZJ5yVgjIjt4lwSSTsTIHqdx/L0qDVlku4za2pERguUtY7hVzmR+XKc4yFBwf4cZ60EMoSWEtvZLDdMk1yo8+4WIZDTycIpHoijp61uGRmkvIIwR9mZYWmJAyyJ8xz2A3Yx/vGqlvbs8tyyRhbT7ThMHnOwBOnYD8+a054QLUwh1t7Qq0skkYyFTdjH+8drfhQO62MeZ5ZrKe7QhLCGGR49ijJc4TH4DccVatdLBtIbSZpmZ45GZSxxncGbOO20dKrSyzHR41FuEluXEawIDtC+YOB6kBSCTyea6S2mNsL2VPmto4igUrySTtGPQ/KB+JpFKdrox9bsB9inmjWWOUs0KkyHIZhzjPAwDj2xWddGB4LN7e3cwFA8HzHlAo3Dr/AHePqK2tdjuILS30oyRuscQu5XPLGRiwJz6YPT3rLtdNku7LTWAWC3s2ZXllGEA4wB/eP3lAHekyqdt2SWmmLdzSSNGscaR7pZHY4VwwU59egx65xUF4LJ9V1g29riBkjVI5eTjkHPoSQfocVralctHp1w1sph0+zdpkDDJlwoZ2Ydz0+maxJX8wbcKHaSJjgfeVlJx6fez+dKTtsa0rSd2ato4jgV4FRhGsRkAGADgHI9ypyfcVFGiW+pNbjcv2jcqMvKhsZ2j3PUeuKrR3LJrupwoN8wH7oLwGKBSR/wB88j6H1q4uxriF1LMkhEsIzyCG3AZHQg9PQ8dKItvcvYdewEQCeFcysxYgYHLDDJ7A8YPYge9Yuyez09ngRntA5cRg7dkZ67Djj5uQO2e2DXRXTM6XqPtM9rIGlC/xRNkgj2KnI+hHaqNpFtm8qZlPmMWzGTtkPrj3GTjp1oaZlzaWKlrexzvEhd0jmP7s48topcZwVPAz1x0OTnIrQ0yD7PfLJaYjR2MVzERhVY8HIPTPp09DWXe6eEDRywxtDHlcnIZUz8siEfxISMjure3MkV1ct1SVL2JfL3lRibjIVx91s44bpn6ilZj57o1zBBrUM0cZMEsY2PHkiSN1PylT35HB+op+mXDyTfaNmZWiUTqAAJnQbWIH8DqRz6giqthKtzqwu7eOezu41RpoJFHlyKRxg9m56dDx6VoeIVQva3h3QxLMsUxUbTE7ZAJHcMQDu7E+1URzcrsSNHJiNgGkcxttEbECQA9j/eGc1I0XmSrNEwC4yy8ZI6Ej68ZHYio9LuJLiOS33D7YIvNRSRhiDguuOOT1/OrSIJ7eWaJSuzJZOhRzwQfb3+lMHJowkUWYktF2zWUzCSMjoQQdyH3AOR64I7Cre+RocQyxM8AWJ1cHbIpHynI6cdG5GeD61cMYvXYMnkzxlcFTw3dPpnG3Pr+FZkahlGyQwPMd0MgGNkmT+7YdgTkY6UmVsSsrwRzywI0iLIEmt5Bghf74PuPzqS32rA0fyuhiZN45+Xlf5FetJbym9tgbmBI7xCYpokyPMQ55Hccj3waZbG4stV0y3Zlns5YXbOMuTk9+/wAuA351I5SVit/x7LHOFdowgDrGd23A5I9RjqKuxBHIRyXjOJFbOOexGORkf4UNHCg1KIHC2kmEdeNqEblIHcZz+FU7RpLSJA8Sx3CbnV1PySLwTtPoCcn09KRSaaubbyPPE7oALmMA7egkZehI7ZUkVialaNBJBLav88a+Zbsf4lPJjJ/P8R6Gti2nVtTi2hRHcrlCR/FjBUn8/wA6W6svO09/IQF4mLpvJI2jqvsQc/nQ1ccJ8juZCyG0uIZ4NxD5IjY5B9vYj2q0IfLmSexcRiQgIcY2v2ViPUdCetQ2TRzLJbvmN4zwH6oOoOfUHj6VYsnlt5JEkj54ycblyOSMfrj8qlKxUmnqjTW/FzBG8ahLgsRJHIMEkDJXHT5lyQfUVX8gxGWK3k3lcPHbkAZ919iO3TP5U61t9uoKCo+zXmRGDk+TMBlOT6kHH4jrVbVJJIbC1ubeGKU2UxE1u+QHifrtYDKlW6djuIPrWid9zlejK81wqsJ2B+zyL82/OYmHDbwR9Oew/OrMcS3GnmHJ+0277o1Y52E9Bk/wHp+NTGK3ureWBZXkVCskbE7ZYsjjkdVwQD1FU7KFrQmJv3kUgwhHVc+2emecDjPTHSl1Kcr7mdKiX7JZ75INSiHm29w5ID8ZGfUjGD3wDWtpd29xG0DxqJWIzz9yTtn+WRwQQaguYVnni3lRIx+X0D5yME994P8A31UEdzHkTIy+ZkpsxtJxyUP+0OWA9M4yM0JdxS1V0ac5Ed0WZWSeHKMVGHQEDqO4/wAKSMMtwYWVmyqyoeiyADnBHAJ54q1qKLeRQTIZRJKg/gJYOB938Rnjv2qC3Z/JBJ3eWwYEHqp7kHt2qxX0HwqWjlVSJlVCpiDYY9OMdj+mRVG5ha3mEiiRoP4sjkj1IPGf1q7IVhvrdBkSEbTEx4kj5AxnoRx9eRTLmLcHhDsM4ZVbO11I5Q/XsexA9aVib2MWGO0tkdYpP3MrFkHysqHqVUnnHfB4q3FLAsaNGHUD5iQwxj++AOmP5deKxRYaVbM8Ek1iz7yUWbGQP7jc9Qfyq1pqwW4ZbSA2sZPmDyhlCw4yRng+4OKTRUXct7FLNunYl13NKRhnycZ/2V7Aeg+tVin20RQ2+/7HGCZZXyPNJOMKepHHJHX6UthbR3Rja+MlwZXMxjwQpI6Mw6kAdM8c9Kn1iULFLLB5hlQi2VQMFmHBGO3Bxke9atnOZdsrreSTOivc7dltG2MR5+6pHQDPzHHYc1uyQRWVmITcSXLSAqjt96Uk/PJjsD0HoDWclo1tpv2m6C5ifbIwY/vW4yqgD6DPvT3dp5Lm4mkRJFi8oHHygDrz2A6DFIB9xd+bE8h8tF2lYEK4Ge7Eegyfy96fvFraqDuV3jUCNuHZjkKG9M8k/THamW0AYI8q7VUnahHBCnCgD6/qKjkkkOrPJKd8cAyY1ODNIPl/IHjPTAagC5DINPhV+pjB8lTjdNO5yz49e/t9BXNQlJIxfXJEkSvk+SC+FXJ2J7k9SevPatfU5Wiji+0hZbt8qQ3ypGuMscDoAuM9yTjqaoxXEbW73EwCWy7Ut4XT5dqtltyjjJbZke23saTNI6K5YtIZLS3t/JifzrkGXys4IJGcHP3VVcD2J9c1fsLZQIUaF97EjdgrtjHUgHlV64HU9+TVNluZC8Zl/wCJpOqRs7DJgiYlivoHPLt3y2O1bFuha6+zaeoB+VfNkb5URQfmb1xycfieMUAtHcnuJTHCBEFF5cIQilceVD0LE9QMDr36CqTSJZ2VztYrb2e5nmkYYZwMvIeTyMgAdugpi6nZXT3MtpgI8nkwbh884Qcsf9kcn09etZdxF9qWHzkyYpY5ltUOVLFiVU/3mJ+YsegoDfcgRmCw2ltGI5WDTgyKVZEC481h/AOoUfeJyeKuLbwR6TZIoMdrb+bPyeSWGxQfc4c/jUWpRrbRXpvXwbkpHI4B33DcM+PQcBQOwU+tWdZ3wxwwbY4nBjYp7sAeP++v0oC5bs5GlVrSRAJpbgNEvH3TGck/TBOKZ4huPsctujus8MUYuGiAwDtAIXA67mZMewNaWpGBJrB0IiaW1nCMw/1S7id5Hr5ZIqnEyy6nLC2P39zugWRccQqBnH90Dr/tZ70ErcqeXcPPo9jKcmMb3dTlh84LsSOhyXBrZ0+QXNvppjBUXMpvUjI5AX7hb1/vY9TWfpjXF34haSAFbbZ98qf3mSdnHuSSR6VpancLY6Lc3UDBpzALa2CcAMcRjn/fYY+h9KA5jLkjWfU5b28PlCfzIUt88+SoCgse33c881UtjeavZaVKzQxl3khAH3Yh94tjphRnJo1aE2WjTwwCRjChAK8szFiufck8/jV9rFrTw5LEZPIupx5nXhFG0svsXCZPsCO9Bonawj3EV3dXdmit9ktrT7LFG3IO/wDjP+9uJPuBWBbwFLXT1YnIMUDkjrtYDn8GrW0F1uGuXDKFuAyZY8Ke2T6fMtQ2xjM0TSQ4MMnnyo38QVcsPrkf+O1D1VzRe7KxXuI3fxDb3ttiEu7uDn7rR7gR/wB8Y/KhXwtszGQW0vzBl6qTkEenAIPv0p2mQtK8kTPiRXWZWPPJ4z/wIHBqpbTRm18h2VPLkjmQMcjDED/P40kdEnrbyNzfJBBJqhVJXt4xG7IcrNDu5b3wM8dRhgetIbfdF5G5lMahoHz9zaQUYEdMEYOfY+tJocrwamqKoNrdb0uIHH+rONu4fjgGn2yshhAlZjE72kUhbBUnlFY/3iCyEHgkL61SMpxUZW7kKFbqKWVbfE6swuLUk4deN3urDO4Ee46dCTTbm3geV7gpYwoD5zJ8zRnleP749uDyDgir8KL/AGm1+XSLAKXIZSu7aMKR6EE4PqrZ7UamsV3pjEv5M2AsAIIXDkKUbqDg8Yx7imYt9ilqSNczpLbQhTECr27n5nUdQfU4rRsJ45pJ9N1CQvYThEidvvxbuVVj1I3AYPYnBqnrOn3AJfT2EF9DkFZeVcDsfUejDkcU5ZRNIHeJYJTEuC3GyTCsYy3Qcgcngj0IqepV7qzFs4LjS7iSyukTmCR7e5UbeA4I3DsecHHpyK0J52ju3lkCgzKo3xnG0HPysOmBzhvQkGtZ4Y5Jp4bqMP5oYgnkLkdcegJ/TNZDxH+y7aOVc3FoWaPLfeDHDLu9MgGrsRe6LF1almJih3MnzyJn/Wx9wD6jqD7e1Z2q2cd1p7w7TumbJkHDMByH+vTPuKtWF61zpoW3kmM8DM1vuXJfHLQn/a6getXdRitm09TbBljVRIowUzn5vw/xFTYOZp2ZyttczvAk7ujTyMY5DkbTKv8AF7bsAEeozWldxR3ml2txaqPMtnaXY/BQ8qw9jznHcZqtq9tE10glkBsL6Mb2C4IK8CQEfeweDn1HNWtKjdoWhuwgw7RSSD7jZTIPtyBxUIuTuiVJRNfI4/eRXNpmJ0bABByQPddxx+VViLizEglIlmhxvZUOXQDBJQcdO46g+1Vbad4FgjUss1ndH5do+XcCCMdCMipNUkH2v7Qsn2chkZWkJCgHgrkdjkDn2oFEdbIBatbRNtU/vrdg/wArKeVKtyMg8Z9x71sRzvb3SXkhLw3Cliq4GQevHYjkVjyWotbgwhQPm89I8YB/vKp6cgn9DVmxuxc29wkqbXs5zFPExyDuAw6+xVgT9Kqw3d7jdRV49VC7fPUMYgQQC0T/AHHyevPBHrVMzTx20V3HM0QhOy4SWM4GOhODwOo9Olal3Z40WO7lGW0+TBYnOEBz+X8uKzrljBqNzEW3LMGwjNtdlI3Aq/Qgg9DUy0NIyTRpWOqbZZradY5IeSjRZAx1BHbI4YY9DWhdWYt3muSiSRyBQWUkAA8bvx4Oa5Ke3ntHikWVmQjaSjEZI74Ptj/E11mhXDXenzW8bB3RS0RjHJB7YPcHtTWpnVjb3kY1u4s57WJswukptXyCRllJjyf4VOeCOM8VKHimhQunlGQsGjyMF+5Hp/KtS6hW/sLeZ4ULwERMSMfxBkJ7/Kwx/wACrnotNnsNSukspi9uSVMMpyY8nK4bvg+o4Bo2ZCdy/fQy3FtOrwFt8bNgNyJQAwUY9doIPr9aoMkd2kbQsXaZSd5wGBX5kJ7blOfqMirOi3xa6jt7nYI3DAbvlZGUHI4z78fiOKoQ2i2V4cyStalvNVQu4/MOWBGOmCCPYdae4X5fdZraHenUNGlgbMN5ZymORFHMQHzL9QDkfSnLOslzH8qMHGA464I/l/h3plgpOpme1dDdNb7XEf3blVIMZ+oyRmodajDZkjQiJjyjHGCT0PoQefxpiW9i5fP+6hScss8ZZFcDKlOCM9xz3pmqxyXellxJ5Mx/d+Z2UsOCf9knuOhNJZyfarSFLsu7B3gEjdGJwQGPY9OfUVCZprGK6g3K7sGiiMg4LMDtDDoDnjPTPShCkjKXdHarFJoM6SxJtkCIjK+P4g/9abpVgZZQTEsEklwHWHdj93xxkcBsZ6cHNSW1g66fBfaM9zII8ebHLIQxcffRgejA5wRwehp/h9Fnnu7iEOIpLvHlNkBfl42g/dOcjjimKLsWoDDPcXCoiS+WP3jADBOQAo9vU1IlgJwl4X224w6eWcEsB80pz0A6Ad+tUrCBW0SW7j3vAV3LFChVrlg3BH8QUngZ69elM1S4mi0ryYlXO3BRGz+8Jzt/28c5P41dmZai3X/EwuVt7bKwxvhd/AXb6+p6kn2pBcwyXMNuxDqXBWNWy0qAEHap9TnnttNSRWbrZRw7ZVM4y7FsNz14HTOPyqaeRbSAyRxqZUTyI0H8WeAq/wCNIoivrlvLa3sSHvXfyIuNoz13c8hRnOe+Pen2ttDBO8ZJkis41eYgY8xwP3cY7gD7x9c5PWoLBAkMl9dkTSRxMFAyQ7EhQR04yQo9snqahk8yNRb+Y0rsAXAbiedz90HsoA5PpxQBRvrhbiRjM7RRRDzZp2XIwPmZsZ9wqjuxB7VaaOCC3gW6iZIYnWd0K+2VjJzyQCox6knvWfKiyXEkzRm5srOQTSqrYN5Nn5Y/93J/AfWtK8Qh83zEsJt8iocNPM7biqjB5OFUf3VFBTelizYedHALmWNn1K9YtHEwH7rceWYDsAAPelvLuCHw/fLZzh45GWza5b+PJ3TMuOpwAvHHI7CnXXmyJLHchfNmAa6EZ6kthIFI6jHGO/c4qC6hF89jayGNLe33M4ROFUHHHbHGM0mOJBp0MdhpCBbdhc3pLO0hyY0ySqc+oXJxxV7Q4JJ7n7W8jtI2SkbDohO0Z7bmOSfwHamXMjtZSXgJ8uFGSCBP4yf4s+mSMA+nNaOlQ/YLC3t45HlaKAvI7MWYyHIGT1yTkg00S2YWo3UF7q+jwGTfEZGeWQdk8wqAPdmGP91T61Oztq/iJpcDyri5kVpPSNDjd7H5AB9aZY2aSeItNQoiW0AV5NoJ+VFJIyevOB+Oe9X9BLT3im5YiCCP7TIowc4c4H1ZiOO+2kV0uauo263PiTRLZSQwSQy7+m3AIH0wAPpmsySffqMt1vURRxsSxb76KSSASOAzsT+Fad/IkEUOqXEqi7W3uCxk6B3yNvHcAAD6e9YcUKpokkmc3F0iR464UuCAfQYBFAomt4bsDvmvZDJJ9pYSJGxIPlBAEAHbgk8dzVbUyLnV9MtpOLa3lWYgDaGKElQfxcn8q2m5sJLqzLmNolCyN1YtwrD2wNwFY90xfVStkvzQzpBuPPyriRs+i9M/SgS3K2oiJDI0jP8AZ0yJJFxuOH3CNMdyCBnsMmptNuFu9NuJrmNJlZ1uTjocNsKj22kAVna7NEZVhV98lni5wCS57E4HY5/Sk8NXotLK+McMjfZ5JDyQBsbDbSD14xSLd+Ug0ZVhH2YqcRJKZFPBZd3yE++1a2PsX2vxIrKwL3VtOjN0y6ruU46c/wCNZFoJI9SuorW1CqIZLfd5nMiD7pzjkg7hWnDdyXLzlrVxJG0kEbQyL8kgXaMfzpW0Kb6mEk+6y0yZsrOuLWfj5io+Uk/T374o8Rwvb30rqihJEU8qMBkfIH0wWH4Gk0y7WTU7tby3dGu/lmUISqSFRvVcZwAec++a1NWniextHSVDMkht5UkOCVGGByehIH57vWpUTT2mzK4aSKN3V2jkMibJW6Z6gn2P+rb32mtKWGLUJXijO2S7h2sm3oyH5Hz3IIIPcg8VlaqEV4QUdIZkGADzubAKk9sjAB/vKp71ci/drHcXOH3xqshPAYMwRnA9CVQn0LU1uOT0uX4riC4RoFVzNH8skcpJywBHJPOTyORyKbGjKIkWKWa1gffMjOAwQ/dGO7Buffbx1rI1rVxpuoxXVxE80Lc+dHzLH6q4PDjgHPUYyPfXXz7dl1C2aK9VkaUmNcCVCAfw4Ax6EU0yGla6LgnZYoluZRPbFtkE235om/55sevrg/gfWrN7YwT3JXOFaPZMq8bl28fRh2/KnPHDe2kE1syxeehJWQH5zx6dD046jIIqKG7kS/lt5vvyhgN3zDaF7+o46jtVEDdRW5ihguIpWLROVDMpBZBwBgfxAFeR1x0q7cSNeRwvIqRyeUFlTOFUkdePU4I+tTKWmsRlVbcqSOoHmCRCMfKTyRnHPUY5oMaC4WaNgQNgUsNofjlT7UENmTpCxtdRuziO3mG5wBwsqAlTn1IyPwFat2PMtZpQDJubBwSAG56+xz26Vl6tHJbfbiI3SL7QCWVTwdwJJA578j0571oae4lS6sJy4dC+Dnny8jb9cZ60hszGtxc2cNsVh2Fy9usqbWjnC5dCfRh6friquns9rp9zYb2lvIAJkJywKNuCbj3xnB9q07FgI44iAhH+sU88q2NwHtwKe9pHNdz3ttKA8MUtvcAjO0EAg8fwn5WB9jSsNyVrGVHturGe6mjWO5hlVriPkhCQNwB7oSNwz71JBaq9rcWtwBc2+MqrgHKHg59RUOmNJDqt3CzxyMbcI6DgPGWIySe65PTsRTrWQx6hCnlzRkfu1dDhTnOTj0JBHsSPWpKvfYg0xRaRtZEeYsBJRZCSRH3APfaenfaSO1Xp7NI7truPazlBHJu77Rxu9QUOPqtR6q6wCG/WRnw2wyCMNhgMruAOeR6dcGtC1jt7iyF9bssqyruxExIyDhxz1AznGP5U0KV90Zl1dtpfnlXkkiZ/M27N29Nudh9fl3YPf8KkeSzuktoElUmGNZI+hJjPAwO2PUZxUVoiomy6IBR1tzIBxuGSh744Ye1UbeznhuoXiEQjtpGi8sj5RHIOMn+HDdxxzzRIpD7qG5srRUWRZvs771UrndG3ocdj6VoeHbqBPLkiZoZJ3OULcbQMEqf94k8/3ai0rVAs1tFdMYmDbDuJxtYcA9ivXn1HWq2pW4e/ijQfZ7yFFEeWCpMDzujbpkk9G/MVL0LT5vdZ0qtidracr++DBhz36nHswBx6GsnXgBqS3Kh4JmjWXdGDlGIwenVcjkHge1aMkpXSLK4kLxyLKIp/MBGwnKhyO3OBTddjdILKWLCDChVzgrkEsG/4FkjPZhV9DHZmWzQyX0kzxIk4jL+Yn3WOOCR26/4GquoLe28we2VZTbusiEciWBsZH1B7+9STW/nQBofkkTIBVsOM88f7PXA7fSi2maA2dxmQbs28iOOBtPXHY4I5HXipKe1w0i7gsNUtbhlZbYu7FD/CrDEgHqO+B0PNa1zHM9jd2tzIiywSFDLGOXUfdcD6YyD2rC1K2YXSmzwrGVmeFGxhtp+dc8Fv9njd061tWczyTefIoSKSABlH99CBvX/Zxjjt+dNEPuY8UpitLi21BVEaMsnmRqdrAjqVHbpyM/hV18TW0sNwVmRlJ83GdwJ6EfxKCDn86mEOGeCV0VPN2QuTjax3fu2Hoc5B79OtY8waawcwGWK6CvGUTKq7Ec5HXORnPBB9aoblc0JtZjjkMqi4ljUfvTBGZF4GGIYfeI6981c02aFp7e4gkT7Ncn5XRcxOT2/2cjjHTPoa5nSr9ms57S5iuopdm+AQdEAAC7GHAXJ59DnIwa1fD8T2928sZRraSfayr0STaA5UdCpbOR36jkUEMsaOjPo63UsjGWeEynZ8oUdFVR2AHFZcTCW4t0CKgkk2nHYBgMD2oorYRo3lw62dxNEFjkS4eNNo4ULhQfc4qjI58q4lCruRlhjGOFBbHT9T60UVDAl2CXVILJi2wsWdwfmcKh+X2yWz+FVIS1wjnKo9zcC3DAf6pf8AZHbjA+goopAQ2kg+ytcBAF+0OqRjoqxkAD3yW3E98dqmsw7aveuJCJFuJLdGPJToCw+o49ufWiigB3iO8awtXaNdzJKsaZJ+UkEbvqO1VbqWWKaHT4HEMUmSzRrhiABhSf7vqO9FFJlrYv3wW61G1hIZIlSPCg/3ic/j8v61rag5hk1KdDyHCIvZcNtB9zgfrRRTRBhW8jWMWjyxkF5Y1ds9DkbiD+IH4VsaBAi2reZl2itxNu6FmVQB+rsfrj0oopFPYPFYk/s+K2LKVmuLUPhexQEjr05NVbljNY6pImIwpkiRQM7TtUBs9yPMJx7CiigIbG9IsaX9ppm1ja21q1wilupVvKTP0Az75rA0xTe6zdWEjskcUouZGQ4aZnVjg+ijjgenWiihbijuVHiSHxNpaQLsS6tZA4Hsxx/6EevrUHhOUHVY4XQOj3UkDBucrHuC/ocUUUjToaWm5/tWaVvmeHLKSOCcAHI9DgUzQFVTc3RXMlxbzzDBx5eWUfL79Dn2oooYdGZlvCja0oizEs5iVgp6MUYFx6HKg10ItBqmh3K3jB3Xy23FR96OUc49wSD9aKKBnPwWMd7ZXqKzwiJ7hFCnI2oflGD6Dj8BUdzfyPpthcOkZIlERAGNwLAN+dFFLqVL4TWvbZZrN1ldyY7ue3VgcEgbWBPqQGx+FUvCt4bebU9NCcadK0cbodowys3C84wV9e5H0KKS3H9k6Lw3i61m30mQDa0YdJh95GCBwcdOhKkdxVi62yPHcOCfN3krnG04PKntRRVGY3T4Ggn+xzTyTJLChDg7GTJOCMfxDAye/cd6vyobu0u43ba0EmwsB98kD5sduvSiimZMqahKz6nZpJlodQjCzISfvxqpVwex7H1FPiG6xt5QziZcxb93UeZnJ9emPzoooNBLeMCMSk/dLgj1zwOfUf4VU0Jgl1cSlQZkEkLv/wA9FUnGf1H0JxRRSM5GTfO1vq9nJHheZoNqjAwpGP5VqrGjpGm3AiuGjUjrg8kfmAfqKKKmJotw1C0S4t0hYkfakC7gPuNk4cD1BANY+ganeWqNYzPHMwV5llCFcMGUHjJ4IYg/h6UUULcr7JsanmOe/jTaI0XzwCM/dA+U+tMgjCaxsjJWG6t8MoPKgqeh9vpRRQxJamJqkZEWokFQbTZJGVXaQW5OMHA5J7d6UXIlvHgljDwG5aHYx4AZQwI9CMkcdRRRWb2Lhub3h93bTLmB3Z4VcxgMSWwffr2GK2byAf2NqIUgeXEkyZGcFVAI98jrRRWi2M5bnIIyiGGRFxHMgkEROQhB6r37mpZ7QXdpI2/ZLHIrB1HXIIOR9AOfaiipG9ilr139mi07UBEjtIoEqHo2cKTnsfzrYswsE/2Nc7AjyKQeQCwBB9evWiiqRL2LurRL50+VUmRY1bjqMMf6Csi/SO5aaOVASvlzo4JDIxz0PXiiiqIHXumWl1I88sIDrtlfYSockYbIB7g9fzzS+GnkW7n06Vg6WVx5MbhcEqDwCOnTiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, keratotic papules at the base of hair follicles and scarring alopecia are present on the scalp in this patient with lichen planopilaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24954=[""].join("\n");
var outline_f24_23_24954=null;
var title_f24_23_24955="Discharge summary contents";
var content_f24_23_24955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elements of discharge and summary",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Dates of admission and discharge",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reason for hospitalization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant findings from history and exam",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant laboratory findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant radiological findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Significant findings from other tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       List of procedures performed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Procedure report findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stress test report findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pathology report findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Discharge diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Condition at discharge",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Discharge medications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Follow-up issues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pending test results",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Information provided to patient and/or family, as appropriate",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: O'Leary, KJ, Liebovitz, DM, Feinglass, J, et al. Creating A Better Discharge Summary: Improvement in Quality and Timeliness Using an Electronic Discharge Summary. J Hosp Med 2009; 4:219.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24955=[""].join("\n");
var outline_f24_23_24955=null;
var title_f24_23_24956="Valproate toxicity rapid overview";
var content_f24_23_24956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Valproate toxicity: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS depression (acute overdose or therapeutic use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension (severe acute overdose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic acidosis (severe acute overdose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolyte abnormalities (acute overdose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated transaminase levels (therapeutic use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperammonemia (therapeutic use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiosyncratic hepatotoxicity (therapeutic use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amount ingested; immediate or sustained release preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concurrent carnitine supplementation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS depression, stigmata of hepatotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measure valproate level every 2-4 hours until declining; check acid-base status, liver function tests, ammonia level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Gastrointestinal decontamination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Single dose (1 g/kg) or multiple dose (0.5 g/kg every 8 hours x 4) charcoal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hypotension in acute overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluid resuscitation; vasopressors if necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Consider hemodialysis or hemoperfusion for refractory hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hyperammonemia, with or without encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carnitine, 50 mg/kg/day PO or IV divided TID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Idiosyncratic hepatotoxicity (Reye's-like illness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Supportive care, carnitine 50 mg/kg/day IV divided TID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        CNS depression in acute overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Supportive care",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24956=[""].join("\n");
var outline_f24_23_24956=null;
var title_f24_23_24957="Discussing hospice care";
var content_f24_23_24957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guide to discussing hospice care with patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"80%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Identify other decision makers",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         \"Is there anyone you rely on to help you make important decisions?\"",
"        </p>",
"        \"Who in the family should be there with us when we discuss the results?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Assess understanding of prognosis",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         \"What have your other doctors told you about your condition?\"",
"        </p>",
"        <p>",
"         \"Have they talked to you about what this latest problem might mean for you?\"",
"        </p>",
"        \"From what you know, do you think that over the next month your cancer will get better, worse, or stay the same?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Define the patient's goals for care",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         \"What do you hope for most in the next few months?\"",
"        </p>",
"        \"Is there anything that you're afraid of?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Reframe goals",
"        </strong>",
"       </td>",
"       <td>",
"        \"I wish we could guarantee that we could keep you alive until your daughter's graduation, but unfortunately we can't. Perhaps we can work together on a letter for her to read on that day, so she will know you are there in spirit in case you cannot be there.\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Identify needs for care",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         \"It can be very difficult to care for a family member at home, and no one can do it alone. Have you thought about what kinds of help you might need?\"",
"        </p>",
"        <p>",
"         \"Would it help if we could find a way to deliver your medications to you?\"",
"        </p>",
"        \"Would it reassure you if we could send a nurse out to your home to check on you?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Summarize and link goals with care needs",
"        </strong>",
"       </td>",
"       <td>",
"        \"So I think I understand that your main goal is to stay at home and spend time with your family. To do that, we will need to help you in several ways, for instance, by sending a nurse out to your home and giving you both some help around the house. Is that right?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Introduce hospice",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         \"One of the best ways to give you the help that you will need to stay at home with your family is a program called hospice. Have you heard of hospice?\"",
"        </p>",
"        <p>",
"         \"Hospice is able to provide more services and support at home than most other home care programs.\"",
"        </p>",
"        \"The hospice team has a lot of experience caring for seriously ill patients at home.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Respond to emotions elicited and provide closure",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acknowledge response",
"       </td>",
"       <td>",
"        <p>",
"         \"You seemed surprised to learn how sick you are.\"",
"        </p>",
"        \"I can see it's not easy for you to talk about hospice.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Legitimize reaction",
"       </td>",
"       <td>",
"        \"Many people are understandably upset when they learn how ill their loved one is and that hospice is a possibility.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Empathize",
"       </td>",
"       <td>",
"        \"I can imagine how hard this is for both of you; you care about each other so much.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Explore concerns",
"       </td>",
"       <td>",
"        \"Tell me what's upsetting you the most.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Explain hospice goals",
"       </td>",
"       <td>",
"        <p>",
"         \"Hospice doesn't help people die sooner. Hospice helps people die naturally, in their own time.\"",
"        </p>",
"        \"Hospice helps people live as well as they can for as long as they can.\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Reassure",
"       </td>",
"       <td>",
"        <p>",
"         \"Hospice's goal is to improve your quality of life as much as possible for whatever time you have left.\"",
"        </p>",
"        \"Hospice can help you and your family make the most of the time you have left.\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Reinforce commitment to care",
"        </strong>",
"       </td>",
"       <td>",
"        \"Let's think this over for a day or two; you know I will continue to care for you whatever decision you make.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Recommend hospice",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         \"I think that hospice would be your best choice right now, but of course, the final decision is yours.\"",
"        </p>",
"        \"Hospice could be very helpful to you in the ways that we've talked about, but I realize it's a big decision. I'd like to arrange for a hospice nurse to visit you so you can decide for yourself whether hospice is right for you.\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Casarett DJ, Quill TE. \"I'm Not Ready for Hospice\": Strategies for Timely and Effective Hospice Discussions. Ann Intern Med 2007; 146:443. Copyright &copy; 2007 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24957=[""].join("\n");
var outline_f24_23_24957=null;
var title_f24_23_24958="Tumescence and REM sleep";
var content_f24_23_24958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Association of nocturnal erections with REM sleep",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 273px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Penile tumescence during the different stages of sleep. Nocturnal erections occurred during periods of rapid eye movement (REM) sleep (green columns).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Karacan, I, Williams, RL, Thornby, JI, Thalis, PJ, Am J Psychiatry 1975; 132:932.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24958=[""].join("\n");
var outline_f24_23_24958=null;
var title_f24_23_24959="Salmonella secretion system";
var content_f24_23_24959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Salmonella type III secretion system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note hollow needle-like structure, 80 nm long and 13 nm wide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Drawing adapted from: Cossart, P, Boquet, P, Normark, S, Rappuoli, R. Cellular Microbiology. ASM Press 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_23_24959=[""].join("\n");
var outline_f24_23_24959=null;
